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ABSTRACT 
Compared to conventional synthetic polymers, protein-based materials have unique 
advantages, such as useful mechanical properties, biocompatibility and biodegradability. 
Protein-based materials have the potential to be customized for a variety of applications, 
for example, biosensor, tissue engineering scaffolds and drug delivery vehicles.  All these 
applications require optimizing the mechanical properties and adding functional proteins.  
Current methods to produce and functionalize protein-based materials are often 
performed in harsh conditions, which is harmful for the functional molecules. Our 
laboratory discovered a protein-based biomaterial made from the Drosophila protein, 
Ultrabithorax (Ubx).  Ubx protein rapidly self-assembles into material in mild aqueous 
buffers. This work explores the possible applications of Ubx materials, by extending the 
capacity to engineer the mechanical and functional properties of these materials.  
Our first objective of this work was to investigate the structure and assembly of Ubx 
materials. We found the strength of Ubx materials is due to dityrosine bonds and located 
the amino acids that participate in these bonds. Tyrosine mutagenesis can decrease the 
strength of these materials, allowing the mechanical properties to be precisely tailored for 
a variety of applications.   
Our second objective was to study how the physicochemical properties of appended 
proteins impact the production of monomer and assembly of Ubx materials. By fusing 
proteins with a variety of physicochemical properties to Ubx. We demonstrated that the 
appended proteins dictate the solubility and purification yield of the corresponding 
protein fusions. Surprisingly, all protein fusions self-assemble equally well to produce 
materials with similar morphologies. We concluded that a far wider range of proteins can 
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be successfully incorporated into elastomeric protein-based materials than originally 
anticipated. 
Finally, we used Ubx materials as tissue engineering scaffolds. We found VEGF-Ubx 
materials trigger corresponding signaling and stimulate migration and attachment of 
endothelial cells, proving that Ubx material can deliver appended functional molecules to 
attaching cells in vitro.   
In summary, this research explores a new way to control the mechanical properties of 
protein-based materials, reveals the great potential of Ubx materials as a system for 
functionalizing materials, and demonstrates the feasibility of using Ubx materials as 
bioactive tissue engineering scaffolds.  
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CHAPTER I 
GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Protein-based materials and their unique advantages 
Protein-based materials are materials made from proteins or peptides.  Natural protein-
based materials have been widely used for different purposes in human history, for 
instance, silk from the silkworm, Bombyx mori, has been used as biomedical suture 
material for centuries (Altman et al., 2003, Scheibel, 2004). Protein-based materials have 
great potential to be used in a variety of biomedical applications. Many laboratories are 
focusing on their uses in tissue engineering and regenerative medicine, in which 
replacements for damaged or diseased organs or tissues are constructed, thes replacement 
requires scaffold that support cell growth in 3-dimensions.  Compared to other 
conventional synthetic polymers that have been used for biomedical purposes, such as 
poly glycolic acid (PGA) (Moran et al., 2003, Asti et al., 2014), Poly lactic-co-glycolic 
acid (PLGA)(Makadia et al., 2011, Gentile et al., 2014) and polylactic acid/poly 
hydroxyester-ether (Garlotta et al., 2003, Shogren et al, 2003),  protein-based materials 
have some unique advantages.   To meet this requirement, spider silk fibers have superior 
strength that can provide structural support and burden the weight of cells and 
surrounding extra cellular matrix when used as a scaffold for hard tissue engineering 
(Gosline et al., 1999). Elastin is extensible and can tolerate repeating stretch /relax cycles 
and resist elastic fatigue (Faury 2001, Pasquali-Ronchetti et al., 1997), which is required 
for artificial tissues/organs like lung, skin and bladder. Both examples highlight the 
useful mechanical properties that can be provided by protein-based materials. Another 
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important property of protein-based materials is biocompatibility. For those materials 
designed to be implanted into or to interact with human bodies, biocompatibility, low 
level toxicity, immunogenicity and inflammation is essential and required (Crawford et 
al., 2008, Williams et al., 2009).  Most useful synthetic polymers are too hydrophobic and 
not biocompatible. Extra modifications are needed to make these sorts of materials more 
biocompatible and suitable for implantation, which is time-consuming and costly (Mark 
et al. 2010). Although monomeric proteins can generate immune response in human 
bodies, some protein-based materials such as elastin, collagen and silk-based materials 
are proven to be biocompatible, when in the forms of polymers/materials (Altman et al., 
2003, Rincon et al, 2006). Biodegradability is another attractive property of protein-based 
materials. For example, protein-based materials can delivery vector hydrophobic drugs 
into human bodies and undergo gradual hydrolysis to release the drugs to target sites 
(Kopecel, 2007, Lutolf, 2009, Geckil et al., 2010).  In addition, an ideal tissue 
engineering scaffold will degrade over time and be replaced by extracellular matrix 
proteins produced by the cells. Degradation can be rely on nonspecific hydrolysis, as is 
often the case in swellen hydrogel, or on proteases, which recognize specific sites 
engineered into the protein sequence (Hu et al., 2012, Wang et al., 2009). This enzyme-
catalyzed degradation is also programmable.  Protein-based materials are also genetically 
engineerable (Bini et al., 2006, Huang et al., 2011). By modifying the amino acid 
sequence of the material-forming protein, the desired physicochemical properties or 
functions can be added to the materials. For example, the flgelliform spider silk protein 
contains repeating (GPGGX)n motifs, by mutating the X amino acid in the (GPGGX)n 
motif from hydrophilic to hydrophobic, the β turn content in this protein-based material 
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can be increased, resulting in higher elasticity of this material (Teule et al., 2007).  
Because of these unique properties, protein-based materials have the potential to be 
customized for a variety of applications, including drug delivery, tissue engineering, 
surgical sealants, medical imaging, biosensors, biofabrication, and biomineralization 
(Baneyx et al., 2007, Deming et al., 2007).  
 
1.2 Common biomedical applications of protein-based materials  
1.2.1 Tissue engineering scaffold 
Autologous and allogenic grafts are the most common treatments of injured tissues or 
organs (Tsubouchi et al. 2008). However, the lack of donors severely limits this 
treatment. Tissue engineering and regenerative medicine offer a route to circumvent these 
conventional therapies.  Constructing the artificial tissues or organs requires scaffolds 
that support cell growth in 3-dimensions and active factors that regulate cell behaviors, 
such as cell attachment, migration, proliferation and differentiation (George et al. 2010).  
Therefore, compatibility, proper mechanical properties and incorporating molecules with 
desired functions are the three basic requirements of scaffolds for tissue/organ 
engineering.   The tunable mechanical properties, biocompatibility, biodegradability and 
engineerability make protein-based material an attractive choice as a tissue engineering 
scaffold.  For example, natural polymers such as collagen, elastin, silk, keratin, chitosan 
and hyaluronic acid are widely used in tissue engineering (Mano et al. 2007, Chung et al. 
2007).   
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1.2.2 Biosensors 
A biosensor is an analytical device that combines a recognition element with a transducer 
(detection element) for the detection of a biological analyte (target) (Newman et al. 
2006).  The recognition process utilizes the affinity of the recognition element for the 
analyte, and the transducer transmits this interaction into a measurable signal (electrical, 
optical, etc.).  At present, patient health status is primarily monitored with supercutaneous 
sensors. However, implantable or subcutaneous biosensors will provide significant 
advantage over conventional methods. For example, the major problem with conventional 
measuring systems is poor contact between the sensor and the human body, leading to 
weak and unstable signals (Turner, 2013, Yoo and Lee, 2010). In subcutaneous 
measuring systems, the sensor-to-body contact is more stable (Rogers and Boutelle, 2013, 
Hwang et al., 2012). In order to be implanted or injected in to human body, subcutaneous 
biosensors need to be biocompatible and biodegradable. Some protein-based materials 
are attractive for this purpose because they are biocompatible and their solubility in water 
can be programmed, over several orders of magnitude, through the control of crosslinking 
and crystallinity of material-forming proteins in the materials (Wang et al.2008).    
 
1.2.3 Drug delivery 
The delivery of therapeutics to target tissues/organs remains a critical problem in the 
treatment of several diseases. Conventional drug delivery systems often encounter 
problems of poor drug efficacy and non-specific delivery, which may cause systemic 
toxicity and undesirable side effects. In addition, some therapeutics are highly 
hydrophobic and poorly soluble in body fluids, leading to low drug concentration in the 
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target tissue/organ (Nerini et al. 2014). To solve these problems, controlled drug delivery 
systems are required. Protein-based materials are promising materials for the delivery of 
drugs and other active ingredients, mainly because of their biocompatibility, 
biodegradability and processability (Raucher et al. 2008, Mura et al. 2013, Ciofani et al. 
2014). To fulfill the specific needs of drugs that target different tissues/organs, protein-
based materials can form different morphologies (such as film, hydrogel or mesh) with 
desired hydrophobicity and biodegradability.      
 
1.3 Common protein-based materials 
The proteins or peptides that comprise protein-based materials can be purified from the 
native organisms that produce the natural protein-based materials, produced as 
recombinant proteins from other organisms (Kyle et al., 2009, Merle et al., 2002, 
Pakkanen et al., 2003), or chemically synthesized (Floss et al., 2010, Papapostolou et al., 
2007).  Depending on the source and production method, material-forming 
proteins/peptides can be classified into: i) naturally-derived proteins, ii) recombinant 
proteins generated in different organisms, and iii) self-assembling peptides.  
 
1.3.1 Naturally derived protein-based materials  
Naturally derived protein-based materials have been widely discovered and used for 
different purposes for centuries. The most studied naturally derived protein-based 
materials are silk, elastin and collagen.  Because of the useful properties of these 
materials, scientists have been putting extensive efforts on studying the assembly 
mechanism, mechanical properties and the structure of these materials. A general 
comparison of common naturally derived protein-based materials is summarized in Table 
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1.1 (Gomez et al., 2012).  These studies have served as a guide for our characterization of 
Ubx materials, described in section 1.4.   
 
Table 1.1 Comparison of common natural protein-based materials. 
Modified from: Gomez et al. 2012.   
 
 Silk Elastin Collagen 
Natural function Web, cocoon Tendon, connective 
tissue, extracellular 
matrix 
Tendon, connective 
tissue, extracellular 
matrix  
Structure Stacked β-sheets, 
Random colis 
Aggregate Triple helix 
Mechanical 
properties 
Sequence 
dependent 
Elastic, extensible Inelastic, strong 
Intermolecular 
forces 
Van der Waal’s, 
H-bond 
Hydrophobic, 
cross-linking 
Disulfide bond, H-
bonds 
 
 
1.3.1.1 Silk 
Silk proteins and silk materials have been found in many organisms, the most common of 
which are silkworms and spiders (Kaplan, 1998).  Silks are composed of many proteins, 
and their composition varies with the intened use. Consequently, different kinds of silk 
fibers have different mechanical properties (Vepari, 2007, Saravanan, 2006).  Silk fiber is 
mainly composed of stacked β-sheet structures separated by glycine-rich regions. In vivo, 
silk protein undergoes a secondary structure as it transitions from a monomer to a fiber 
(van Beek et al., 1999). When stored in the silk-producing glands, the poly-Alanine 
regions of the spider fiber protein form α-helical structure while the poly-glycine regions 
form β-turns.  During assembly, the spider fiber protein rapidly passes through the 
spinning duct, a low pH environment. The low pH environment forces the denaturation of 
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spider fiber protein, combined with the high flow rate and shearing force in the spinning 
duct, together, these forces drive the transition of the poly-Alanine regions from α-helical 
structure to stacked β-sheet structures (Hu et al., 2006).  In this stacked β-sheet structures, 
H-bonds form between the β strands and the β-sheets are stabilized by the van der Waal’s 
forces (Romer et al, 2008).    
 
1.3.1.2 Elastin 
Elastin is a highly elastic protein in connective tissue and allows many tissues in the body 
to resume their original shape after stretching or contracting. It is found in all vertebrates 
above the jawless fish (Swatland et al., 1994). In humans, elastin is found in tendons, 
ligaments, skin, blood vessel, and elastic organs that undergo the stretch and relax cycle, 
for example lungs and bladders (Martyn and Greenwald, 2001, Faury, 2001). Elastic fiber 
is composed mainly of an amorphous component, the microfibril, which is extensively 
cross-linked elastin.  Elastin protein is mainly composed of simple repetitive amino acid 
sequences that contains large amount of glycine, valine, alanine, and proline.  The 
process of assembly and formation of elastin materials called coacervation (Cox et al., 
1974).  The precursor, tropoelastin is transcribed and translated from the elastin (ELN) 
gene and transported to the plasma membrane. Tropoelastin is then released and 
aggregates on the cell surface. Lysyl oxidase then oxidize the tropoelastin aggregates. 
This process cross-links the tropoelastin aggregates into microfibrils.  Continuous 
deposition of the microfibrils then leads to the formation of mature elastic fibers/material 
(Wu et al., 1999). Because of its superior elasticity, elastin-derived materials are widely 
used in a variety of biomedical applications, for instance, vascular grafts (McClure et al., 
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2010, Boland et al., 2004), heart valves (Schmidt et al., 2006), and skin substitutes 
(Powell et al., 1992).   
 
1.3.1.3 Collagen 
Collagen is the most abundant protein in mammals (Gloria, 2002). Collagen is the main 
extracellular protein in the connective tissue (Frantz et al., 2010).  Collagen is mostly 
found in tissues such as tendons, ligaments and skin. The collagen protein is composed of 
a triple helix formed by two identical α1-chains and an additional α2-chain.  The 
composition of α2-chain is only slightly different from the α1 chain (Antipova et al., 
2008).  Collagen protein contains a high ratio of hydroxyproline (Paul, 2001).  The most 
common motifs in the amino acid sequence of collagen are glycine-proline-X and 
glycine-X-hydroxyproline, where X is any amino acid other than glycine, proline or 
hydroxyproline. During assembly, procollagen precursor protein first forms the triple 
helix structure. Di-sulfide bonds form between each procollagen chains to stabilize the 
triple helix. The triple-helix is then exported outside the cells and undergoes cleavage by 
procollagen peptidase, to form the tropocollagen triple helices.  Tropocollagen triple 
helices then spontaneously assemble into fibrils. H-bond and extensive cross-linking 
form to stabilize the fibril structure. The fibrils then continue assemble into higher 
hierarchical structures and form the collagen fiber (Khoshnioodi et al., 2006, Kyle et al., 
2009). Collagen has a wide variety of biomedical applications. For example, Apligraf, the 
first FDA approved artificial skin, contains two types of cells-an outer layer of protective 
skin cells, and an inner layer of cells contained within collagen. This artificial skin 
mimics real skin and can be used to cover burn wounds (Zaulyanov and Kirsner, 2007).   
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1.3.2 Recombinant proteins generated in different organisms 
Organisms that produce protein-based materials can be difficult to cultivated in large 
numbers. For example, most spider species are solitary and cannot live in large 
population.   Therefore, producing enough natural material-forming proteins for industrial 
or biomedical applications has always been challenging.  The development of 
recombinant DNA technology in past decades provides a solution for this obstacle. A 
variety of material-forming proteins have been genetically cloned and produced in other 
organisms, for example, E.coli, yeast and plants (Du et al., 2008, Kyle et al., 2009, 
Pakkanen et al., 2003).   Using recombinat DNA techniques for producing material- 
forming proteins also enables the addition of desired functionalization and mechanical 
properties (Romer et al., 2007, Heim et al., 2010, Hardy et al., 2009).  By gene fusion, 
ideally, proteins with desired functions can be produced as fusion proteins with the 
material forming protein and consequenly be incorporated into the material. However, 
not every protein can be fused to the material-forming protein without affecting the 
production and assembly of the material-forming protein. This fact is further discussed in 
Chapter III.     
 
1.3.3 Engineered self-assembling proteins 
The amino acid sequence of a protein drives its folding into a unique shape. The 
chemistry and topology of the resulting surface determines whether the protein remains a 
monomer, dimer or form larger oligomers. Based on this fact, some studies were 
conducted and aimed to analyze and isolate regions that drive self-assembly from the 
naturally derived material-forming proteins, for example, silk proteins and elastin 
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proteins (Woolfson et al., 2010, Daamen et al., 2007, Gosline et al., 2002, Herrero-
Vanrell et al., 2005).  These regions, when isolated, retain the ability to self-assemble into 
materials.  In addition, these peptides can be chemically synthesized into homogenous 
product in large quantities (Lutolf et al., 2003, Deming et al., 2007), facilitating studies of 
the product materials.  The simplified sequences also facilitate sequence engineering and 
allow easier monitoring when scientists try to modify or adjust the properties of the 
materials.  Recombinant elastin-like protein (ELPs), derived from elastin, is one of the 
most studied self-assembling proteins (Li et al., 2003, Nicol et al., 1992).  ELPs are 
composed of repetitive elastin peptide sequences, for example, VPGXG and VPVGP. 
These repetitive peptides are able to self-assemble into different hierarchical structures 
and form different materials, such as fibers, sheets and films (Urry, 1993).  In silico de 
novo design of the self-assembling peptides has drawn more attention over the past 
decade (Woolfson et al., 2010). By computational simulation and chemically synthesis, 
these peptides are able to mimic the natural material-forming protein and self-assemble 
into materials with different structures (Kyle et al. 2009, Gelain et al., 2006, Galler et al., 
2008, Beniash et al., 2005).   
 
1.4 Challenges of current protein-based materials 
1.4.1 Fine-tuning the mechanical properties of protein-based materials remains 
challenging 
Protein-based materials can be used in a variety of biomedical applications, all of which 
require specific structure and mechanical properties.  Current methods to modify the 
mechanical properties of protein-based materials are mainly focused on mutating the 
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amino acids in the repetitive motifs of silk proteins (Gosline et al., 1999, Tuele et al., 
2012), elastin protein (Saumonneau et al., 2011, Miao et al., 2013) and collagen 
(Muiznieks and Keely, 2013).  However, it is difficult to make mutations in these motifs 
to gain the desired mechanical properties without dramatically affecting the overall 
structure, morphology, biocompatibility, and biodegradability. Engineering covalent 
bonds such as disulfide bond (via cysteine) or dityrosine bond (via tyrosine) into protein-
based material can potentially enhance the strength of the materials, however, current 
studies using this approach remain focusing on the repetitive motifs, the exact locations 
of the covalent bonds are unknown (Grip et al., 2009).  Therefore, placing covalent bonds 
in a non-repetitive motif or domain may provide a useful tool for fine-tuning the 
mechanical properties of protein-based materials.  In Chapter II, dityrosine bonds are 
identified in Ubx materials. The strength of these materials can be increased or decreased 
by tyrosine mutation.  
 
1.4.2 Protein-based materials are difficult to functionalize in mild conditions  
Current studies of protein-based materials, especially the functionalization of protein-
based materials, expand our creativity and imagination on a variety of useful applications 
in different fields. However, the existing common approaches to incorporate functional 
molecules into protein-based materials, including chemical cross-linking and physical 
entrapment, both have problems and therefore limit the applications of protein-based 
materials.  Chemical cross-linking requires the catalysis by chemical reagents, which 
creates toxic byproduct (Heck et al., 2013). Also, the reaction is usually performed in 
harsh conditions (low pH, extreme temperature and pressure), which are harmful for the 
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proteins, whose structures are held together by non-covalent bonds (Sperling et al., 2010).  
By physical entrapment, such as electrospinning (Khadka et al., 2012, Hardy et al., 2008), 
functional molecules and the material-forming proteins are together entrapped into 
materials (Hardy et al., 2008). However, this approach alters the mechanical properties of 
the protein-based materials, and the functional molecules may gradually diffuse out from 
the materials. The diffusion rate is dependent on the pore sizes of the materials, which 
also dictates mechanical properties of the materials. Gene fusion may provide an 
alternative solution.  By gene fusion, the desired functional protein can be produced 
simultaneously, in addition, the functional protein is automatically linked to the material-
forming proteins.  However, most current protein-based materials still require denaturing 
environment for assembly (Gomez et al., 2011), which is still harmful for the functional 
proteins. Furthermore, the appended proteins are likely to interfere the assembly of 
material-forming proteins (Scherzinger et al., 1997), therefore only small, stable and 
simple (i.e. monomeric, neutrally charged) protein or peptide can be fused to current 
protein-based materials (Jansson et al., 2014, DiMarco and Heilshorn, 2011).     
 
1.4.3 The difficulty of making a gradient of functional protein on protein-based 
materials 
When utilizing protein-based materials as scaffold to create artificial tissues/organs, it is 
important to consider the nature of the cells and the interaction between cells and 
materials.  Not all cell types are morphologically and functionally homogenous. For 
example, neuron cells need to develop polarity (Jun et al, 2009) to implement their 
functions.  A neuron receives signals from neighboring cells through its dendrites. The 
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neuron then propagates an electrical signal down to the synapse, where neurotransmitters 
are released to propagate the signal to another neuron or effector cells (Rasband and 
Matthew, 2010).  To guide the neuron stem cells to generate polarity on protein-based 
materials is challenging, because it requires a gradient or a heterogeneous distribution of 
functional molecules, such as BDNF and CTNF (Wittmer et al., 2011). By mixing 
proteins from two pumps that have different flow rate and passing the mixture through 
electrospinning apparatus, a gradient of functional molecules can be created, however, 
this method still faces the same limitation of conventional physical entrapment approach 
(Sundararaghavan and Burdick. 2011). Therefore, the development of an effective 
approach to generate a gradient of functional molecules on protein-based materials 
without sacrifice the desired mechanical properties is needed and important for next-
generation protein-based materials.    
 
1.5 Ubx material and its unique advantages as a protein-based material 
Our laboratory discovered a novel protein-based biomaterial made from the Drosophila 
protein, Ultrabithorax (Ubx).  Ultrabithorax (Ubx) protein is a transcription factor that 
regulates the development of the third thoracic and first abdominal segments of 
Drosophila (Figure 1.1) (Weatherbee et al., 1998).   Our lab has discovered that the 
Ultrabithorax (Ubx) protein rapidly self-assembles into material in mild aqueous buffers 
such as phosphate buffer saline (Greer et al., 2009). By incubating the Ubx protein in a 
Teflon coated tray or adding a Ubx protein drop on a glass slide, Ubx materials form as a 
film at the air-liquid interface and can be pulled into different morphologies such as film, 
sheet, bundle or fiber (Greer et al., 2009) (Figure 1.2). The mechanical and 
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immunological properties of the materials determine their potential applications. Ubx 
materials are strong and remarkably extensible. By varying ﬁber diameter, the 
extensibility, the force required to rupture the meaterials and the mechanism of extension 
can be altered (Huang et al., 2010).  In Chapter II, a method to alter the mechanical 
properties by changing the amino acid sequence is described. This approach allows a 
more accurate alteration of the mechanical properties and also enables engineering of he 
strength of the materials indepent of the area of their cross section. Both in vivo and in 
vitro assays showed that Ubx materials are cell compatible and not cytotoxic, suggesting 
Ubx materials can be used for biomedical applications (Patterson et al., 2013).  In 
addition, Ubx materials do no activate macrophages or elicit immune response in vivo 
(Patterson et al., 2014) (Figure 1.3).   
 
A major goal in material engineering is to functionalize the materials with bioactive 
compounds, especially, proteins. We found that when fused to Ubx protein and 
incorporated into materials, four tested appended proteins retain their function within 
Ubx material (Huang et al., 2011) (Figure 1.4). These four proteins are monomeric, 
stable, soluble, and have near neutral charge.  Finally, Ubx materials can be patterned 
during assembly to create a gradient of functional proteins, which is useful as the tissue 
engineering scaffold of cells that possess polarity (Figure 1.5). Together, these unique 
features demonstrate that Ubx material may have great potential as a novel protein-based 
material.  However, not every functional protein is likely to be incorporated into 
materials via gene fusion.  Unstable or insoluble functional proteins could hamper 
expression of the fusion protein, or large/multimeric functional proteins may mis-position 
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the self-assembling protein, altering the mechanical properties of the materials or even 
preventing materials assembly.   The impact of these properties on the assembly of Ubx 
materials is explored in Chapter III, and the activities of incorporated proteins are 
evaluated in Chapter IV and the appendix.   
     
                    
Figure 1.1 Homeobox gene expression in Drosophila melanogaster.  The dark green-
colored region in the fruit fly in this figure is the segment regulated by Ubx protein 
during morphological development.  
 
     
Figure 1.2 Ubx protein self-assembles into polymer/materials. 
Basic materials formed in a hierarchical manner by Ubx. (A) A Ubx ﬁber, 50 nm in 
diameter (arrow). (B) Ubx ﬁlm, formed from self-associating ﬁbers. (C) Ubx sheet, 
generated by continuing to allow assembly after Ubx ﬁlm has been formed. (D) A Ubx 
rope being pulled from a Ubx ﬁlm. (E,F) Ubx rope at low and high magniﬁcation, 
respectively. (G) Ubx rope, fractured by the SEM beam, splinters into 50 nm ﬁbers 
aligned along the main axis (arrow). (H) The free end of a severed rope shows a solid 
core.  (Greer et al., 2009) 
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Figure 1.3 Ubx are biocompatible and not cytotoxic. (A) Endothelial cells, pericyte 
and smooth muscle cell interact with Ubx materials well and show no toxicity (B) LDH 
release. (C) TNF-a production. (D) Nitric oxide production. In each experiment, media 
was used as a negative control and lipopolysaccharide as a positive control. Ubx 
monomer and ﬁber concentrations were 0.45 lg/mL (red bar), 4.5 lg/mL (yellow bar), and 
9 lg/mL (green bar). Lipopolysaccharides (LPS) served as a positive control, and media 
lacking any additives as a negative control. While Ubx monomers showed a positive 
response, Ubx ﬁbers did not affect macrophages.  (Patterson et al., 2013, Patterson et al., 
2014) 
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Figure 1.4 Fused protein retains function within monomeric fusion and in Ubx 
material. (A) EGFP-Ubx solution is green in color, (B) and its ﬂuorescence 
excitation/emission spectra resemble those for EGFP. (C) EGFP-Ubx ﬁbers retained the 
green ﬂuorescence and (D) exhibit near identical excitation/emission spectra to EGFP-
Ubx monomers.  (Huang et al., 2011) 
 
 
 
 
 
 
 
 
 
 
18 
 
 
Figure 1.5 Patterning of Ubx chimeric materials during materials assembly. (A) 
Schematic and (B,C) fluorescence microscopy images of faced fibers produced along the 
boundary of side-by-side arranged solutions. (D) Schematic and (E-F) fluorescence 
microscopy images of striped fibers produced across the boundary of side-by-side 
solutions. G) Schematic and (H,I) fluorescence images of spotted fi bers produced from 
prearranged protein drops. (J) Schematic and (K) photograph of a film made from EGFP-
Ubx and mCherry-Ubx chimeras. (L) Fluorescence microscopy image of a chimeric film  
containing EGFP-Ubx and mCherry-Ubx strands. All scale bars are 100 μm except for 
(K) (1 mm). (Huang et al., 2011) 
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CHAPTER II 
IDENTIFICATION OF MULTIPLE DITYROSINE BONDS IN MATERIALS 
COMPOSED OF THE DROSOPHILA PROTEIN ULTRABITHORAX* 
 
2.1 Introduction 
Protein-based materials have the potential to be customized for a variety of applications, 
including drug delivery, tissue engineering, surgical sealants, medical imaging, 
biosensors, biofabrication, and biomineralization (Baneyx and Schwartz, 2007, Deming, 
2007). However, realization of these innovations requires development of a variety of 
materials with different structural, mechanical, and functional properties (Maskarinec and 
Tirrel, 2005). For instance, macroscale materials in medical applications must be 
biodegradable (Velema and Kaplan, 2006, Grevellec et al., 2001), biocompatible 
(Rodriguez-Cabello et al., 2007, Ong et al., 2006), and have mechanical properties 
matching the tissues of interest (Chilkoti et al., 2006, Hollister et al., 2002); whereas 
materials destined for biofabrication must form rigid nanoscale three-dimensional 
structures (Lagziel-Simis et al., 2006, Gazit, 2007). The methods used to generate and 
process protein-based materials can have a substantial impact on both the mechanical and 
functional properties of the products (Huang et al., 2000, Qiu et al., 2009, Liivak et al., 
1998, Leal-Egana and Scheibel, 2010, Engler et al., 22006, Georges et al., 2007). 
 
 
 
*Reprinted with permission from “Identification of multiple dityrosine bonds in materials composed of the Drosophila 
protein Ultrabithorax” by Howell DW, Tsai SP, Churion K, Patterson J, Abbey C, Atkinson JT, Porterpan D, You YH, 
Meissner KE, Bayless KJ, Bondos SE, 2015. Advanced Functional Materials, 25, 5988-5998, Copyright 2015 by John 
Wiley & Sons. 
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Recombinant production of proteins provides a renewable supply of monomers for 
assembly whose sequences, and hence properties, can be easily engineered (Gomez, et 
al., 2012). Multiple approaches to rationally engineer or control the mechanical properties 
of materials formed from recombinant proteins have been explored, including chemical 
cross-linking, oxidation to form disulfide or dityrosine bonds, and incorporation of 
nanoparticles and metal films (Brooks et al., 2008, Grip et al., 2009, Teng et al., 2009, 
Lazaris et al., 2002, Kharlampieva, et al., 2010, Lee et al, 209, Ding et al., 2013, Souza et 
a., 2000).  
 
Of these approaches, oxidation to form disulfide or dityrosine bonds is particularly 
attractive because these bonds do not always require additional steps for materials 
synthesis. The reversibility of disulfide bonds enables materials’ strength and stability to 
be responsive to external conditions (Vaccaro and Waite, 2001, Meng et al., 2009). In 
contrast, dityrosine bonds are useful when the mechanical properties must be consistent 
in a variety of chemical environments, reflecting their inclusion in many natural and 
engineered materials, including resilin, silk, fibrinogen, keratin, elastin, and collagen 
(Nairn et al., 2008, Sando et al., 2010, Elvin et al., 2009, Chen et al., 2010, Mullerova et 
al., 1974, Qin et al., 2009, Ding et al., 2013, Fang and Li, 2012, Lin et al., 2015, 
Aparecido dos Santos‐Pinto et al., 2014). In many cases, photocrosslinking is used to 
rapidly form dityrosine bonds throughout a material (Vashi et al., 2012, Fang et al, 2013). 
Dityrosine crosslinks have also been used to drive assembly of proteins or peptides that 
would not otherwise form materials, or to covalently link multiple proteins for materials 
assembly (Fang et al, 2013). However, the specific amino acids that form these bonds in 
protein-based materials have not been identified, information that is vital for engineering 
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the sequence to control bond formation, and hence the structure and mechanical 
properties of the resulting materials. Although in some materials, dityrosine bonds have 
been attributed to a single tyrosine residue in a repeated motif (Elvin et al., 2015, 
Waffenschmidt et al., 1993), each tyrosine motif is equally likely to participate in 
dityrosine bonds, resulting in monomer-to-monomer variation in the location of these 
bonds that would further complicate bond identification and sequence engineering. 
 
In this study, we investigated the formation of dityrosine bonds in materials composed of 
Ultrabithorax (Ubx), a recombinant Drosophila melanogaster Hox transcription factor. In 
vitro, Ubx monomers coalesce in aqueous buffers near neutral pH to form globular 
aggregates, which further rearrange at the air-water interface to form nanoscale fibrils 
(Majithia et al., 2011). Fibrils associate laterally to generate macroscopic films, which are 
the building blocks for various macroscale Ubx architectures such as fibers, sheets, and 
bundles (Greer et al, 2009). Ubx materials have many useful properties, including 
cytocompatibility, biocompatibility, and nonimmunogenicity (Patterson et al., 2014, 
Patterson et al., 2015). Ubx materials can be functionalized i) with full-length proteins via 
gene fusion (Huang et al., 2011, Tsai et al., 2015), ii) with DNA by sequence-specific 
recognition (Churion et al.), and iii) with nanoparticles by non-covalent surface 
interactions (Majithia et al., 2011). Finally, Ubx materials are strong and remarkably 
extensible (Huang et al., 2010).  
 
Ubx contains 15 tyrosines that are embedded in distinct regions of the amino acid 
sequence (Figure 2.1A). Therefore, Ubx has the potential to form unique, and thus 
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identifiable, dityrosine bonds in materials. In this study, we demonstrate that Ubx 
materials oxidize to form three dityrosine bonds, two of which are mutally exclusive, and 
we identify the participating tyrosine residues. In fibers pre-assembled in the absence of 
oxygen, exposure to oxygen rapidly triggers dityrosine formation, with biphasic bond 
formation kinetics. Because all Ubx monomers within the materials do not form both 
possible bonds, the dityrosine content can be increased by removing competing 
interactions. Dityrosine content directly correlates with the strength of the materials, 
suggesting these bonds are intermolecular and providing a mechanism to genetically tune 
the mechanical properties of the materials. These data illuminate the role of tyrosine 
residues in the formation and structure of Ubx materials, provide vital information for 
engineering the mechanical properties of Ubx fibers, and suggest approaches to insert 
specific dityrosine bonds into the sequence of other materials-forming proteins. 
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Figure 2.1 Location and functionality of Ubx tyrosine mutants. (A) Sequence 
schematic of Ubx, showing the location of tyrosine residues relative to functional 
domains and structural motifs. (B) ANCHOR schematic showing areas of disorder in 
Ubx. (C) Light microscopy of overlapping fibers shows that they are transparent and can 
diffract light. (D) The three tyrosines in the Ubx homeodomain all lie on the surface of 
the domain (pdb: 1B8I) (Passner et al., 1999). (E) Tyrosines 4 and 12 are not buried 
within this portion of Ubx. (F) DNA binding data showing that the homeodomain 
remains functional in tyrosine mutants. 
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2.2 Materials and methods 
2.2.1 Production of Ubx materials  
Protocols were used as established in the Bondos lab for expression, purification, and 
assembly of Ubx and Ubx fusion proteins into materials (Huang et al., 2011, Tsai et al., 
2015). In brief, the ubx gene, cloned into pET-19b vector, was transformed into Rosetta 
(DE3) pLysS cells (Novagen). Single colonies were used to inoculate overnight liquid 
cultures. Protein expression was induced at mid-log phase with 1 mM IPTG for 4 hrs and 
cells were harvested by centrifugation and stored at -20 ⁰C. Frozen cell pellets were lysed 
and cell debris was removed by centrifugation for 30 min at 35,000 x g (17,000 rpm by 
JA25.5 rotor). Ubx protein was purified from the clarified cell lysate by Ni-NTA 
chromatography and, as previously described, fibers were pulled from films produced in 
a “buffer reservoir” (Huang et al., 2011) using a buffer containing 50 mM sodium 
phosphate buffer, 500 mM NaCl, 5% glucose w/v, pH 8.0. Fibers were wrapped around a 
5 mm sterile plastic inoculation loop and stored in a sterile tissue culture dish until use.  
 
2.2.2 Measuring fluorescent intensity in Ubx materials  
The fluorescent intensity of both the auto-fluorescent and dityrosine antibody signal 
(N=2, sample=15, replicates=45) were measured using identical DAPI and FITC settings 
on the microscope and analyzed using Nikon Elements Imaging Software normalized to 
fiber width, which averaged approximately 15 µm. Z-stack images were captured using a 
40X objective with a field depth of 1.1 µm and step sizes of 0.25 µm. Data in figures are 
displayed as average intensities +/- the standard deviation. 
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Quantitative measurement of dityrosine content based on fluorescence intensity requires 
tyrosine content to be the only variable.  Since removal of specific tyrosine residues also 
prevents Ubx materials from being fluorescent, then there is clearly no other source of 
fluorescence that could interfere with our measurements.   Since the materials can vary in 
size, the fluorescence intensity was always normalized to fiber diameter.  This precaution 
allows us to quantitatively measure fluorescence, as previously demonstrated in 
measuring incorporation of different concentrations of Enhanced Green Fluorescent 
Protein-Ubx into Ubx materials (Tsai et al.,). Since the fluorescence intensity of the 
dityrosine signal is directly proportional to the fluorescence intensity of signal from anti-
dityrosine antibodies (Figure 2.2), fluorescence intensity is a quantitative measure of 
dityrosine content. 
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Figure 2.2 A comparison of auto fluorescence and immunohistochemistry using 
antidityrosine antibodies for fibers composed of selected Ubx mutants. Scale bar 
equals 30mm. (B) The auto-fluorescent intensity divided by fiber width corresponds to 
reactivity with dityrosine antibodies using immunohistochemistry. 
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2.2.3 Immunofluorescence  
Ubx fibers wrapped around inoculation loops were allowed to dry at room temperature on 
the lab bench for 2 hrs. Loops were placed in sterile 4 well cell culture plates and 
incubated in 250 µL of blocking solution (0.1% Triton X-100, 1% BSA, 0.2% sodium 
azide, and 5% goat serum in PBS) at room temperature for 1 hr. Primary antibodies 
raised against dityrosine (Genox) were diluted 1:500 in blocking solution and incubated 
with Ubx fibers for 1 hr. After two washes for 10 min each in 0.1% Triton X-100 in PBS 
(250 µL), loops were incubated with goat anti-rabbit Alexa 488 conjugated secondary 
antibodies (Molecular Probes, diluted 1:300 in blocking solution) for 1 hr. Loops were 
washed twice (10 min per wash) in 0.1% Triton X-100 in PBS (250 µL), placed on a 22 
mm x 55 mm coverslip, and imaged immediately using a 40X objective Nikon Eclipse Ti 
A1R inverted confocal microscope equipped with NIS Elements AR 4.10.01 software to 
analyze fluorescent intensity. 
 
2.2.4 Measurement of absorption/emission spectra 
A Ubx fiber was dissolved in commercially available 10 mM PBS buffer solution. The 
dispersed Ubx solution was transferred into a four sided quartz cuvette for the 
photoluminescence measurement. Steady state emission spectra were recorded using a 
QuantaMaster 40 spectrofluorometer (Photon Technology International, Canada). Light 
from the excitation source, a Xenon arc lamp, was dispersed by a 1200 line/mm grating 
blazed at 500 nm and focused on the sample. A 380 nm long-pass filter was placed in the 
emission path to remove excitation light. The Ubx solution was excited at 325 nm. 
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Emission was collected for 0.1 sec at each data point from 300 to 700 nm in steps of 1 
nm.   
 
2.2.5 Fiber assembly and imaging in low oxygen atmosphere 
Ubx protein was purified as previously described; however, Ubx monomers were 
assembled into films and drawn into fibers in an argon-atmosphere glovebox (MBraun 
Labmaster, ~ 2 ppm O2). Fibers were placed in a custom sealed imaging chamber (Figure 
2.3) filled with N2 gas to capture any O2-independent auto-fluorescence. Ubx fibers were 
subsequently exposed to O2 by removing the flow of N2 gas and pushing room air into the 
chamber using a 50 mL syringe. The blue auto-fluorescence resulting from oxidation of 
Ubx fibers was analyzed over time using a Nikon Eclipse Ti A1R inverted confocal 
microscope equipped with NIS Elements AR 4.10.01 software. 
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Figure 2.3 Custom imaging chamber with a coverslip bottom and removable screw 
cap with viewing window. 
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2.2.6 Mutagenesis of tyrosine 
Tyrosines in the Ubx homeodomain region were mutated to leucine or serine using 
AccuPrime Pfx PCR kit (Invitrogen). (Figure 2.4) Primers (Table 2.1) for each mutation 
were designed using the OligoCalc (northwestern.edu/biotools/oligocalc) and mfold web 
servers (http://mfold.rna.albany.edu/?q=mfold). Mutated plasmids were transformed into 
DH5α competent cells (Zymo Research) and plated on LB agar with 50 µg/mL 
carbenicillin overnight at 37 ºC. Colonies were selected and grown in 5 ml cultures of LB 
for plasmid purification using QIAprep miniprep (Qiagen) kit. Plasmids were sequenced 
to confirm each mutation prior to use. Ubx mutants were expressed in E. coli and purified 
as described above for the wild-type protein.  
 
 
Figure 2.4 General setup for site-directed mutagenesis reaction. 
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Table 2.1 DNA primers used for mutagenesis. 
Mutation Primer Sequence 
Y4S 
FWD: 5'- CATATGAACTCGTCCTTTGAACAGGCC-3'  
REV: 5'- GGCCTGTTCAAAGGACGAGTTCATATG -3' 
Y12S 
FWD: 5’- GCCTCCGGCTTTTCTGGCCATCCGCAC -3’  
REV: 5’- GTGCGGATGGCCAGAAAAGCCGGAGGC-3’ 
Y52S 
FWD: 5’- GGCATGAGTCCCTCTGCCAACCACCATC-3’ 
REV: 5’- GATGGTGGTTGGCAGAGGGACTCATGCC -3’ 
Y85S 
FWD: 5'- GGAGCCGGAGCCTCCAAACAGGACTGC-3' 
REV: 5'- GCAGTCCTGTTTGGAGGCTCCGGCTCC-3' 
Y100S 
FWD: 5'- CGGTGAATGGCTCCAAAGACATTTGGAAC-3'  
REV: 5'- GTTCCAAATGTCTTTGGAGCCATTCACCG-3' 
Y167S 
FWD: 5’- GAGTGGGCGGCTCCTTGGACACGTC-3’  
REV: 5’- GACGTGTCCAAGGAGCCGCCCACTC-3’ 
Y240S 
FWD: 5'- CAATCACACATTCTCCCCCTGGATGG -3' 
REV: 5'- CCATCCAGGGGGAGAATGTGTGATTG-3' 
Y293L 
FWD: 5'- GGCCGACAGACATTAACCCGCTACCAG-3'  
REV: 5'- CTGGTAGCGGGTTAATGTCTGTCGGCC-3' 
Y296L 
FWD: 5’-ACATACACCCGCTTACAGACGCTCGAG-3’ 
REV: 5’- CTCGAGCGTCTGTAAGCGGGTGTATGT-3’ 
Y310L 
FWD: 5’- CACACGAATCATTTGCTGACCCGCAGA-3’ 
REV: 5’- TCTGCGGGTCAGCAAATGATTCGTGTG-3’ 
Y293S/ Y296S 
FWD: 5'-
GGCCGACAGACATCCACCCGCTCCCAGACGCTCGAG-3' 
REV: 5'-
CTCGAGCGTCTGGGAGCGGGTGGATGTCTGTCGGCC-3' 
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2.2.7 DNA binding assay 
 Ubx materials were produced using the drop method and DNA binding was measured as 
previously described (Churion et al.). Ubx was diluted in 250 μl of a solution containing 
50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, 10 mM β-mercaptoethanol, 5% glucose, and 
200 mM imidazole, for a final protein concentration of 3 - 6 μM depending on the 
purification yield. Protein was carefully pipetted onto the surface of a siliconized glass 
slide, and covered with a screw cap from a 50 mL conical centrifuge tube (VWR 
International) and the slides were covered to prevent evaporation. After a 16 hr 
incubation at room temperature and humidity, a film, formed at the air-water interface, 
and was drawn into fibers using a sterile inoculating loop. Fibers were subsequently 
washed three times in PBS buffer and dried for 1-2 hrs at room temperature. The DNA 
stock was diluted to a final concentration of 10 μg/mL in phosphate buffered saline. Fiber 
loops were then placed in a well (24 well culture plate); subsequently, 200 μL of the 
diluted DNA was pipetted in each well and allowed to incubate at room temperature 
(parafilm wrapped) overnight. Fibers were washed three times in PBS buffer (3-5 
minutes each) to remove excess DNA from the fiber. The Ubx fiber was removed from 
the inoculating loop with micro-scissors and transferred to a PCR tube containing the  
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following components: 1x PCR ThermoPol buffer (NEB), 50 μM each of dATP, dCTP, 
dGTP, dTTP, 0.5 μM of each primer, and 1 unit of Taq DNA polymerase (NEB) in a 50 
μl reaction. The PCR reaction products were analyzed by electrophoresis through a 2% 
agarose gel, which was stained with ethidium bromide and visualized using a UV light 
source. 
 
2.2.8 Fiber length measurements 
 Ubx protein was diluted to 1 mg in 590 mL of buffer in a shallow Teflon-coated tray 
(Nordic Ware), covered to prevent surface disruptions, and incubated 18 hrs at room 
temperature (approximately 25 ⁰C) and 40 - 60% humidity. To measure changes in fiber 
production, which depends on both fiber assembly and fiber strength, the length of fibers 
drawn from the resulting films were measured. A minimum of eight measurements, 
produced from a minimum of two purifications, were made for each Ubx variant. 
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2.3 Results and discussion 
2.3.1. Ubx fibers are not amyloid 
Elucidating the structure of protein-based materials is the first step toward understanding, 
and ultimately manipulating the mechanical properties of these materials. In contrast to 
amorphous protein aggregates which often appear as white flocculates, Ubx materials are 
transparent (Figure 2.1C) and can diffract light (Majithia et al., 2011), suggesting a more 
regular structure. Since Ubx does not form materials as part of its natural function, one 
possibility is that Ubx fibers are amyloid, thus accounting for their transparency and 
strength (Knowles and Buehler, 2011). However, X-ray diffraction and Thioflavin T 
binding studies of Ubx materials lack any indications of amyloid structure (data not 
shown). Furthermore, a large fraction of Ubx is extremely glycine-rich (Liu et al., 2008), 
and thus unlikely to form amyloid. The major structured region of Ubx is its DNA 
binding homeodomain, whose function is retained in the materials (Figure 2.1 A, D) 
(Churion et al.). Therefore, the helical structure of the homeodomain is likely intact as 
well. If both the unstructured and the structured regions of Ubx are unlikely to form 
amyloid, then amyloid structure cannot be responsible for the strength of Ubx materials. 
 
2.3.2 Ubx materials contain dityrosine 
Intermolecular covalent cross-links could also account for the strength of Ubx materials. 
Many natural macroscale materials rely on covalent crosslinks for strength (Elvin et al., 
2009, Endrizzi et al., 2006, Kelley, 1968), and engineering covalent bonds into 
recombinant protein materials can dramatically improve both strength and assembly 
(Fang and Li, 2012). During fluorescent microscopy experiments, we observed that Ubx 
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materials autofluoresce when excited at 305 nanometers (nm) (Figure 2.5A). The 
fluorescence emission spectrum (Figure 2.5B) corresponds with dityrosine, formed by 
oxidation of two tyrosine residues (Endrizzi et al., 2006, Marquez and Dunford, 1995, 
Aeschbach et al., 1976). The emission maximum of dityrosine typically ranges from 410 
nm to 430 nm (Aeschbach et al., 1976, Harms, et al., 1997). For Ubx fibers, the emission 
peak is more red-shifted (438 nm). This difference may be due to proximity of the 
dityrosine bonds to positively charged amino acids, which can red-shift the emission 
spectra of aromatic amino acids by tens of nanometers (Vivian and Callis, 2001). Ubx has 
a predicted net charge of +9, and the Ubx homeodomain, which contains 3 tyrosines, has 
a predicted net charge of +11 (Figure 2.5D) (Majithia et al., 2009, Tsai et al., 2015). Anti-
dityrosine antibodies specifically recognize Ubx fibers in immunohistochemistry 
experiments, thus confirming the presence of dityrosine in Ubx materials (Figure 2.5C). 
The secondary antibodies alone are unable to bind fibers in the absence of primary 
antibodies (Figure 2.5D), demonstrating the specificity of the interaction. Together, the 
fluorescence and immunohistochemistry data demonstrate that dityrosine is present in 
Ubx fibers.  
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Figure 2.5 Ubx materials contain dityrosine. (A) Fibers autofluoresce blue. (B) The 
Ubx emission spectrum, with a peak at 438 nm when excited at 305 nm is similar to other 
dityrosine containing proteins. (C) Immunofluorescence of Ubx fiber demonstrating anti-
dityrosine primary antibodies recognize a Ubx fiber. (D) A negative control experiment 
with the primary antibody omitted demonstrates that secondary antibodies do not adhere 
non-specificially to Ubx fibers. Scale bar equals 30 µm in all panels. 
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2.3.3 Measuring the kinetics of dityrosine bond formation 
Because tyrosine must oxidize to form dityrosine bonds, the kinetics of dityrosine bond 
formation can be monitored by assembling Ubx in a low oxygen environment and then 
exposing the resulting fibers to oxygen. To this end, Ubx was allowed to assemble in an 
argon-atmosphere glovebox. Because films could be assembled and fibers could be 
drawn from films in this low oxygen environment, dityrosine bond formation is clearly 
not required for Ubx assembly. However, it is worth noting that these fibers were quite 
fragile and very difficult to handle. 
 
Fibers were placed in a custom imaging chamber (Figure 2.3) under nitrogen gas flow to 
maintain a low oxygen environment during transfer of the chamber from the glove box to 
a microscope. Cover slips on the top and bottom of the chamber allowed fibers inside the 
chamber to be analyzed by fluorescence microscopy. In a nitrogen environment, the blue 
dityrosine signal was nearly undetectable (Figure 2.6A). However, once the nitrogen gas 
in the chamber was replaced with air, the fibers gradually began to fluoresce blue (Figure 
2.6B). Measurement of fluorescent intensity over time reveals two distinct transitions 
(Figure 2.6C): a fast initial transition followed by a slow transition.  
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Figure 2.6 The kinetics of dityrosine bond formation reveals two transitions. (A) A 
fluorescent miscroscopy image of a Ubx fiber pulled and imaged in low oxygen 
environment N2 compared to a fiber pulled in normal atmosphere (control). (B) Time-
lapse images of a fiber pulled in low O2 after exposure to normal atmosphere. (C) Graph 
of fluorescent intensity of the fiber shown in panel B over time showing 2 distinct 
transitions caused by dityrosine bond formation. Scale bar equals 30 µm in all panels. 
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2.3.4 Mutagenesis strategy 
The presence of dityrosine provides an opportunity to manipulate the properties of Ubx 
materials by controlling dityrosine bond formation. To do so, the number of dityrosine 
bonds formed and the identity of the tyrosine residues that participate in these bonds must 
be determined. Because Ubx is produced as a recombinant protein in E. coli, we were 
able to use site-directed mutagenesis to identify participating tyrosines. This approach 
would be challenging to apply to many natural proteins that form materials. Because the 
amino acid sequence surrounding tyrosine residues impacts dityrosine bond formation 
(Harms et al., 1997), tyrosines located in repeating motifs in natural materials should 
have equal probabilities of participating in a dityrosine bond (Elvin et al., 2015, 
Waffenschmidt et al., 1993). In contrast, the unique sequences surrounding tyrosines in 
Ubx should lead to preferential interactions between specific tyrosines and thus 
consistent formation of the same dityrosine bonds. Furthermore, Ubx monomers rely on 
specific, long-range intramolecular interactions to regulate DNA binding (Liu et al., 
2009). These interactions involve regions of the protein containing tyrosine.  Therefore, 
any intermolecular dityrosine bonds based on these interactions should form between 
specific residues.    
 
A complication of the site-directed mutagenesis approach stems from the fact that Ubx 
has 15 tyrosine residues. The identity of tyrosines contributing to a single bond may vary, 
and more than one dityrosine bond may be present in the materials, creating an enormous 
array of possible bond arrangements. We narrowed our initial search based on 
interactions formed by Ubx monomers in DNA binding. When bound to DNA, Ubx can 
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oligomerize in multiple orientations: side-to-side cooperative interactions when binding 
to linear DNA, and back-to-back interactions between clusters of cooperatively bound 
Ubx proteins to form the stem of a DNA loop (Beachy et al., 1993). Because Ubx fibers 
retain the ability to bind DNA (Figure 2.1F), it is possible that interactions used on a 
small scale to enable cooperative DNA binding and DNA loop formation in vivo may 
also be applied on a much larger scale to form Ubx materials in vitro: side-to-side 
interactions to form nanoscale fibrils, and back-to-back interactions to allow the fibrils to 
interact to form films and fibers. Therefore, our first criterion for selecting tyrosines for 
mutagenesis was that the tyrosine should be located in a region important for regulating 
DNA binding (Liu et al., 2009). Extending this logic, any tyrosine important for DNA 
binding is also expected to be evolutionarily conserved (Figure 2.1B), our second 
criterion. Next, for specific dityrosine bonds to form, the tyrosines would need to be 
embedded in regions of Ubx likely to participate in protein-protein interactions. The 
location of molecular recognition features, motifs capable of engaging in protein 
interactions, was predicted by the ANCHOR algorithm (Figure 2.1B) (Dosztanyi et al., 
2008, Meszaros et al., 2009). It is important to note that this algorithm only identifies 
motifs located in intrinsically disordered regions; thus, it cannot provide information 
about the structured homeodomain. Finally, as demonstrated by the fragility of fibers 
drawn in a low-oxygen environment, dityrosine bonds significantly strengthen Ubx 
materials. Because fiber strength is one factor that determines the length of fibers that can 
be drawn from film, we reasoned that tyrosine residues, lost through truncation of the 
Ubx sequence, would shorten the average length of fibers produced by that Ubx variant. 
Fiber lengths were previously measured for a series of Ubx N-terminal and C-terminal 
 
 
41 
 
truncation mutants (Greer et al., 2009). This data provided the fourth criterion for 
selecting tyrosines for mutagenesis.  
The ability of each of the 15 tyrosines in Ubx to meet these criteria is summarized in 
Table 2.2 Based on the logic described above, we hypothesized that tyrosines 4, 12, 100, 
167, and 240 were most likely to be involved in dityrosine bonds. The three tyrosines on 
the surface of the homeodomain (HD) (293, 296, and 310; Figure 2.1A, D) were also 
selected because the homeodomain participates in long-range interactions with much of 
the rest of the protein (Liu et al., 2009), and because the dityrosine spectrum is red-
shifted. Conversely, tyrosines 40, 52, 66, 78, 85, 265, and 276 were deemed less likely 
candidates. The goal of our mutagenesis study was to remove the ability to form 
crosslinks, while retaining as much of the chemical nature of tyrosine as possible to 
prevent mutagenesis-induced structural rearrangements. Tyrosines in intrinsically 
disordered regions outside the homeodomain were mutated to serine, because the transfer 
coefficient of serine best mimics that of tyrosine as a free amino acid, leading to their 
similar values on the Kyte-Doolittle hydropathy scale (Kyte and Doolittle et al., 1982). 
Tyrosines within the homeodomain were mutated to leucine, because leucine most 
closely resembles the hydropathy of tyrosine on the surface of a protein (Pace et al., 
2014). These mutations do not alter the structure or function of the homeodomain, 
because fibers composed of homeodomain mutants can successfully bind DNA (Figure 
2.1F). To confirm that hydrophobic patches created by the tyrosine to leucine mutants on 
the homeodomain surface were not causing a loss of fluorescence due to altered 
interactions with the rest of the protein, we also changed these three residues to serine. 
All Ubx variants carrying mutations in the homeodomain were able to form fibers, these 
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fibers all bound DNA (Figure 2.1F), and circular dichroism spectra of materials 
composed of wild-type Ubx and these mutants are similar (Figure 2.7), indicating the 
structure of the fibers was not significantly perturbed. Furthermore, for each position, the 
serine and leucine mutations had a similar impact on dityrosine fluorescence (Figure 2.8). 
Therefore, leucine mutations do not cause unanticipated effects on the structure of Ubx 
materials. 
 
Table 2.2 Criteria used to select tyrosines for mutagenesis studies. 
Tyrosine Regulating DNA 
bindinga 
Sequence 
conservationb 
Anchorc Fiber 
lengthd 
Selected? 
4 Yes Yes Yes Yes Yes 
12 Yes Yes No Yes Yes 
40 Yes Yes Yes No No 
52 No No No No No 
66 No Yes No No No 
78 No Yes No No No 
85 No No No No No 
100 Yes Yes Yes Yes Yes 
167 Yes No Yes Yes Yes 
240 Yes Yes Yes N/A Yes 
265 Yes No No N/A No 
276 Yes No No N/A No 
293 Homeodomain Yes N/A No Yes 
296 Homeodomain Yes N/A No Yes 
310 Homeodomain Yes N/A No Yes 
aBased on data published by Liu et al. 2009 
bBased on the sequence alignment established by Liu et al. 2009 
cThe results of the Anchor prediction algorithm are shown in Figure 2.4B. 
dThe length of fibers produced by N- and C-terminal Ubx truncation mutants was 
previously reported (Greer et al., 2009). 
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Figure 2.7 Circular dichroism of films composed of wild-type and mutant Ubx.  
Because the ellipticity depended both on the concentration of the sample in the beam, 
which we could not measure, and the dryness of the sample, which caused scattering, all 
data was normalized by setting the ellipticity at 200 nm to 0, and the minimum ellipticity 
to -1.0.  This normalization allows comparison of the shape of the curves. (A) CD spectra 
for three wild-type Ubx films.  The film corresponding to the light gray spectrum was 
thinner than the other films. (B) CD spectra for two films composed of the Y293L/Y296L 
double mutant.  (C)  A CD spectrum of a Y167S/Y240S Ubx film. (D) Average spectra 
for wild-type (black) and Y293L/Y296L (red) films superimposed on the Y167S/Y240S 
spectrum reveals little difference in the shape of the curves.  In particular, the relative 
ellipticity at 208 nm and 22 nm is similar for these samples, suggesting a similar content 
of -helices and -sheets or -turns in wild-type and mutant films. 
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Figure 2.8 Immunofluorescence of fibers composed of selected Ubx mutant proteins. 
Scale bar equals 30 µm in all panels. (B) Graph of fluorescent intensity showing 
significant (p < 0.01 indicated by *) decrease in both L and S mutants relative to wild-
type Ubx. (C) DNA binding assay comparing S and L mutation of Y293 and Y296.  
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2.3.5 Tyrosines that regulate DNA binding in Ubx monomers also participate in 
dityrosine bonds in Ubx fibers 
To find tyrosines involved in dityrosine bonds, we tested whether single mutations of the 
selected tyrosines reduce Ubx fiber fluorescence. Of these eight mutants, the fluorescent 
intensities from Y12S, Y167S, Y240S, and Y296L mutants significantly decrease while 
the intensities from Y100S and Y310L mutants increase when compared to wild-type 
Ubx fiber fluorescence (Figure 2.9A; p ≤ 0.01 indicated by *). The intensity of blue 
fluorescence corresponds very well with the fluorescent intensity from immunostaining 
using the anti-dityrosine primary antibody (Figure 2.10, r2 = 0.99), confirming that 
changes in fiber fluorescence directly correspond to alterations in dityrosine content. The 
Y167S and Y240S mutations both reduce the fluorescent intensity to a similar degree, 
suggesting that Y167 and Y240 participate in the same dityrosine bond.  
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Figure 2.9 Graph of fluorescent intensity divided by fiber width. (A) Single mutations 
of the 8 tyrosines predicted to be involved show that only Y12S, Y167S, Y240S, Y296L, 
and Y310L show a significant difference (p≤0.01 indicated by *) in fluorescent intensity 
when compared to Ubx. (B) Comparison of mutants containing Y240S shows that Y240 
binds Y167. Comparisons to Ubx are indicated by * (p=0.005) and to Y240 indicated by 
# (p=0.04) using t-tests. (C) Comparison of mutants containing combinations of N-
terminal (Y4 and Y12), Y100, and homeodomain mutants. (D) A closer examination of 
N-terminal mutants with all three homeodomain mutants. 
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To test this hypothesis, we created a Y167S + Y240S double mutant. If these residues 
participate in different dityrosine bonds, the loss of fluorescent intensity should be 
additive. If Y167 and Y240 contribute to the same bond, then removing the second 
tyrosine should not cause an additional reduction in fluorescence. No further reduction in 
fluorescence was observed for the Y167S + Y240S double mutant (Figure 2.10B, 2.11, 
Table 2.3), suggesting that Y167 and Y240 form a single dityrosine bond (Figure 2.12). 
This assignment is supported by the fact that double mutants combining Y240S with 
other affected tyrosines (for instance, Y12S + Y240S and Y240S + Y296L) all fluoresce 
less than the isolated Y240S mutant, indicating that Y12 and Y296 participate in a 
different bond than Y240 (Figure 2.9B; p ≤ 0.04 indicated by #). The Y167S + Y240S 
bond is responsible for a significant portion of the observed fluorescence in Ubx fibers 
(200/360 fluorescence units/m). Finally, fibers composed of the Y293 mutant fluoresce 
to a similar extent as wild-type Ubx fibers. The fluorescent intensity of the Y240S + 
Y293L mutant fibers is similar to that of Y240S mutant fibers. Thus the Y240 mutant 
does not uncover any hidden contributions of Y293 to the Y167 + Y240 dityrosine bond. 
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Figure 2.10 More than one bonds in Ubx materials. (A) The mutants Y4S + Y12S + 
Y240S, Y240S + Y296L, Y100S + Y240S + Y296L, and Y293L + Y296L + Y310L all 
show a loss of 250 fluorescent units per μm when compared to Ubx suggesting a loss of 
more than one tyrosine bond (p=0.005 indicated by *). (B) Mutation of tyrosines Y52 and 
Y85 which were not predicted to be involved in dityrosine bonds has no effect, either in 
wild-type Ubx or in the Y296 background. 
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Figure 2.11 Autofluorescence of all mutants. (A) Y12S + Y240S, (B) Y240S + Y296L, 
(C) Y293L + Y296L + Y310L, (D) Y4S + Y12S + Y240L, (E) Y100S + Y240S + 
Y296L, (F) Y12S + Y296L, (G) Y293L + Y296L, (H) Y240S + Y310L, (I) Y4S + Y12S, 
(J) Y240S + Y293L, (K) Y4S + Y293L, (L) Y240S, (M) Y100S + Y296L, (N) Y167S, 
(O) Y167S + Y240S, (P) Y4S + Y296L, (Q) Y12S, ®  Y12S + Y293L, (S) Y100S + 
Y293L, (T) Y52S + Y296L, (U) Y85S + Y296L, (V) Y296L, (W) Y100S + Y310L, (X) 
Y293L, (Y) Y52S, (Z) Y4S, (AA) Ubx, (BB) Y83S, (CC) Y100S, (DD) Y310L, (EE) 
Y293L + Y310L, (FF) Y296L + Y310L. 
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Table 2.3 Fluorescence and physical parameter data for fibers composed of wild-type 
and mutant Ubx, arranged by increasing fluorescence. 
 
ID Mutant 
DAPI 
Fluorescence 
DAPI SE of 
the Mean 
Avg. 
Width 
Width SE 
of the 
Mean 
Avg. 
Pull 
Length 
Pull Length 
SE of the 
Mean 
A Y12S + Y240S 71 9 11.6 0.67 1.3 0.2 
B Y240S + Y296L 94 9 12.9 0.54 1.6 0.2 
C Y293L + Y296L + Y310L 103 7 13.5 0.65 1.7 0.4 
D Y4S + Y12S + Y240L 110 4 10.1 0.08 1.6 0.5 
E Y100S + Y240S + Y296L 112 10 15.7 0.36 1.8 0.1 
F Y12S + Y296L 119 4 9.7 0.18 1.9 0.3 
G Y293L + Y296L 119 5 13.8 0.38 1.9 0.2 
H Y240S + Y310L 138 4 10.4 1.28 2.0 0.2 
I Y4S + Y12S 150 5 10.3 0.23 2.0 0.2 
J Y240S + Y293L 152 12 9.4 1.19 2.3 0.5 
K Y4S + Y293L 154 4 8.8 0.18 2.1 0.1 
L Y240S 157 4 7.5 0.12 2.2 0.2 
M Y100S + Y296L 158 8 10.9 1.54 2.3 0.4 
N Y167S 160 2 13.1 1.18 2.2 0.2 
O Y167S + Y240S 175 10 11.3 1.28 2.3 0.2 
P Y4S + Y296L 236 16 7.2 0.43 3.2 0.1 
Q Y12S 264 9 7.4 0.18 3.4 0.2 
R Y12S + Y293L 293 25 6.6 0.30 3.7 0.6 
S Y100S + Y293L 297 8 8.5 0.11 3.7 0.2 
T Y52S + Y296L 319 7 7.2 0.06 3.7 0.2 
U Y85S + Y296L 322 9 7.3 0.07 3.8 0.4 
V Y296L 323 6 8.6 0.08 3.8 0.5 
W Y100S + Y310L 335 11 6.6 0.63 4.0 0.6 
X Y293L 352 25 7.6 0.05 4.1 0.7 
Y Y52S 353 8 7.0 0.16 4.1 0.5 
Z Y4S 358 9 8.2 0.12 4.1 0.4 
AA Ubx 359 4 6.9 0.04 4.0 0.7 
BB Y85S 360 8 6.9 0.26 4.5 0.2 
CC Y100S 398 5 5.9 0.15 4.4 0.3 
DD Y310L 409 5 5.2 0.06 4.6 0.5 
EE Y293L + Y310L 411 15 6.0 0.04 4.7 0.5 
FF Y296L + Y310L 423 2 7.2 0.04 4.6 0.5 
 
 
 
 
51 
 
 
 
Figure 2.12 Graph of mutants from smallest to largest fluorescent intensity. (A) 
Normalized to fiber width (black bars) and fiber length (grey bars). (B) Scatter plot of 
fluorescent intensity compared to fiber length using linear regression with a coefficient of 
determination of 0.994. 
 
Since all of the fluorescence cannot be attributed to the Y167/Y240 bond, at least one 
other bond is present. This additional bond(s) contributes less to the total fluorescence, 
indicating every monomer in the materials does not participate in this bond or bonds. 
This hypothesis is confirmed by the fact that Y12S and Y296L mutations decrease 
fluorescence while Y310L increases the fluorescence when compared to wild-type Ubx 
(Figure 2.9A). The impact of mutagenesis varies between these three residues; therefore, 
either i) there are multiple additional bonds, ii) there is one bond, but tyrosines that do not 
engage in the bond contribute to a chemical environment that regulates bond formation, 
iii) there is one bond formed by different tyrosine residues in different monomers, or iv) 
some combination of these possibilities. 
 
Mutation of tyrosines 12, 296, and 310 also alter fiber fluorescence. These residues are 
located in two regions of Ubx: the N-terminus and the homeodomain, suggesting a 
dityrosine bond may form between these two regions. Indeed, the sequence conservation 
of both the N-terminus and the homeodomain in Hox proteins (Tour et al., 2005) suggests 
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these regions may interact. Furthermore, the N-terminus has a large impact on the DNA-
binding affinity of the homeodomain. Finally, the ANCHOR algorithm identifies the N-
terminus as a region likely to engage in protein interactions. 
 
Any bond or bonds between the N-terminus and the homeodomain could also involve 
two other tyrosines: Y4 and Y293. For any of these tyrosines to participate in dityrosine 
bond formation, they must be exposed to the solvent. X-ray crystallography data of the 
Ubx homeodomain (Passner et al., 1999) reveals Y293, Y296, and Y310 are all located 
on the homeodomain surface (Figure 2.1D). Likewise, a model of the structure of the N-
terminus suggests both Y4 and Y12 are also solvent exposed (Figure 2.1E). Although any 
of these surfaces could potentially pack against other regions of Ubx, the extreme 
flexibility of the intervening intrinsically disordered regions suggests that these residues 
are likely to be occasionally exposed. 
 
To determine which, if any, of these residues participate in dityrosine bond formation, we 
created a series of double and triple mutants involving these five amino acids. First, we 
assessed the role of the three tyrosines on the surface of the homeodomain (Y293, Y296, 
Y310). We have already established that the Y296L and Y310L mutants alter 
fluorescence (Figure 2.9A). In addition, we find that the Y293L mutation, when 
combined with Y296L, causes an additional loss of fluorescence (Figure 2.9C, 2.11). The 
difference in fluorescence between wild type fibers and Y293L + Y296L fibers is similar 
to the difference between Y240 and wild type fibers, and thus is equivalent to the loss of 
one bond. This suggests that either Y293 or Y296 can contribute one tyrosine to a single 
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bond. This interpretation also explains why the Y293L mutation in isolation had no 
impact on fluorescence: Y296 provided an effective substitute. 
 
Based on the logic described above, the other half of this bond may originate from the N-
terminus of Ubx. Although the single Y4S mutation does not impact fiber fluorescence, 
Y4S in combination with Y12S significantly reduces fluorescence relative to Y12S fibers 
(Figure 2.9C). Thus, Y4 also impacts dityrosine content. The Y4 + Y12 scenario is 
similar to the one described above for Y293 + Y296: either Y4 or Y12 can participate in 
the dityrosine bond. Within a single fiber, different Ubx molecules may form a bond 
between the N-terminus and the homeodomain using different combinations of residues 
4, 12, 293, and 296. However, the different chemical environments surrounding these 
residues should make some tyrosine pairs more likely to form a dityrosine bond. 
Comparison of pairs of double mutants should reveal if there are preferential interactions 
between 4 or 12 and 293 or 296. The Y4S + Y12S mutant removes all tyrosines from the 
N-terminus, and therefore prevents any possibility of forming a dityrosine bond with the 
homeodomain. The Y4S + Y293L double mutant had a similar level of fluorescence as 
Y4S + Y12S, suggesting neither possible N-terminus/homeodomain bond could form and 
thus Y4S does not bind Y293L. Therefore Y4 must bind Y296. Consistent with this 
conclusion, the fluorescence of Y4S + Y296L (one possible bond lost) was higher than 
Y4S + Y12S (both possible bonds lost), reflecting the fact that the Y12 and Y293 can still 
form a bond. Likewise, the Y12S + Y296 fibers fluoresce similar to Y4S + Y12S fibers, 
and with much less intensity than Y12S + Y293L fibers. Therefore Y12 binds Y293. 
Together, these results indicate that either a Y4/Y296 bond forms, or a Y12/Y293 bond 
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forms.  
Interestingly, the fluorescence of many variants involving Y310 (Y310L, Y293L + 
Y310L, and Y296L + Y310L) fibers is increased relative to wild-type Ubx fibers.  If 
Y310 quenched fluorescence of a dityrosine bond or induced a structure in which a 
dityrosine bond was quenched, then the same number of dityrosine bonds should be 
present in the wild type protein and the Y310 mutant.  Consequently, 
immunofluorescence, using the anti-dityrosine antibody, should remain the same as for 
the fibers composed of wild-type Ubx.  Instead, removal of Y310 increases 
immunofluorescence in proportion to the increase in dityrosine fluorescence. This 
increase in immunofluorescence was not only observed for fibers composed of wild-type 
versus Y310 Ubx, but also for other pairs of Ubx variants in which the only difference is 
the presence or absence of the Y310 mutation. Therefore, removal of Y310 must increase 
the average number of dityrosine bonds formed per molecule of Ubx. These results 
suggest that Y310 acts as a decoy, in which tyrosines can interact with Y310, but not 
form a dityrosine bond. Removal of Y310 prevents Y4 and Y12 from forming 
unproductive interactions and thus increases the percentage of monomers that participate 
in a dityrosine bond.  
 
In the resulting model (Figure 2.12A), the N-terminus of Ubx (Y4 or Y12) interacts with 
the homeodomain (Y293, Y296, or Y310) but can only form a dityrosine bond with Y293 
or Y296; while Y167/Y240 forms a second bond. Two separate bonds must form, 
because 
mutation of tyrosines from at least two groups results in a greater loss of fluorescent 
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intensity than removing multiple amino acids attributed to a single bond (Figure 2.10A; 
p<0.005 indicated by *).  
 
Finally, plotting all mutants in order of increasing fluorescence clearly reveals two 
distinct transitions, corresponding to the presence of 0, 1, or 2 dityrosine bonds (Figure 
2.13A). If this model is a complete description of the N-terminus/homeodomain 
interaction, then the fluorescence of Y4S + Y12S (150 units/m) should equal that of 
Y293L + Y296L (100 units/m). The discrepancy between these measurements may be 
due to differential contributions of Y100 to dityrosine bond formation. As a single 
mutant, Y100S increases fluorescence relative to wild-type Ubx, suggesting it is a decoy, 
like Y310, rather than a participant in dityrosine bonds. However, double mutants of 
Y100S with Y293L, Y296L, or Y310L all fluoresce less than the corresponding Y293L, 
Y296, or Y310L single mutants (Figure 2.9D). Thus, Y100 may contribute to a chemical 
environment that can either aid dityrosine bond formation or act as a decoy, depending on 
the Ubx variant. In this model, differential contributions of Y100 and Y310 account for 
the differences in the fluorescence of Y4S + Y12S and Y293L + Y296L fibers.  
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Figure 2.13 Artistic representation of proposed dityrosine bonds. (B) Artistic 
representation options for intramolecular or intermolecular bonds. 
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2.3.6 Regions that do not regulate DNA binding in Ubx monomers also do not 
participate in dityrosine bonds in Ubx fibers 
The data presented thus far only tested the tyrosines we selected based on involvement in 
DNA binding, conservation, predicted ability to participate in protein interactions, and 
location in a region that impacts fiber length (Table 2.2). To determine whether tyrosines 
outside of our selected group can also contribute to bond formation, we created the Y52S 
and Y85S mutants. Neither single mutant had any effect on fiber fluorescence (Figure 
2.10B). However, the contributions of Y4 and Y293 were only apparent when mutated in 
combination with other tyrosines. Therefore we mutated Y52S and Y85S in conjunction 
with Y296L, a mutation that was able to uncover the contributions of both Y4 and Y293. 
The fluorescence of Y52S + Y296L and Y85S + Y296L mutant fibers was similar to the 
single Y296L mutant (Figure 2.10B). Therefore, Y296L does not reveal a hidden 
contribution of either Y52 or Y85, and these residues do not contribute to dityrosine 
bonds. 
 
2.3.7 Only two dityrosine bonds are formed by Ubx in materials 
Both the mutant data and the kinetic data reveal two transitions, suggesting no more than 
two bonds are present (Figure 2.6, 2.12A). However, the mutants tested thus far do not 
eliminate absolutely all fluorescence from Ubx fibers. The remaining fluorescence could 
be due to random dityrosine bonds formed by the remaining amino acids, or it could be 
evidence of a third dityrosine bond. However, if our hypothesis is correct and Y167 and 
Y240 always participate in dityrosine bonds with each other, then one dityrosine bond 
contributes approximately 200 intensity units/m, on our scale. Likewise, the Y4S + 
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Y12S mutations completely remove the other dityrosine bond, also resulting in a loss of 
approximately 200 intensity units per m. The maximum intensity observed, close to 400 
intensity units/m, was observed for the Ubx variants Y100L, Y310L, Y293L+Y310L, 
and Y296L+Y310L. Therefore, if a single bond is worth 200 units/m per and our 
maximum value for any of our mutants is 400 units/m, then only 2 bonds can form. 
Thus any remaining fluorescence is likely due to random bond formation. Interestingly, 
the fluorescent intensity of fibers composed of wild-type Ubx is only 359 units/m, 
suggesting that monomers in these fibers only form approximately 1 ¾  bonds on average.  
 
2.3.8 Dityrosine bonds are intermolecular and contribute to the strength of the 
materials 
Although mutagenesis can identify the amino acids that participate in dityrosine bonds, 
this approach does not establish whether these bonds are intramolecular, intermolecular, 
or a mix of both types of bonds (Figure 2.13B). Many natural macroscale materials rely 
on intermolecular covalent crosslinks for strength, including disulfide and dityrosine 
bonds (Elvin et al., 2009, Endrizzi et al., 2006, Kelly, 1968). Consequently, adding 
covalent bonds to protein materials can dramatically improve both strength and assembly 
(Asai et al., 2012).Therefore, if the dityrosine bonds in Ubx are intermolecular, they 
should impact the strength of the materials.  The length to which a fiber can be pulled is 
dependent on protein assembly and the fibers’ inherent strength (Greer et al., 2009). 
Since dramatic sequence changes, like fusing large, charged proteins to Ubx monomers 
do not impact assembly, tyrosine point mutations are also unlikely to impact materials 
assembly. Therefore, changes in fiber length are expected to reflect changes in fiber 
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strength. We observed that fibers formed in a low oxygen environment lack dityrosine 
bonds and are extremely short and fragile (data not shown). Plotting increasing values of 
both the normalized fluorescent intensity and the average fiber length reveals two 
transitions, corresponding to the formation of two bonds (Figure 2.12A). Comparison of 
fluorescent intensity with fiber length using linear regression (Figure 2.12B) revealed a 
striking correlation of 0.993. This correlation suggests that fiber strength directly depends 
on dityrosine bond formation, and thus the bonds are intermolecular. It is important to 
note that a subset of mutants – those that remove decoy tyrosines - increase Ubx 
fluorescence. These point mutations also increase fiber strength. Thus, point mutations 
can either increase or decrease the average number of dityrosine bonds formed per 
monomer and consequently increase or decrease the strength of the resulting fibers. 
 
2.3.9 Ubx tyrosine motifs as transferable motifs for strengthening protein-based 
materials 
We have demonstrated that bonds are only formed between specific tyrosine residues in 
Ubx materials. These residues are located in conserved regions of the protein sequence 
which are separated by intrinsically disordered (unstructured) regions of the Ubx protein 
(Liu et al., 2008). Therefore, it should be possible to add these conserved sequences to 
loops or unstructured regions of other self-assembling proteins, and thus add specific 
dityrosine bonds to increase the strength of those materials. As an example, the N-
terminus-homeodomain bond yields less fluorescence than the Y167-Y240 bond due to 
competing interactions with the two decoy tyrosines, Y100 and Y310. Therefore, we 
reasoned that duplicating one of the tyrosines that can participate in this bond could allow 
 
 
60 
 
both decoy binding and dityrosine bond formation. We created the 2x296 Ubx mutant in 
which amino acids G289-Q297, which includes Y296, were duplicated.  In this variant, 
both the original Y293 and the duplicated Y293 were mutated to leucine.  Fibers formed 
by this mutant were significantly more fluorescent than wild-type fibers (Figure 2.14). 
Furthermore, the mutant protein created longer fibers, reflecting their increased strength.  
Therefore, the duplicated region was able to bind the decoy tyrosines and/or form a 
dityrosine bond, and thus can be considered active. 
 
 
 
 
Figure 2.14 Duplicating Y296 and its surrounding region in the 2x296 mutant 
increases the fluorescence of Ubx materials. 
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Since adding an entire region of the Ubx protein might not be feasible for some self-
assembling proteins, we have identified shorter sequences likely to replace the large 
insertion. The sequences surrounding tyrosines that form dityrosine bonds must 
contribute to interaction specificity, and thus would need to be transferred to the 
heterologous system.  Based on Ubx sequence conservation, structure/disorder data (Liu 
et al., 2008), and the predicted propensity to engage in protein interactions (Figure 2.1), 
we recommend below sequences for transfer to other proteins to create dityrosine bonds.  
For proteins systems that can accommodate large insertions, the homeodomain (60 amino 
acids, RRRGR…LKKEI) and the N-terminus (MNSYFEQA) could be used. As an 
additional benefit, the solubility and stability of the homeodomain is expected to improve 
protein production when fused to a self-assembling protein (Tsai et al., 2015). For protein 
systems that can only tolerate small insertions or that self-assemble upon exposure to 
denaturing conditions, the conserved motifs surrounding residues 167 
(VRPSACTPDSRVGGYLDTS) and 240 (FYPWMAIA) could be used.  Thus the 
specific dityrosine-bond forming motifs in Ubx have the potential to be a useful tool for 
engineering the fluorescent and mechanical properties of other protein systems. 
 
2.4 Conclusion 
Although the extensibility of Ubx materials had previously been attributed to glycine-rich 
sequences resembling elastin (Greer et al., 2009, Huang et al, 2010), the molecular 
interactions responsible for the strength of Ubx materials were unknown. We have shown 
that Ubx materials auto-fluoresce blue as a result of two intermolecular dityrosine bonds 
that rapidly and spontaneously form as the materials oxidize. The bonds, located between 
 
 
62 
 
the N-terminus (Y4 or Y12) and the homeodomain (Y293 or Y296), and between Y167 
and Y240 contribute to the strength of Ubx materials. Mutations that ablate one or both 
dityrosine bonds reduce fiber strength, whereas removing competing interactions or 
duplicating tyrosine-containing motifs both increase the strength of the materials.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
CHAPTER III  
THE EFFECT OF PROTEIN FUSIONS ON THE PRODUCTION AND 
MECHANICAL PROPERTIES OF PROTEIN-BASED MATERIALS* 
 
3.1 Introduction 
Proteins implement most of the vital molecular functions of living organisms, including 
providing structural support, generating energy, sensing biomolecules, and catalyzing, 
storing, and degrading important biomolecules.  Proteins are particularly adept at highly 
specific molecular recognition, which can be adapted to bind virtually any ligand, ranging 
from small chemicals to specific types of cells.  Such interactions are often regulated by 
the chemical environment, by binding additional ligands (allostery), or by post-
translational modification of the protein. 
 
Devices that capture proteins in materials have the potential to mimic these functions and 
be regulated by externally applied factors.  However, this approach is technically 
challenging.  The three-dimensional structures of proteins are maintained by non-
covalent bonds, which are sensitive to the surrounding medium.  Perturbations of this 
chemical environment can easily result in loss of protein function.  Proteins are 
commonly incorporated into materials either by physically trapping them within the 
matrix of the materials during assembly or by covalently crosslinking them to the surface 
of the materials post-assembly.   
 
*Reprinted with permission from “The Effect of Protein Fusions on the Production and Mechanical Properties of 
Protein-Based Materials” by Tsai SP, Howell DW, Huang Z, Hsiao HC, Lu Y, Matthews KS, Lou J, Bondos SE, 2015. 
Advanced Functional Materials, 25, 1442-1450, Copyright 2015 by John Wiley & Sons. 
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Both of these approaches can result in the loss of functional proteins.  Physically trapped 
proteins can be inactivated by the harsh chemical environment often used to trigger 
materials assembly.  Furthermore, the functional proteins are free to diffuse out of the 
materials (Woolfson and Mahmoud, 2010).  Although crosslinking covalently tethers 
functional proteins to the materials, the crosslinking agent can also inactivate the 
appended protein or remain embedded in the materials, rendering them toxic to cells 
(Hershel et al., 2003).  In addition, materials held together by non-covalent bonds may be 
too fragile for chemical modifications after assembly (Woolfson and Mahmoud, 2010).  
Finally, depending on the specificity of the cross-linking strategy, some portion of the 
functional protein may be oriented such that the materials’ structure blocks ligand 
binding and hence function (Adak et al., 2014). 
 
For materials composed of recombinant proteins, the use of protein fusions provides an 
attractive alternative.  By fusing a gene encoding a functional protein to a gene encoding 
a self-assembling protein, a single polypeptide can be produced that contains the 
sequences of both proteins.  This fusion protein should retain both the functional and self-
assembly properties of the parent proteins.  This method offers several advantages for 
incorporating functional proteins: (i) materials assembly and functionalization can be 
combined into a single step, (ii) stoichiometric levels of functionalization can be 
achieved, (iii) covalent attachment prevents loss of the functional protein due to 
diffusion, (iv) toxic by-products (remnants of chemical cross-linking) are not created, and 
(v) the functional proteins can be patterned within the materials (Woolfson and 
Mahmoud, 2010, Huang et al., 2011).  In addition, all of the appended proteins have a 
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uniform orientation, although there are only two possible points of attachment – the N- 
and C-termini of the self-assembling protein.  The gene fusion approach requires mild 
conditions for materials assembly that will not perturb the structure of the appended 
functional protein.  Even so, full-length protein fusions have been successfully used to 
functionalize materials composed of many proteins, including elastin, silk, amyloid-
forming proteins, and Ubx (Huang et al., 2011, Jansson et al., 2014, Huang et al., 2007, 
Kumar et al., 2006, Ngaoka et al., 2010, Sackewitz et al., 2008) . 
 
Not every functional protein is likely to be a good candidate for incorporation into 
materials via gene fusion.  For instance, unstable or insoluble functional proteins could 
hamper expression of the fusion protein, or large/multimeric functional proteins may mis-
position the self-assembling protein, altering the mechanical properties of the materials or 
even preventing materials assembly.  We have fused 24 proteins to the Drosophila 
melanogaster transcription factor Ultrabithorax (Ubx) to examine their impact on Ubx 
assembly and properties.  Ubx self-assembles rapidly in gentle buffers to form films and 
fibers (Greer et al., 2009).  Ubx materials are biocompatible, strong, and remarkably 
extensible.  Furthermore, proteins fused to Ubx retain their activity once incorporated 
into materials (Huang et al., 2011, Huang et al., 2010, Patterson et al., 2014, Patterson et 
al., 2015).   In this study, we find that inclusion in Ubx materials stabilizes the appended 
proteins.  Because the fusions do not impact Ubx assembly, the concentration of 
functional protein in the materials can be predictably controlled by co-assembling the 
Ubx fusion protein with unmodified Ubx.  The proteins appended to Ubx by gene fusion 
were selected to vary, as systematically as possible, the size, fold, quaternary structure, 
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stability, solubility, and charge density.  We find that the appended protein had a large 
effect on the production of the fusion protein, with the solubility and quaternary structure 
of the appended protein best predicting successful expression and purification.  In 
contrast, the ability to self-assemble into materials was dominated by Ubx, and the 
presence or identity of a fused protein had little impact on materials assembly.  Although 
an appended protein can alter the mechanical properties of the materials, these properties 
still lie in a biologically relevant range.  Finally, two proteins can be simultaneously 
fused to Ubx to create double fusions that still assemble into functionally active 
materials.  These double fusions can be used to incorporate multiple activities at 
stoichiometric levels into the protein materials, or to improve the solubility or expression 
of a poorly performing single Ubx fusion. 
 
3.2 Materials and methods 
3.2.1 Construction of plasmids 
pET19b-Ubx plasmid was used as the parent vector for all fusion proteins.  In this 
plasmid, the gene encoding Ubx mRNA splicing isoform Ia (Figure 3.1) was inserted 
between the NdeI and BamHI sites of pET19b vector (Novagen), thus adding a 10xHis-
tag and a hydrophilic linker (SSGGHDDDDK) to the amino-terminus of Ubx (Greer et 
al., 2009).  DNA sequences encoding all protein fusion partners were inserted into the 
NdeI site of pET19b-Ubx, between the N-terminal His-tag and Ubx. General PCR and 
plasmid construction protocols are shown in Figure 3.2, 3.3. DNAs encoding the genes 
for SDF-1a and bFGF were cloned from a cDNA library derived from human cells and 
provided by Dr. Kayla Bayless (Texas A&M Health Science Center).  The plasmids 
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expressing the isolated functional proteins were generated from plasmids that encode 
corresponding Ubx fusions by introducing a stop codon before the ubx gene using the 
following primers: Forward: 5’-CATATGAACTCGTAGTTTGAACAGGCCTCC-3’ and 
Reverse: 5’-GGAGGCCTGTTCAAACTACGAGTTCATATG-3'. Table 3.1 lists the full 
length sequences of all fusions.  Table 3.2 lists the sequence of Gly and Ser linkers which 
separate the fused protein from Ubx and provide sufficient flexibility for Ubx assembly 
and appended protein function.  A general schematic of Ubx and Ubx fusions is shown in 
Figure 3.5A.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Figure 3.1 DNA and protein sequences of Ubx. 
Ultrabithorax (Ubx)  
DNA Sequence 
ATGAACTCGTACTTTGAACAGGCCTCCGGCTTTTATGGCCATCCGCACCAGGCCACCGGAATGGCG
ATGGGCAGCGGTGGCCACCACGACCAGACGGCCAGTGCAGCGGCGGCCGCGTACAGGGGATTCC
CTCTCTCGCTGGGCATGAGTCCCTATGCCAACCACCATCTGCAGCGCACCACCCAGGACTCGCCCT
ACGATGCCAGCATCACGGCCGCCTGCAATAAGATATACGGCGATGGAGCCGGAGCCTACAAACAG
GACTGCCTGAACATCAAGGCGGATGCGGTGAATGGCTACAAAGACATTTGGAACACGGGCGGCTC
GAATGGCGGCGGGGGTGGCGGCGGAGGCGGTGGTGGCGGCGGAGCGGGCGGAACAGGTGGAG
CCGGCAATGCCAATGGCGGTAATGCGGCCAATGCAAACGGACAGAACAATCCGGCGGGCGGTATG
CCCGTTAGACCCTCCGCCTGCACCCCAGATTCCCGAGTGGGCGGCTACTTGGACACGTCGGGCGG
CAGTCCCGTTAGCCATCGCGGCGGCAGTGCCGGCGGTAATGTGAGTGTCAGCGGCGGCAACGGC
AACGCCGGAGGCGTACAGAGCGGCGTGGGCGTGGCCGGAGCGGGCACTGCCTGGAATGCCAATT
GCACCATCTCGGGCGCCGCTGCCCAAACGGCGGCCGCCAGCAGTTTACACCAGGCCAGCAATCAC
ACATTCTACCCCTGGATGGCTATCGCAGGTAAGATAAGATCTGATTTAACACAATACGGCGGCATAT
CAACAGACATGGGTAAGAGATACTCAGAATCTCTTGCGGGCTCACTTCTACCAGACTGGCTAGGTA
CAAATGGTCTGCGAAGACGCGGCCGACAGACATACACCCGCTACCAGACGCTCGAGCTGGAGAAG
GAGTTCCACACGAATCATTATCTGACCCGCAGACGGAGAATCGAGATGGCGCACGCGCTATGCCTG
ACGGAGCGGCAGATCAAGATCTGGTTCCAGAACCGGCGAATGAAGCTGAAGAAGGAGATCCAGGC
GATCAAGGAGCTGAACGAACAGGAGAAGCAGGCGCAGGCCCAGAAGGCGGCGGCGGCAGCGGCT
GCGGCGGCGGCGGTCCAAGGTGGACACTTAGATCAG  
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  Figure 3.1 Continued. 
 
 
 Figure 3.2 General PCR reaction setup for constructing the fusions. 
 
 
 
 
 
 
 
 
Protein Sequence 
MNSYFEQASG FYGHPHQATG MAMGSGGHHD QTASAAAAAY RGFPLSLGMS PYANHHLQRT  
TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY KDIWNTGGSN GGGGGGGGGG  
GGGAGGTGGA GNANGGNAAN ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG  
GSAGGNVSVS GGNGNAGGVQ SGVGVAGAGT AWNANCTISG AAAQTAAASS LHQASNHTFY  
PWMAIAGKIR SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE  
LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE LNEQEKQAQA  
QKAAAAAAAA AAVQGGHLDQ  
 
 
69 
 
 
 
                    
                                                           Ligation  
 Figure 3.3 Flow chart of constructing the Ubx fusions. 
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Table 3.1 Amino acid sequences of all fusions. 
 
 
Protein name   Protein sequence 
His-Ubx MGHHHHHHHHHHSSGHIDDDDKHMNSYFEQASG FYGHPHQATG 
MAMGSGGHHD QTASAAAAAY RGFPLSLGMS PYANHHLQRT  
TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY KDIWNTGGSN 
GGGGGGGGGG GGGAGGTGGA GNANGGNAAN ANGQNNPAGG 
MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ 
SGVGVAGAGT AWNANCTISG AAAQTAAASS LHQASNHTFY PWMAIAGKIR 
SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE 
LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE 
LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
RGD-Ubx M G H H H H H H H H H H S S G H I D D D D K G S R G D G S G S 
H MNSYFEQASG FYGHPHQATG MAMGSGGHHD QTASAAAAAY RGFPLSLGMS 
PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY 
KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA GNANGGNAAN 
ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS 
GGNGNAGGVQ SGVGVAGAGT AWNANCTISG AAAQTAAASS LHQASNHTFY 
PWMAIAGKIR SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR 
QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK 
LKKEIQAIKE LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ  
YKLKYY-Ubx M G H H H H H H H H H H S S G H I D D D D K G S Y K L K Y Y G S G S H  
MNSYFEQASGFYGHPHQATGMAMGSGGHHDQTASAAAAAYRGFPLSLGMSPYA
NHHLQRTTQDSPYDASITAACNKIYGDGAGAYKQDCLNIKADAVNGYKDIWNTGGS
NGGGGGGGGGGGGGAGGTGGAGNANGGNAANANGQNNPAGGMPVRPSACT
PDSRVGGYLDTSGGSPVSHRGGSAGGNVSVSGGNGNAGGVQSGVGVAGAGTAW
NANCTISGAAAQTAAASSLHQASNHTFYPWMAIAGKIRSDLTQYGGISTDMGKRYS
ESLAGSLLPDWLGTNGLRRRGRQTYTRYQTLELEKEFHTNHYLTRRRRIEMAHALCLT
ERQIKIWFQNRRMKLKKEIQAIKELNEQEKQAQAQKAAAAAAAAAAVQGGHLDQ 
WRW-Ubx M G H H H H H H H H H H S S G H I D D D D K G S WRW G S G S H  
MNSYFEQASGFYGHPHQATGMAMGSGGHHDQTASAAAAAYRGFPLSLGMSPYA
NHHLQRTTQDSPYDASITAACNKIYGDGAGAYKQDCLNIKADAVNGYKDIWNTGGS
NGGGGGGGGGGGGGAGGTGGAGNANGGNAANANGQNNPAGGMPVRPSACT
PDSRVGGYLDTSGGSPVSHRGGSAGGNVSVSGGNGNAGGVQSGVGVAGAGTAW
NANCTISGAAAQTAAASSLHQASNHTFYPWMAIAGKIRSDLTQYGGISTDMGKRYS
ESLAGSLLPDWLGTNGLRRRGRQTYTRYQTLELEKEFHTNHYLTRRRRIEMAHALCLT
ERQIKIWFQNRRMKLKKEIQAIKELNEQEKQAQAQKAAAAAAAAAAVQGGHLDQ 
GSGSGS-Ubx M G H H H H H H H H H H S S G H I D D D D K G S G S G S H  
MNSYFEQASGFYGHPHQATGMAMGSGGHHDQTASAAAAAYRGFPLSLGMSPYA
NHHLQRTTQDSPYDASITAACNKIYGDGAGAYKQDCLNIKADAVNGYKDIWNTGGS
NGGGGGGGGGGGGGAGGTGGAGNANGGNAANANGQNNPAGGMPVRPSACT
PDSRVGGYLDTSGGSPVSHRGGSAGGNVSVSGGNGNAGGVQSGVGVAGAGTAW
NANCTISGAAAQTAAASSLHQASNHTFYPWMAIAGKIRSDLTQYGGISTDMGKRYS
ESLAGSLLPDWLGTNGLRRRGRQTYTRYQTLELEKEFHTNHYLTRRRRIEMAHALCLT
ERQIKIWFQNRRMKLKKEIQAIKELNEQEKQAQAQKAAAAAAAAAAVQGGHLDQ 
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Table 3.1 Continued 
 
Protein name   Protein sequence 
EGFP-Ubx MGHHHHHHHHHHSSGHIDDDDKHMVSKGEELFTGVVPILVELDGDVNGHK
FSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMK
QHDFFKSAMPEGYVQER TIFFKDDGNYKTRAEVKFEGD 
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADK 
QKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGP 
VLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKGHMNSY
FEQASG FYGHPHQATG MAMGSGGHHD QTASAAAAAY RGFPLSLGMS 
PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY 
KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA GNANGGNAAN 
ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG  
GSAGGNVSVS GGNGNAGGVQ SGVGVAGAGT AWNANCTISG 
AAAQTAAASS LHQASNHTFY PWMAIAGKIR SDLTQYGGIS TDMGKRYSES 
LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA 
HALCLTERQI KIWFQNRRMK LKKEIQAIKE LNEQEKQAQA  
QKAAAAAAAA AAVQGGHLDQ 
mCherry-Ubx MGHHHHHHHHHHSSGHIDDDDKHMVSKGEEDNMAIIKEFMRFKVHMEGS
VNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYV
KHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLR
GTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDA
EVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDE
LYKGHMNSYFEQASG FYGHPHQATG MAMGSGGHHD QTASAAAAAY 
RGFPLSLGMS PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL 
NIKADAVNGY KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA 
GNANGGNAAN ANGQNNPAGG MPVRPSACTP DSRVGGYLDT 
SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ SGVGVAGAGT 
AWNANCTISG AAAQTAAASS LHQASNHTFY PWMAIAGKIR SDLTQYGGIS 
TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE LEKEFHTNHY 
LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE LNEQEKQAQA  
QKAAAAAAAA AAVQGGHLDQ 
AmCyan-Ubx MGHHHHHHHHHHSSGHIDDDDKHMALSNKFIGDDMKMTYHMDGCVNG
HYFTVKGEGSGKPYEGTQTSTFKVTMANGGPLAFSFDILSTVFMYGNRCFTA
YPTSMPDYFKQAFPDGMSYERTFTYEDGGVATASWEISLKGNCF EHKST 
FHGVNFPADGPVMAKKTTGWDPSFEKMTVCDGILKGDVTAFLMLQGGGN
YRCQFHTSYKTKKPVTMPPNHVVEHRIARTDLDKGGNSVQLTEHAVAHITSV
VPFG HM NSYFEQASG FYGHPHQATGMAMGSGGHHD QTASAAAAAY 
RGFPLSLGMS PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL 
NIKADAVNGY KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA 
GNANGGNAAN ANGQNNPAGG MPVRPSACTP DSRVGGYLDT  
SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ SGVGVAGAGT 
AWNANCTISG AAAQTAAASSLHQASNHTFY PWMAIAGKIR SDLTQYGGIS 
TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE LEKEFHTNHY 
LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE  
LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
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Table 3.1 Continued 
Protein name   Protein sequence 
EBFP-Ubx MGHHHHHHHHHHSSGHIDDDDKHMVSKGEELFTGVVPILVELDGDVNGHKFSV
SGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTHGVQCFSRYPDHMKQHDFF
KSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKL
EYNFNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLP
DNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKGHM NSYFEQASG  
FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS PYANHHLQRT  
TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY KDIWNTGGSN  
GGGGGGGGGG GGGAGGTGGA GNANGGNAAN ANGQNNPAGG 
MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ 
SGVGVAGAGT AWNANCTISG AAAQTAAASSLHQASNHTFY PWMAIAGKIR 
SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE 
LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE  
LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
Osteopontin-Ubx MGHHHHHHHHHHSSGHIDDDDKHMRIAVICFCLLGITCAIPVKQADSGSSEEKQL
YNKYPDAVATWLNPDPSQKQNLLAPQNAVSSEETNDFKQETLPSKSNESHDHMD
DMDDEDDDDHVDSQDSIDSNDSDDVDDTDDSHQSDESHHSDESDELVTDFPTD
LPATEVFTPVVPTVDTYDGRGDSVVYGLRSKSKKFRRPDIQYPDATDEDITSHMES
EELNGAYKAIPVAQDLNAPSDWDSRGKDSYETSQLDDQSAETHSHKQSRLYKRKA
NDESNEHSDVIDSQELSKVSREFHSHEFHSHEDMLVVDPKSKEEDKHLKFRISHELD
SASSEVNGHMNSYFEQASG FYGHPHQATG MAMGSGGHHD QTASAAAAAY 
RGFPLSLGMS PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL 
NIKADAVNGY KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA 
GNANGGNAAN ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG 
GSAGGNVSVS GGNGNAGGVQ SGVGVAGAGT AWNANCTISG AAAQTAAASS 
LHQASNHTFY PWMAIAGKIR SDLTQYGGIS TDMGKRYSES LAGSLLPDWL 
GTNGLRRRGR QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA HALCLTERQI 
KIWFQNRRMK LKKEIQAIKE LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
VEGF165a-Ubx MGHHHHHHHHHHSSGHIDDDDKHMS APMA EGGGQNHHEV VKFMDVYQRS 
YCHPIETLVDIFQEYPDEIE YIFKPSCVPL MRCGGCCNDE GLECVPTEES 
NITMQIMRIK PHQGQHIGEM  SFLQHNKCEC RPKKDRARQE NPCGPCSERR 
KHLFVQDPQT CKCSCKNTDS RCKARQLELN  ERTCRCDKPR RNHM 
NSYFEQASG FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS 
PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY 
KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA GNANGGNAAN 
ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS 
GGNGNAGGVQ SGVGVAGAGT AWNANCTISG AAAQTAAASS 
LHQASNHTFY PWMAIAGKIR SDLTQYGGIS TDMGKRYSES LAGSLLPDWL 
GTNGLRRRGR QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA HALCLTERQI 
KIWFQNRRMK LKKEIQAIKE LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ  
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Table 3.1 Continued 
Protein name   Protein sequence 
SDF-Ubx MGHHHHHHHHHHSSGHIDDDDKHMKPVSLSYRCP CRFFESHVAR 
ANVKHLKILN T PNCAL QIVAR LKNNNRQVCI DPKLKWIQEY LEKALNKHM 
NSYFEQASG FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS 
PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY 
KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA GNANGGNAAN 
ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS 
GGNGNAGGVQ SGVGVAGAGT AWNANCTISG AAAQTAAASS 
 LHQASNHTFY PWMAIAGKIR SDLTQYGGIS TDMGKRYSES LAGSLLPDWL 
GTNGLRRRGR QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA HALCLTERQI 
KIWFQNRRMK LKKEIQAIKE LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
bFGF-Ubx MGHHHHHHHHHHSSGHIDDDDKHMAAGSITTLP ALPEDGGSGA 
FPPGHFKDPK RLYCKNGGFF LRIHPDGRVD GVREKSDPHI 
 KLQLQAEERG VVSIKGVCAN RYLAMKEDGR LLASKCVTDE CFFFERLESN 
NYNTYRSRKYTSWYVALKRT GQYKLGSKTG PGQKAILFLP MSAKSHM 
NSYFEQASG FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS 
PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY 
KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA GNANGGNAAN 
ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS 
GGNGNAGGVQ SGVGVAGAGT AWNANCTISG AAAQTAAASSLHQASNHTFY 
PWMAIAGKIR SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR 
QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK 
LKKEIQAIKE LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
Luciferase-Ubx MGHHHHHHHHHHSSGHIDDDDKHMEDAKNIKKG PAPFYPLEDG 
TAGEQLHKAM KRYALVPGTI AFTDAHIEVN ITYAEYFEMS  
VRLAEAMKRY GLNTNHRIVV CSENSLQFFM PVLGALFIGV AVAPANDIYN 
ERELLNSMNI SQPTVVFVSK KGLQKILNVQ KKLPIIQKII IMDSKTDYQG 
FQSMYTFVTS HLPPGFNEYD FVPESFDRDK TIALIMNSSG STGLPKGVAL 
PHRTACVRFS HARDPIFGNQ IIPDTAILSV  VPFHHGFGMF TTLGYLICGF 
RVVLMYRFEE ELFLRSLQDY KIQSALLVPT LFSFFAKSTL IDKYDLSNLH 
EIASGGAPLS KEVGEAVAKR FHLPGIRQGY GLTETTSAIL ITPEGDDKPG  
AVGKVVPFFE AKVVDLDTGK TLGVNQRGEL CVRGPMIMSG YVNNPEATNA 
LIDKDGWLHS GDIAYWDEDE HFFIVDRLKS LIKYKGYQVA PAELESILLQ 
HPNIFDAGVA GLPDDDAGEL PAAVVVLEHG KTMTEKEIVD YVASQVTTAK 
KLRGGVVFVD EVPKGLTGKL DARKIREILI KAKKGGKSKL GHM NSYFEQASG  
FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS PYANHHLQRT  
TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY KDIWNTGGSN  
GGGGGGGGGG GGGAGGTGGA GNANGGNAAN ANGQNNPAGG 
MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ 
SGVGVAGAGT AWNANCTISG AAAQTAAASSLHQASNHTFY PWMAIAGKIR 
SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE 
LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE  
LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
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Table 3.1 Continued 
Protein name   Protein sequence 
Myoglobin-Ubx MGHHHHHHHHHHSSGHIDDDDKHMVLSEGEWQLVLHVWAKVEADVAGHGQD
ILIRLFKSH PETL EKFDRFKHLKTEAEMKASEDLKKHGVTVLTAL 
GAILKKKGHHEAELKPLAQSHATK HKIPIKYLEFISEAIIHVLHSRHPGNFGADA 
QGAMNKALELFRKDIAAKYKELGYQGGGH M NSYFEQASG 
FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS PYANHHLQRT  
TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY KDIWNTGGSN  
GGGGGGGGGG GGGAGGTGGA GNANGGNAAN ANGQNNPAGG 
MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ 
SGVGVAGAGT AWNANCTISG AAAQTAAASSLHQASNHTFY PWMAIAGKIR 
SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE 
LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE  
LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ  
Thioredoxin-Ubx MGHHHHHHHHHHSSGGTMSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPC
KMIAPIL DEIADEYQGKLTVAKLNIDQNPGTAPKYGIRGIPTLLLFKNGE 
VAATKVGALSKGQLKEF LDANLAGTNIDDDDKHMSGSG M NSYFEQASG  
FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS PYANHHLQRT  
TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY KDIWNTGGSN  
GGGGGGGGGG GGGAGGTGGA GNANGGNAAN ANGQNNPAGG 
MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ 
SGVGVAGAGT AWNANCTISG AAAQTAAASS LHQASNHTFY PWMAIAGKIR 
SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE 
LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE  
LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
MBP-Ubx 
(Maltose 
binding protein) 
MGHHHHHHHHHHSSGGTMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVT
VEHPDK LEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITP 
DKAFQDKLYPFTWDAVRYNGK LIAYPIAVEALSLIYNKDLLPNPPKTWEE 
IPALDKELKAKGKSALMFNLQEPYFTWPLIA ADGGYAFKYENGKYDIKDVGV 
DNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGET AMTINGPWAW 
SNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLEN YL 
LTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAF
WYA VRTAVINAASGRQTVDEALKDAQTGTNIDDDDKHMSGSG MNSYFEQ 
ASG FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS 
PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY 
KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA GNANGGNAAN 
ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS 
GGNGNAGGVQ SGVGVAGAGT AWNANCTISG AAAQTAAASS 
 LHQASNHTFY PWMAIAGKIR SDLTQYGGIS TDMGKRYSES LAGSLLPDWL 
GTNGLRRRGR QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA HALCLTERQI 
KIWFQNRRMK LKKEIQAIKE LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
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Table 3.1 Continued 
Protein name   Protein sequence 
GST-Ubx MGHHHHHHHHHHSSGGTMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDK
WRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAV
LDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDAL
DVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPP
KGTNIDDDDKHMSGSG MNSYFEQASG FYGHPHQATGMAMGSGGHHD 
QTASAAAAAY RGFPLSLGMS PYANHHLQRT TQDSPYDASI TAACNKIYGD 
GAGAYKQDCL NIKADAVNGY KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA 
GNANGGNAAN ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG 
GSAGGNVSVS GGNGNAGGVQ SGVGVAGAGT AWNANCTISG AAAQTAAASS 
 LHQASNHTFY PWMAIAGKIR SDLTQYGGIS TDMGKRYSES LAGSLLPDWL 
GTNGLRRRGR QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA HALCLTERQI 
KIWFQNRRMK LKKEIQAIKE LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ  
NusA-Ubx MGHHHHHHHHHHSSGGTMNKEILAVVEAVSNEKALPREKIFEALESALATATKKKYEQ
EIDVRVQIDRKSGDFDTFR RWLVVDEVTQPTKEITLEAARYEDESLNLG 
DYVEDQIESVTFDRITTQTAKQVIVQKVRE AERAMVVDQFREHEGEIITGVVKKV 
NRDNISLDLGNNAEAVILREDMLPRENFRPGDRVR GVLYSVRPEARGAQ 
LFVTRSKPEMLIELFRIEVPEIGEEVIEIKAAARDPGSRAKIAVKTNDKRIDPVGACVGMR
GARVQAVSTELGGERIDIVLWDDNPAQFVINAMAPADVASIVVDE 
DKHTMDIAVEAGNLAQAIGRNGQNVRLASQLSGWELNVMTVDDLQAKHQAEAHAA
IDTFTKYLDIDEDFATVLVEEGFSTLEELAYVPMKELLEIEGLDEPTVEALRERAKNALATI
AQA QEESLGDNKPADDLLNLEGVDRDLAFKLAARGVCTLEDLAEQGIDDLAD 
IEGLTDEKAGA LIMAARNICWFGDEA GTNIDDDDKHMSGSG MNSYFEQASG 
FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS PYANHHLQRT  
TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY KDIWNTGGSN  
GGGGGGGGGG GGGAGGTGGA GNANGGNAAN ANGQNNPAGG MPVRPSACTP 
DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ SGVGVAGAGT 
AWNANCTISG AAAQTAAASSLHQASNHTFY PWMAIAGKIR SDLTQYGGIS 
TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE LEKEFHTNHY 
LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE LNEQEKQAQA 
QKAAAAAAAA AAVQGGHLDQ 
SUMO-Ubx MGHHHHHHHHHHSSGGTMSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKK
TTPLRRLMEAFAKRQGKEM DSLRFLYDGIRIQADQTPEDLDMEDND 
IIEAHREQIGGGTNIDDDDKHMSGSG MNSYFEQASG FYGHPHQATGMAM 
GSGGHHD QTASAAAAAY RGFPLSLGMS PYANHHLQRT TQDSPYDASI 
TAACNKIYGD GAGAYKQDCL NIKADAVNGY KDIWNTGGSN GGGGGGGGGG 
GGGAGGTGGA GNANGGNAAN ANGQNNPAGG MPVRPSACTP DSRVGGYLDT  
SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ SGVGVAGAGT AWNANCTISG 
AAAQTAAASSLHQASNHTFY PWMAIAGKIR SDLTQYGGIS TDMGKRYSES 
LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA 
HALCLTERQI KIWFQNRRMK LKKEIQAIKE LNEQEKQAQA QKAAAAAAAA 
AAVQGGHLDQ  
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Table 3.1 Continued 
 
 
Protein name   Protein sequence 
Tma-Ubx MGHHHHHHHHHHSSGHIDDDDKHMSFFNKIILIGRLVRDPEERYTLSGTPVTTFTIA
VDRVPRKNAPDDAQTTDFFRIVTFGRLAEFARTYLTKGRLVLVEGEMRMRRWETPT
GEKRVSPEVVANVVR FMDRKPAETVSETEEELEIPEEDFSSDTFSEDEPPFGSGSHM 
NSYFEQASG FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS 
PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY 
KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA GNANGGNAAN 
ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS 
GGNGNAGGVQ SGVGVAGAGT AWNANCTISG AAAQTAAASSLHQASNHTFY 
PWMAIAGKIR SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR 
QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK 
LKKEIQAIKE LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
Tne-Ubx MGHHHHHHHHHHSSGHIDDDDKHMSFFNRIILIGRLVRDPEERYTLSGTPVTTFTIA
VDRVPRKNAPDDAQTTDFFRVVTFGRLAEFARTYLTKGRLILVEGEMRMRRWETQT
GEKRVS PEVVANVVRFMDRKPVEMPSEDIEEKLEIPEEDFTDDTFSEDEPPFHM 
NSYFEQASG FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS 
PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY 
KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA GNANGGNAAN 
ANGQNNPAGG MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS 
GGNGNAGGVQ SGVGVAGAGT AWNANCTISG AAAQTAAASSLHQASNHTFY 
PWMAIAGKIR SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR 
QTYTRYQTLE LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK 
LKKEIQAIKE LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
LPYK-Ubx MGHHHHHHHH HHSSGHIDDD DKHMEGPAGY LRRASVAQLT QELGTAFFQQ 
QQLPAAMADT FLEHLCLLDI DSEPVAARST SIIATIGPAS RSVERLKEMI 
KAGMNIARLN FSHGSHEYHA  ESIANVREAV ESFAGSPLSY RPVAIALDTK 
GPEIRTGILQ GGPESEVELV KGSQVLVTVD PAFRTRGNAN TVWVDYPNIV 
RVVPVGGRIY IDDGLISLVV QKIGPEGLVT QVENGGVLGS RKGVNLPGAQ 
VDLPGLSEQD VRDLRFGVEH GVDIVFASFV RKASDVAAVR AALGPEGHGI 
KIISKIENHE GVKRFDEILE VSDGIMVARG DLGIEIPAEK VFLAQKMMIG 
RCNLAGKPVV CATQMLESMI TKARPTRAET SDVANAVLDG ADCIMLSGET 
AKGNFPVEAV KMQHAIAREA EAAVYHRQLF EELRRAAPLS RDPTEVTAIG 
AVEAAFKCCA AAIIVLTTTG RSAQLLSRYR PRAAVIAVTR SAQAARQVHL 
CRGVFPLLYR EPPEAIWADD VDRRVQFGIE SGKLRGFLRV GDLVIVVTGW 
RPGSGYTNIM RVLSISGGSG SHMNSYFEQA SGFYGHPHQA TGMAMGSGGH 
HDQTASAAAA AYRGFPLSLG MSPYANHHLQ RTTQDSPYDA SITAACNKIY 
GDGAGAYKQD CLNIKADAVN GYKDIWNTGG SNGGGGGGGG GGGGGAGGTG 
GAGNANGGNA ANANGQNNPA GGMPVRPSAC TPDSRVGGYL DTSGGSPVSH 
RGGSAGGNVS VSGGNGNAGG VQSGVGVAGA GTAWNANCTI SGAAAQTAAA 
SSLHQASNHT FYPWMAIAGK IRSDLTQYGG ISTDMGKRYS ESLAGSLLPD 
WLGTNGLRRR GRQTYTRYQT LELEKEFHTN HYLTRRRRIE MAHALCLTER 
QIKIWFQNRR MKLKKEIQAI KELNEQEKQA QAQKAAAAAA AAAAVQGGHL DQ 
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Table 3.1 Continued 
Protein name   Protein sequence 
PFK-Ubx MGHHHHHHHH HHSSGHIDDD DKHMVKRIGV LTSGGDSPGM NAAIRSVVRK 
AIYHGVEVYG VYHGYAGLIA GNIKKLEVGD VGDIIHRGGT ILYTARCPEF 
KTEEGQKKGI EQLKKHGIEG LVVIGGDGSY QGAKKLTEHG FPCVGVPGTI 
DNDIPGTDFT IGFDTALNTV IDAIDKIRDT ATSHERTYVI EVMGRHAGDI 
ALWSGLAGGA ETILIPEADY DMNDVIARLK RGHERGKKHS IIIVAEGVGS 
GVDFGRQIQE ATGFETRVTV LGHVQRGGSP TAFDRVLASR LGARAVELLL  
EGKGGRCVGI QNNQLVDHDI AEALANKHTI DQRMYALSKE LSIGSGSHMN 
SYFEQASGFY GHPHQATGMA MGSGGHHDQT ASAAAAAYRG FPLSLGMSPY 
ANHHLQRTTQ DSPYDASITA ACNKIYGDGA GAYKQDCLNI KADAVNGYKD 
IWNTGGSNGG GGGGGGGGGG GAGGTGGAGN ANGGNAANAN GQNNPAGGMP 
VRPSACTPDS RVGGYLDTSG GSPVSHRGGS AGGNVSVSGG NGNAGGVQSG 
VGVAGAGTAW NANCTISGAA AQTAAASSLH QASNHTFYPW MAIAGKIRSD  
LTQYGGISTD MGKRYSESLA GSLLPDWLGT NGLRRRGRQT YTRYQTLELE 
KEFHTNHYLT RRRRIEMAHA LCLTERQIKI WFQNRRMKLK KEIQAIKELN 
EQEKQAQAQK AAAAAAAAAA VQGGHLDQ 
NusA-NusA-
Ubx 
MGHHHHHHHHHHSSGGTMNKEILAVVEAVSNEKALPREKIFEALESALATATKKKYEQ
EIDVRVQIDRKSGDFDTFR RWLVVDEVTQPTKEITLEAARYEDESLNLGDY 
VEDQIESVTFDRITTQTAKQVIVQKVRE AERAMVVDQFREHEGEIITGVVKKV 
NRDNISLDLGNNAEAVILREDMLPRENFRPGDRVR GVLYSVRPEARGAQ 
LFVTRSKPEMLIELFRIEVPEIGEEVIEIKAAARDPGSRAKIAVKT NDKRIDPVGAC 
VGMRGARVQAVSTELGGERIDIVLWDDNPAQFVINAMAPADVASIVVDE 
DKHTMDIAVEAGNLAQAIGRNGQNVRLASQLSGWELNVMTVDDLQAKHQAEAHAA
IDTFT KYLDIDEDFATVLVEEGFSTLEELAYVPMKELLEIEGLDEPTVEAL 
RERAKNALATIAQA QEESLGDNKPADDLLNLEGVDRDLAFKLAAR 
GVCTLEDLAEQGIDDLADIEGLTDEKAGA LIMAARNICWFGDEA GTNIDDDDKHM 
MNKEILAVVEAVSNEKALPREKIFEALESALATATKKKYEQEIDVRVQIDRKSGDFDTFR 
RWLVVDEVTQPTKEITLEAARYEDESLNLGDYVEDQIESVTFDRITTQTAKQVIVQKVRE 
AERAMVVDQFREHEGEIITGVVKKVNRDNISLDLGNNAEAVILREDMLPRENFRPGDR
VR GVLYSVRPEARGAQLFVTRSKPEMLIELFRIEVPEIGEEVIEIKAAARDPGSRAKIAVKT 
NDKRIDPVGACVGMRGARVQAVSTELGGERIDIVLWDD 
NPAQFVINAMAPADVASIVVDEDKHTMDIAVEAGNLAQAIGRNGQNVRLASQLSGW
ELNVMTVDDLQAKHQAEAHAAIDTFT KYLDIDEDFATVLVEEGFSTLEELAYVP 
MKELLEIEGLDEPTVEALRERAKNALATIAQA QEESLGDNKPADDLLNLEGVDRDL 
AFKLAARGVCTLEDLAEQGIDDLADIEGLTDEKAGA LIMAARNICWFGDEA HMSGSG  
MNSYFEQASG FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS 
PYANHHLQRT TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY 
KDIWNTGGSN GGGGGGGGGG GGGAGGTGGA GNANGGNAAN ANGQNNPAGG 
MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ 
SGVGVAGAGT AWNANCTISG AAAQTAAASSLHQASNHTFY PWMAIAGKIR 
SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE 
LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE  
LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
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Protein name   Protein sequence 
EGFP-VEGF-Ubx MGHHHHHHHHHHSSGHIDDDDKLMVSKGEELFTGVVPILVELDGDVNGHKFSV
SGEGEGD ATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRY 
PDHMKQHDFFKSAMPEGYVQER TIFFKDDGNYKTRAEVKFEGDTLVNRIELK 
GIDFKEDGNILGHKLEYNYNSHNVYIMADK QKNGIKVNFKIRHNIEDGS 
VQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRD HMVLLEFVTAAG 
ITLGMDELYKGHMSAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYP
DEIEYIFKPSCVPLMRCGG CCNDEGLECVPTEESNITMQIMRIKPHQ 
GQHIGEMSFLQHNKCECRPKKDRARQENPCGP CSERRKHLFVQDPQT 
CKCSCKNTDSRCKARQLELNERTCRCDKPRRNHM NSYFEQASG  
FYGHPHQATGMAMGSGGHHD QTASAAAAAY RGFPLSLGMS PYANHHLQRT  
TQDSPYDASI TAACNKIYGD GAGAYKQDCL NIKADAVNGY KDIWNTGGSN  
GGGGGGGGGG GGGAGGTGGA GNANGGNAAN ANGQNNPAGG 
MPVRPSACTP DSRVGGYLDT SGGSPVSHRG GSAGGNVSVS GGNGNAGGVQ 
SGVGVAGAGT AWNANCTISG AAAQTAAASSLHQASNHTFY PWMAIAGKIR 
SDLTQYGGIS TDMGKRYSES LAGSLLPDWL GTNGLRRRGR QTYTRYQTLE 
LEKEFHTNHY LTRRRRIEMA HALCLTERQI KIWFQNRRMK LKKEIQAIKE  
LNEQEKQAQA QKAAAAAAAA AAVQGGHLDQ 
Fibronectin 
domain8-10-Ubx 
MGHHHHHHHH HHSSGHIDDD DKHMAVPPPT DLRFTNIGPD TMRVTWAPPP 
SIDLTNFLVR YSPVKNEEDV AELSISPSDN AVVLTNLLPG TEYVVSVSSV 
YEQHESTPLR GRQKTGLDSP TGIDFSDITA NSFTVHWIAP RATITGYRIR 
HHPEHFSGRP REDRVPHSRN SITLTNLTPG TEYVVSIVAL NGREESPLLI 
GQQSTVSDVP RDLEVVAATP TSLLISWDAP AVTVRYYRIT  
YGETGGNSPV QEFTVPGSKS TATISGLKPG VDYTITVYAV TGRGDSPASS 
KPISISSGSG GHMNSYFEQA SGFYGHPHQA TGMAMGSGGH HDQTASAAAA 
AYRGFPLSLG MSPYANHHLQ RTTQDSPYDA SITAACNKIY GDGAGAYKQD 
CLNIKADAVN GYKDIWNTGG SNGGGGGGGG GGGGGAGGTG 
GAGNANGGNA ANANGQNNPA GGMPVRPSAC TPDSRVGGYL DTSGGSPVSH  
RGGSAGGNVS VSGGNGNAGG VQSGVGVAGA GTAWNANCTI SGAAAQTAAA 
SSLHQASNHT FYPWMAIAGK IRSDLTQYGG ISTDMGKRYS ESLAGSLLPD 
WLGTNGLRRR GRQTYTRYQT LELEKEFHTN HYLTRRRRIE MAHALCLTER 
QIKIWFQNRR MKLKKEIQAI KELNEQEKQA QAQKAAAAAA AAAAVQGGHL 
DQ 
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3.2.2 Protein expression and purification  
All Ubx-fusion expressing plasmids were transformed individually into 
Rosetta(DE3)pLysS competent cells.  For each growth, a single colony was inoculated 
into l00 ml of Luria broth plus 100 mg/L carbenicillin and 34 mg/L chloroamphenicol 
and incubated with shaking overnight.  The overnight culture (5 ml) was then sub-
cultivated into 1 L Luria broth plus the same antibiotics at 37 °C.  Once the absorbance at 
600 nm reached 0.6-0.65, 1 mM IPTG was added to induce protein expression.   For 
protein expression, all cultures were grown for 16 hours at 25 °C.  Cells were harvested 
by centrifugation at 3500 RCF for 30 minutes at 4 ˚C and stored as frozen pellet at -20 
°C.  For purification, all procedures were performed carefully on ice to prevent protease 
degradation. In order to compare final protein yield of all fusions, a more complete lysis 
protocol was performed.  Each aliquot was thawed and lysed in 10 mL of lysis buffer (50 
mM sodium phosphate buffer, pH 8.0, 5 % glucose w/v, 500 mM NaCl, 1 protease 
inhibitor tablet (Roche), 0.8 mg/L DNase I, 5 mg Lysozyme, and 2 mM DTT).  Thawed 
lysate was frozen again at -80°C.  The freeze and thaw procedure was performed twice 
more, followed by ultrasound sonication (Branson digital sonicator, Model S250) at 25 % 
intensity in 10 second intervals for 5 minutes.   Cell lysates were centrifuged at 37000 
RCF for 30 minutes. The supernatant was loaded on a gravity column with 3-5 ml nickel-
nitrilotriacetic acid (Ni-NTA) agarose resin (Qiagen), which was pre-equilibrated with 
equilibration buffer (5% glucose w/v, 500 mM NaCl, 50 mM sodium phosphate buffer, 1 
mM DTT, pH 8.0).  The column was then washed with 10 column volumes of W1 buffer, 
10 column volumes of W2 buffer, and 5 column volumes of W3 buffer (W1, W2, W3 
buffers are equilibration buffer containing 20 mM, 40 mM, and 80 mM imidazole, 
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respectively).  Protein was eluted with 10 mL of elution buffer (equilibration buffer plus 
200 mM imidazole).  Concentrations of the purified Ubx samples were determined using 
the BioRad protein assay (BioRad).  
 
3.2.3 Quantification of total (soluble + insoluble) protein   
For all fusion proteins, a single colony containing transformed cells was inoculated into 
250 ml flask containing 50 ml Luria broth with 100 mg/L carbenicillin and 34 mg/L 
chloroamphenicol and grown at 37 ⁰C at 250 r.p.m.  When the absorbance at 600 nm 
reached 0.6 to 0.65, 1 mM IPTG was added to induce protein expression and the 
temperature was lowered to 25 °C, for an additional 16 hours.  The final absorbance at 
600 nm for fermentations to produce all Ubx fusion proteins ranged from 1.2-1.3.  An 
aliquot (0.5 ml) of cell culture was collected from each flask and spun down by 
centrifugation at 16000 RCF for 3 minutes. Pelleted cells were lysed by 0.5 ml SDS 
PAGE sample buffer and heating at 95 ⁰C for 10 minutes. Protein sample and cell debris 
were then separated by centrifugation at 16000 RCF for 15 minutes. Protein sample was 
then resolved using 10 % SDS-PAGE followed by western blotting (Bio-Rad).  Low 
molecular weight proteins (39.0-61.4 kD) were transferred to nitrocellulose membrane at 
50 V, 150 mA for 2 hours.  High molecular weight proteins (67.2-102.7 kD) were 
transferred at 50 V, 200 mA for 3 hours. A monoclonal mouse anti His-tag antibody 
(Qiagen, Cat# 34670) was used as primary antibody at a 1:5000 dilution. An antibody 
conjugated to a near infrared fluorescence dye, IRDye 800CW Goat anti-Mouse IgG (Li-
Cor), was used as secondary antibody. Signal generated by the secondary antibody was 
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detected by an Odyssey Imaging System. All fusions were tested 3 times from the 
plasmid transformation step to final scanning step.   
 
3.2.4 Solubility assays  
 To test solubility of all fusions, an ammonium sulfate tolerance assay was performed 
(Trevino et al., 2007, Trevino et al., 2008).  Purified Ubx-fusions were concentrated and 
dialyzed into assay buffer (50 mM sodium phosphate buffer, pH 8.0, 5% glucose w/v, 
500 mM NaCl, 100 mM imidazole).  All measurements were performed at room 
temperature (25°C). The solubility of fusion proteins was measured as the quantity of 32 
M fusion protein that remains in solution in 1.1 M ammonium sulfate dissolved in assay 
buffer.  The mixture was allowed to equilibrate for 3 minutes at room temperature.  
Samples were then centrifuged for 3 minutes at 18000 RCF.  The protein concentrations 
in the supernatants were quantified by BioRad protein assay (BioRad).  Assays of all 
fusions were replicated for 3 times, and reported as an average with standard deviation.   
 
3.2.5 Assembly of Ubx fibers  
All assays were performed with same protein concentration, fixed incubation time, and 
controlled environmental parameters (temperature at 25 ˚C and 40-60% humidity).  Ubx 
fusion protein (30 nmol) was placed in a Teflon-coated tray filled with material forming 
buffer (50 mM sodium phosphate buffer, pH 8.0, 5% glucose w/v, 500 mM NaCl).  The 
tray was then incubated for 16 hours at room temperature (approximately 25°C) and 30-
40 % humidity.  Fibers were pulled using a 4 mm diameter inoculating loop from the air-
water interface. Figure 3.4 shows the method for trays setting and fibers pulling. Only the 
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length of the first fiber of each tray was measured.  At least 5 fibers, each pulled from an 
operating tray, were measured for each Ubx-fusion, and the results were evaluated by 
statistical analysis.   
 
Step 1: Add 590 ml buffer G into tray 
 
Step 2: Spread the purified Ubx protein into the tray equally 
 
Step 3: Cover the tray and incubate for 4 hours- 2days (longer time allows more material 
formation, which means stronger fiber/film) 
 
 
Figure 3.4 Assembly of Ubx materials. 
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Step 4: Ubx forms islet on the air/ aqueous interface.  Use plastic rack to collect the 
material. 
 
Step 5: Ubx material is now concentrated near the rack.   Use plastic loop, touch the surface of 
the buffer.  Let Ubx material stick to the loop.  Then gently pull fiber /film.     
 
 
 
 
Figure 3.4 Continued. 
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3.2.6 Ethanol washing and autoclaving of Ubx materials   
mCherry-Ubx fibers were pulled using a 4 mm diameter plastic inoculating loop (VWR) 
from Teflon tray and dried in air for 30 minutes as described above.  Loops with mCherry 
fiber were either dipped into 100% ethanol solution for 30 minutes or autoclaved, the 
loops were sterilized in steam sterilizer for 20 minutes (121°C, 1.27 kg/cm).  mCherry-
Ubx fibers were then observed, and the fluorescence intensity was measured by confocal 
microscopy.   
 
3.2.7 Mixing Ubx and EGFP-Ubx 
Protein mixtures to assess the efficiency of fiber assembly were made by first purifying 
and quantifying pET19b-Ubx and EGFP-Ubx as previously described. The 
concentrations of each protein were used to create mixtures of 0, 20, 40, 60, 80, and 
100% EGFP-Ubx by pipetting the appropriate amount of each protein into 6 micro 
centrifuge tubes and allowing them to incubate at room temperature for 15 minutes. Each 
mixture was added into a separate Teflon coated tray filled with material forming and 
incubated for 20 hours at room temperature (approximately 25°C) and 30-40 % humidity.  
Fibers (N=5) were pulled by a 4 mm diameter inoculating loop from the air-water 
interface, covered, and allowed to dry on the lab bench at room temperature for 30 
minutes. The loops were then placed on a 22 mm x 55 mm coverslip, and imaged 
immediately using a Nikon Eclipse Ti A1R inverted confocal microscope equipped with 
NIS Elements AR 4.10.01 software to analyze fluorescent intensity of both the DAPI and 
FITC channels. 
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3.3 Results 
3.3.1 Generating Ubx fusion proteins 
Previously, we demonstrated that four proteins could be fused to Ubx and retain their 
function once incorporated into materials (Huang et al., 2011).  However, all of these 
proteins were stable monomers – traits that may have facilitated their successful use.  
Conversely, less stable functional proteins could potentially hamper expression of the 
fusion protein, highly charged proteins could inhibit assembly by charge-charge 
repulsion, or very large/multimeric functional proteins may mis-position the self-
assembling region of Ubx, creating weaker materials or possibly even preventing 
assembly.  Our goal was to test the impact of fusing single proteins to Ubx on monomer 
production, materials assembly, and mechanical properties, and identify properties of the 
appended proteins that predict whether a specific fusion can be successfully produced and 
assembled into useful materials.  To accomplish this, we fused 24 peptides or proteins to 
the N-terminus of Ubx (Figure 3.5A, Table 3.1).  We also tested several fusions to the C-
terminus of Ubx, but these proteins did not express well in E. coli, and further C-terminal 
fusions were not pursued.  A similar effect of fusion order on protein expression and 
activity has been previously reported for other protein systems (Jansson et al., 2014, 
Christensen et al., 2009).  
 
By carefully selecting peptides and proteins, we were able to test a wide range of physical 
properties: size (0.45 – 60.9 kDa), predicted charge (-47 - +8.5 at pH =8), stability 
(intrinsically disordered as well as thermostable proteins), secondary structure (, , +, 
/), quaternary structure (monomer, dimer, and tetramer) and solubility.  When 
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possible, groups of related proteins were selected so that as few of these properties as 
possible were simultaneously varied.  Consequently, we focused on 6 categories of 
fusions: peptides, cytokines, fluorescent proteins, solubility tags, enzymes, and ligand 
binding proteins (Table 3.2).  A series of charged peptides were generated to test the 
impact of charge density on the appended moiety as well as provide additional positively 
charged fusions.  In particular, monomeric and tetrameric fluorescent proteins, which 
have similar charges, monomer sizes, and tertiary structures, provided a direct test of the 
role of quaternary structure in materials production.  The series of solubility tags are 
collectively far more soluble and stable than the other proteins.  To examine stability, we 
compared Ubx fused to osteopontin (Opn), an intrinsically disordered protein, with 
mesostable human proteins, and proteins derived from thermophilic bacteria.   
 
Peptide linking sequences were included between the appended proteins and Ubx to 
ensure both proteins had sufficient space to fold and function.  These sequences are rich 
in glycine (to provide flexibility) and serine or histidine (to provide solubility) (Table 
3.2).  For fusions of Ubx to peptides, we used a Gly-Ser-Gly-Ser linking sequences.  For 
full-length proteins fused to Ubx, the sequence linking the two proteins was Gly-His.  
The one exception was pyruvate kinase-Ubx, in which the C-terminus of this tetrameric 
protein has the potential to interfere with subunit contacts.  Therefore, in pyruvate kinase-
Ubx we used a longer and more flexible Gly-Gly-Ser-Gly-Ser linker. 
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3.3.2 Ubx protein fusions are more stable in materials than as free monomers 
Purified recombinant proteins are both expensive and labile (Chatterjee et al., 2010).  
Single-pot synthesis of functionalized materials would significantly lower production 
costs.  The structure and function of protein monomers are notoriously sensitive to 
environmental conditions.  Since the material is in an altered environment relative to bulk 
solvent, it is possible that the material itself could stabilize or destabilize a fused protein.  
Conversely, confining the functional protein within the materials could stabilize the 
functional protein by preventing the motions required for denaturation.  To determine 
whether incorporation of protein fusions alters the stability of the appended protein, we 
examined the structure and fluorescence of mCherry-Ubx fibers under the denaturing 
conditions imposed by sterilization procedures: autoclaving and ethanol washing. Ubx 
materials are remarkably robust and can even survive boiling (Greer et al., 2009).  
Interestingly, mCherry-Ubx fibers remained intact and retained almost 80% of 
fluorescence intensity after incubation in 100% ethanol for 30 minutes (Figure 3.5 B-E). 
After autoclaving mCherry-Ubx fibers in steam sterilizer for 20 minutes (121°C, 1.27 
kg/cm2), 20% of the fluorescence intensity remained.  In both cases, the fiber structure 
appeared undamaged by treatment.  For comparison, monomeric mCherry-Ubx and 
mCherry unfolded, releasing their chromophores, and precipitated when treated with 
alcohol and precipitated when autoclaved (data not shown).  These results imply that Ubx 
fibers remarkably stabilize proteins incorporated by gene fusion. These results are 
consistent with prior studies in which immobilization improved enzyme efficiency or 
stability (Cummings et al., 2013, Forstater et al., 2013, Ma et al., 2007). 
 
 
 
88 
 
 
 
Figure 3.5 Incorporation into materials stabilizes proteins fused to Ubx.  (A) 
Schematic depicting a Ubx fusion protein, in which an N-terminal histidine tag, linker, 
and a functional protein is linked to Ubx via a glycine-histidine linker in a single 
polypeptide chain.  Protein assembled into Ubx material retains some activity under harsh 
sterilization methods.  (B) Photomicrograph of mCherry-Ubx fibers.  (C) Fiber that has 
been incubated for 30 min. in 100% EtOH.  (D) An mCherry-Ubx fiber that has been 
autoclaved for 30 min.  (E) mCherry in fibers exposed to EtOH or autoclaved retain more 
activity than monomeric mCherry in the same conditions.  (F) Fluorescence from fibers 
produced from mixtures of EGFP-Ubx and Ubx correlates with the percentage of EGFP-
Ubx.  (G-L) Fluorescent micrographs of fibers composed of 0, 20, 40, 60, 80, and 100% 
EGFP-Ubx, respectively.   
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Table 3.2 Properties of proteins fused to Ubx. 
Fusion 
category 
Fusion Size 
(kDa) 
Charge 
at pH 8 
SCOP 
Classification 
Quaternary 
Structure 
Linker 
Peptides1 GSGSGS 0.45 -0.5  Peptide Monomer H 
 RGD 0.78 -0.5  Peptide Monomer GSGSH 
 WRW 0.98 0.5  Peptide Monomer GSGSH 
 YKLKYY 1.3 1.5  Peptide Monomer GSGSH 
Cytokines SDF-1 8.2 7.5  + Dimer GH 
 bFGF 17.4 8.5   Dimer GH 
 VEGF 19.6 -3.2   Dimer GH 
 Osteopontin 35.6 -46.9  N/A3 Monomer GH 
Fluorescent 
protein 
AmCyan 25.5 -2.6  + Tetramer GH 
mCherry 26.9 -6.6  + Monomer GH 
EBFP 27.1 -8.9  + Monomer GH 
EGFP 27.1 -9.0  + Monomer GH 
Fusion tags SUMO 12.2 -6.5  + Monomer GSGSH 
 Thioredoxin 12.8 -6.0  / Dimer GSGSH 
 GST 26.5 -4.6   Dimer GSGSH 
 MBP 41.3 -10.9  / Monomer GSGSH 
 NusA 55.8 -41.4   Monomer GSGSH 
Enzymes PFK 34.6 -4.1  / Tetramer GSGSH 
 L-PYK 58.9 -4.1   Tetramer GGSGSH 
 Luciferase 60.9 -5.6  +/ Monomer GH 
Ligand 
Binding 
Protein 
TneSSB 16.7 -7.5   Tetramer GSGSH 
TmaSSB 16.7 -7.5   Tetramer GSGSH 
Myoglobin 17.6 2.7   Monomer GH 
FN 30.0 -6.4   Monomer GH 
1The sequences of appended peptides are listed 
2Abbreviations: SDF-1a, Stromal cell-derived factor-1; bFGF, basic Fibroblast growth 
factor; VEGF, vascular endothelial growth factor; EBFP, Enhanced blue fluorescent 
protein; EGFP, Enhanced green fluorescent protein; SUMO, Small ubiquitin-like 
modifier protein; GST, Glutathione S-transferase; MBP, Maltose binding protein; PFK, 
phosphofructokinase; L-PYK, liver pyruvate kinase; TneSSB, Thermotoga neapolitana 
Single-stranded DNA binding protein; TmaSSB, Thermatoga maritime Single-stranded 
DNA binding protein; FN, type III domain 8-10 of Fibronectin. 
3Not Applicable 
 
 
 
 
 
90 
 
3.3.3 The appended proteins determine Ubx fusion protein expression levels 
In addition to the fibers altering the fused protein, the fused protein could impact Ubx 
materials.  In particular, proteins fused to Ubx could impact various aspects of materials 
production: expression, solubility, purification yield, and assembly (Table 3.3).  Materials 
assembly is strongly dependent on protein concentration (Figure 3.6), and therefore any 
factors that alter protein production or assembly will also impact the amount of materials 
that can be produced.  In general, high levels of protein expression are desirable because 
they increase the yield of purified protein and ultimately the amount of materials 
produced.  However, robust expression of a polymer-forming protein, such as Ubx, in 
bacteria may lead to aggregation / inclusion body formation and thus lower the total 
yield.  It is well established that protein fusions can dramatically alter the expression of 
proteins (Bondos, 2006, Davis et al., 2000, Forrer and Jaussi, 1998, Zhang et al., 2004). 
To determine how fusions alter Ubx expression in E. coli, we used Western blots to 
compare the expression of Ubx and its variants 16 hrs after induction with IPTG.  This 
method measures total (soluble and insoluble) protein produced by the bacteria (Figure 
3.7, Figure 3.8).  We found the results varied significantly among the Ubx fusion 
proteins, ranging from more than tripling protein expression to reducing expression to 
nearly undetectable levels.   
 
We also measured the expression of a subset of the functional proteins not fused to Ubx.  
Proteins were selected to test the range of productive expression levels observed.  The 
expression of the isolated functional protein and the corresponding Ubx fusion protein 
correlate very well, suggesting that the protein appended to Ubx determines the 
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expression level (Figure 3.7).  We examined whether properties of the fused protein 
could predict expression levels.  Expression does not appear to correlate with the 
molecular weight, the predicted charge density, or the quaternary structure of the 
appended proteins (Figure 3.9).   
 
Protein solubility is another factor that influences the production of recombinant proteins 
(Bondos, 2006, Davis et al., 2000, Forrer and Jaussi, 1998, Zhang et al., 2004).  Protein 
solubility was determined by measuring the resistance of each protein to ammonium 
sulfate precipitation.  In the presence of ammonium sulfate, solubility determines the 
concentration of protein that remains in solution (Trevino et al., 2007, Trevino et al., 
2008).  Our measurements were performed at 1.1 M ammonium sulfate, at which 
concentration differences in the solubility of Ubx fusions are most pronounced (Figure 
3.10).  This observation is consistent with data from other proteins. The solubility varies 
> 3-fold among Ubx fusion proteins (Figure 3.11), and fusions can either increase or 
decrease solubility relative to Ubx.  The measured solubilities roughly correlate with the 
yield from the protein purification (r = 0.83).  Monomeric proteins were more soluble, on 
average, when fused with Ubx than dimeric or tetrameric proteins.  The reduced 
solubility of dimeric and tetrameric Ubx fusions is not an artifact of protein selection; the 
corresponding isolated proteins have solubilties similar to the monomeric proteins tested 
(Figure 3.12).  Because fusions solubility is related to the solubility of the appended 
protein, the solubility and quaternary structure of the appended protein can be used to 
estimate the relative purification yield of the Ubx fusion.  Neither the size nor the charge 
density of the appended proteins correlated with the solubility (Figure 3.13). 
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Furthermore, the expression level of the fusion protein also did not correlate with the 
solubility of the appended protein (Figure 3.13). 
 
 
 
 
Table 3.3 Definition of terms. 
Term Definition 
Expression The amount of soluble and insoluble Ubx 
or fusion protein generated in E. coli. 
  
Yield The amount of soluble protein purified 
from E. coli. 
  
Solubility The maximum amount of protein that be 
dissolved in 1.1 M ammonium sulfate. 
  
Assembly The ability of a protein to self-assemble 
into materials. 
 
 
 
Figure 3.6 Protein concentration is a determinative factor in materials assembly.  
The length of fiber that can be drawn from solution is dependent on the ability of the Ubx 
variant to self-assemble into materials.  Fiber assembly is strongly dependent on protein 
concentration for (A) bFGF-Ubx and (B) mCherry-Ubx, even though these proteins have 
a different charge (20 kDa vs. 30 kDa), fold as defined by SCOP (loops/strands vs b 
barrel), and quaternary structure (dimer vs. monomer). 
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Figure 3.7 Expression of Ubx fusion proteins varies significantly with the identity of 
the appended protein.    (A) Expression of all tested Ubx fusion proteins.  (B) 
Comparison of the expression Ubx fusions proteins (black bars) with the isolated 
functional proteins.   Expression was measured by Western blot of whole-cell lysates, and 
representative results are shown. 
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Figure 3.8 Western blot showing the relative expression levels of plain Ubx and a 
subset of Ubx fusion proteins.   
 
 
 
Figure 3.9 The expression of Ubx fusion proteins relative to Ubx does not correlate 
with the size, charge, or quaternary structure. Theoretical charge density was 
calculated as Charge*1000/Molecular weight.  M, monomer.  D, dimer, T, tetramer. 
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Figure 3.10 Measuring the solubility of Ubx fusions by their resistance to 
ammonium sulfate precipitation.  Differences in protein solubility are reflected in the 
differences in the concentration of protein that remain in solution at each ammonium 
sulfate concentration.  Ubx and representative Ubx fusion proteins are shown.  Because 
the rank order of protein solubility persists at every concentration of ammonium sulfate, 
all proteins were analyzed based on the concentration of each proteins’ soluble fraction at 
1.1 M ammonium sulfate, where the differences between proteins are largest.  This 
approach has been used previously (Trevino 2007, Trevino 2008). 
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Figure 3.11 Assessing the solubility of Ubx and Ubx fusion proteins.  (A) Relative 
solubility of Ubx-fusions measured by ammonium sulfate precipitation.  (B) Solubility 
correlates with protein yield (r=0.83). (C) Formation of quaternary structure correlates 
with reduced protein solubility (r= 0.69).  M, monomer.  D, dimer, T, tetramer.  
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Figure 3.12 The observation of low solubility in fusions that form quaternary 
structure is not an artifact that caused by the selection of less soluble appended 
proteins. The solubility of selected functional proteins (blue) and fusion proteins (red) in 
1.1 M ammonium sulfate is shown. 
 
 
Figure 3.13 The solubility of Ubx fusion proteins relative to Ubx does not correlate 
with the size, or the charge of the appended protein. (C) Furthermore, protein 
expression and solubility also do not correlate (r = 0.03). Theoretical charge density was 
calculated as Charge*1000/Molecular weight. 
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3.3.4 The appended proteins have no significant effect on materials assembly 
Solubility and stability tags are widely used to prevent aggregation, assist folding, and 
improve protein yield (Bondos, 2006, Davis et al., 2000, Forrer and Jaussi, 1998, Zhang 
et al., 2004). Thus, they have the potential to positively contribute to the production of 
protein-based materials.  On the other hand, very soluble proteins may also impede 
protein polymerization and thus reduce materials production. For example, fusing GST to 
a Huntington protein fragment can prevent aggregation to amyloid (Scherzinger et al., 
1997).  In contrast, GST improves Ubx solubility without impacting self-assembly 
(Figure 3.11 and 3.14).  Although the reason for this difference is not known, one 
reasonable hypothesis is that the GST protein (26.5 kDa) is more easily accommodated in 
the extensible Ubx materials than in rigid amyloid fibrils.  Furthermore, the density of 
GSTs would be lower in Ubx materials because Ubx is a much larger protein (13.7 kDa 
Huntingtin fragment vs. 40 kDa Ubx).  Nevertheless, proteins appended to Ubx can 
potentially impede self-assembly by many additional mechanisms.  If the appended 
protein carries a large charge, then charge-charge repulsion could inhibit the 
intermolecular interactions required for self-assembly.  The appended protein could bind 
Ubx and block the assembly interface.  This mechanism is especially concerning for Ubx, 
since, like many transcription factors, it has a net positive charge, whereas many 
cytosolic or secreted proteins have a negative charge.  Finally, fusing large or multimeric 
proteins could mis-position the self-assembling protein such that it cannot form the 
necessary intermolecular interactions. 
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To determine whether the presence of the functional proteins compromises material 
assembly, we compared the ability of Ubx fusions to assemble under constant conditions.  
Ubx fusions were incubated at a fixed protein concentration (50 nM), temperature (25˚C) 
and humidity (40-60%) to form a film at the air-water interface.  This film was 
subsequently drawn into fibers.  The length of fiber produced depends, in part, on the 
ability of Ubx variants to assemble; proteins that assemble poorly produce less film and 
thus shorter fibers (Greer et al., 2009).  Surprisingly, despite the variations in size, 
charge, stability, and quaternary structure, all Ubx-fusions formed materials equally well 
(Figure 3.14).  This similarity was not an artifact of the selected conditions, since the 
similarities persist at different protein concentrations (Figure 3.6).  Given we observed no 
significant variation, there was of course no correlation with molecular weight, charge 
density, or quaternary structure (Figure 3.15).  Confocal microscopy confirms that fibers 
produced by all Ubx-fusions have nearly identical morphology (Figure 3.14, Figure 
3.16).   
 
If Ubx and Ubx fusion proteins form materials equally well, then a mixture of the two 
proteins should produce fibers containing the same ratio of the two proteins.  However, if 
one protein assembles more efficiently than the other, then the protein content in the fiber 
should be biased toward the protein that assembles more efficiently.  We generated a 
series of assembly trays containing the same total concentration of protein, but different 
ratios of Ubx to EGFP-Ubx.  The EGFP content of fibers drawn from these trays was 
measured by fluorescence microscopy (Figure 3.5).  The intensity of the natural blue 
fluorescence of Ubx fibers were used to gauge the reproducibility of these measurements.  
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We found the EGFP-Ubx content in fibers linearly correlates with percentage of EGFP-
Ubx in the original protein mixture, indicating that these two proteins are equally able to 
self-assemble into materials (Figure 3.5).  Together, these results indicate that the strong 
tendency of Ubx protein to self-assemble is not altered by the use of fusion proteins. 
 
Figure 3.14 Materials assembly is not significantly impacted by protein fusion.   (A) 
For all experiments, 50 nM of the Ubx variants were incubated at room temperature for 
16 hrs.  Materials formation was measured as length of fiber that can be drawn from the 
surface of the assembly solution. (B-E) Differential interference contrast microscopy of 
Ubx, VEGF-Ubx, MBP-Ubx, and Phosphofructokinase-Ubx, respectively.  Images of the 
remaining Ubx fusions are in Figure 3.16.  
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Figure 3.15 Fiber length of the Ubx fusion fibers does not correlate with size and 
charge. Theoretical charge density was calculated as Charge*1000/Molecular weight. M, 
monomer; D, dimer; T, tetramer. 
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Figure 3.16 Confocal differential interference contrast (DIC) microscopy images of 
fibers composed of Ubx and Ubx fusions are similar. Panel (A) GSGSGS-Ubx, (B) 
RGD-Ubx, (C) WRW-Ubx, (D) YKLKYY-Ubx, (E) SDF1a-Ubx, (F) bFGF-Ubx, (G) 
AmCyan-Ubx, (H) mCherry-Ubx, (I) EGFP-Ubx, (J) SUMO-Ubx, (K) Thioredoxin-Ubx, 
(L) GST-Ubx, (M) NusAUbx, (N) Myoglobin-Ubx, (O) Luciferase-Ubx, (P) TmaSSB-
Ubx, (Q) TneSSB-Ubx, (R) L-PYK-Ubx. 
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3.3.5 Double Ubx fusion proteins self-assemble 
Despite the differences in the properties of the appended proteins, the possibility exists 
that all Ubx variants only appear to self-assemble equally well because we did not select 
proteins that produce a difference.  In particular, the size and charge of the appended 
proteins were expected to have a large impact on Ubx self-assembly.  To push both of 
these boundaries, we fused two NusA proteins to Ubx.  Thus, the appended portion adds 
110.6 Da, which is approximately 3 times the size of Ubx.  Furthermore, the triple fusion 
has a theoretical charge of -82.2 at pH = 8.0.  To our surprise, the NusA-NusA-Ubx 
protein still self-assembled into materials (Figure 3.17).   
 
The fact that double fusion proteins can be successfully produced and incorporated into 
materials creates two additional advantages.  First, by using double fusions, two proteins 
can be simultaneously incorporated into Ubx at stoichiometric ratios, increasing the 
functional capacity of the materials.  Second, the solubility or purification yield of 
difficult fusions can be potentially enhanced by adding a well-behaved protein.  To test 
this possibility, we created EGFP-VEGF-Ubx.  Both the solubility and purification yield 
of the double fusion was improved relative to VEGF-Ubx (Figure 3.17).  In a second test, 
we fused NusA to the N-terminus of Opn-Ubx, which does not express in E. coli.  In 
contrast, the NusA-Opn-Ubx double fusion does express (Figure 3.18).  Finally, a fusion 
of domains 8-10 of fibronectin type III to Ubx could not be reliably expressed in E. coli 
due to severe proteolysis.  Additional fusion of GST to the N-terminus reduces this 
proteolysis, allowing production of the full-length fusion protein (Figure 3.18).  Thus, 
double fusions can facilitate the production of many problem proteins.  Notably, this 
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solution requires a self-assembling protein, like Ubx, that can accommodate large 
fusions.        
 
 
 
Figure 3.17 Double fusions solve low solubility / yield problems.   (A) Ubx can 
assemble large, highly charged triple fusion proteins, i.e. NusA-NusA-Ubx (110.6kD, -
82.2 charge at pH=8) into material.   (B-C) Fusion with soluble protein increases 
solubility and boosts the yield of VEGF-Ubx.   
 
 
 
Figure 3.18 Double fusion solves problems in different steps of producing Ubx 
materials. (A) Western blot with infra-red dye showed that fusion with NusA protein 
increases the expression of Osteopontin-Ubx.  (B) Relative expression level of Ubx, 
OPN-Ubx and NusA-OPN-Ubx.  (C) Fusion with GST stabilizes Fibronectin domains-
Ubx (*:FN-Ubx,     :GST-FN-Ubx)   
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3.3.6 A comparison of the mechanical properties of Ubx and EGFP-Ubx  
In addition to altering monomer production and materials assembly, fusing proteins to 
Ubx may also impact the mechanical properties of the resulting materials.  Fiber diameter 
dictates the mechanical properties of unmodified Ubx materials: small diameter (5-10 
m) Ubx fibers have high breaking stress and low breaking strain and undergo elastic 
deformation, whereas larger Ubx fibers exhibit a combination of elastic and plastic 
deformation, are highly extensible, and rupture at lower stress.  To test whether protein 
fusions impact the mechanical properties of Ubx fibers, we examined EGFP-Ubx fibers. 
Similar to Ubx fibers, the mechanical properties of EGFP-Ubx fibers were strongly 
dependent on fiber diameter (Figure 3.19). In addition, EGFP-Ubx fibers wrinkle, similar 
to Ubx fibers, upon unloading, to an extent that depends on both strain and fiber diameter 
(Figure 3.20) (Huang et al., 2010). Compared to Ubx fibers of the same diameter, the 
breaking strain is reduced in the EGFP-Ubx fusion fibers.  Indeed, a 20 m Ubx fiber is 
~120% extensible, whereas a 20 m EGFP-Ubx fiber is only 40% extensible.  Since the 
mechanical properties of all fibers are diameter-dependent, a specific breaking strain can 
still be achieved by generating fibers with the appropriate diameter.  Even with these 
alterations, it is important to note that the mechanical properties of EGFP-Ubx fibers are 
still in a biologically relevant range. 
 
At any given fiber diameter, the breaking stress of the EGFP-Ubx chimera fibers is 
slightly higher than that for the Ubx fibers, suggesting that the presence of EGFP may 
contribute to the tensile strength of the fibers.  This increased strength may be due to 
intermolecular interactions in the materials between the negatively charged EGFP and the 
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positively charged DNA binding domain in the Ubx protein (Majithia et al., 2011).  From 
these data, we conclude that the chimeric partner for Ubx is capable of influencing the 
mechanical properties of the fiber. Consequently, mechanical properties should be 
considered when engineering a novel chimeric monomer for materials assembly. 
 
Figure 3.19 Although fusions don’t impact fiber morphology, the mechanical 
properties of fibers are altered. (A) Stress-strain curves for small (x-y um) medium (a-b 
um) and wide (>z um) EGFP-Ubx fibers.  (B-C) Comparing engineering stress and 
engineering strain for Ubx (grey) and EGFP-Ubx (green) fibers as a function of fiber 
diameter. 
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Figure 3.20 SEM images of EGFP-Ubx fibers of different diameters before and after 
stretching. Plastic deformation is more pronounced as the diameters of EGFP-Ubx fibers 
increase, as observed for Ubx fibers. 
 
3.4. Conclusions  
Protein fusions provide a facile mechanism to incorporate a broad array of chemical 
functions into protein-based materials.  Not only can proteins be safely incorporated by 
this method, incorporation into materials can also enhance their stability.  However, the 
presence of the appended protein has the potential to compromise production of the 
fusion protein monomers, assembly of the monomers into materials, and the mechanical 
properties of the functionalized materials.  We created >20 fusion proteins to determine 
to what extent the appended proteins impact the production and properties of the final 
materials.  Proteins were selected with a range of sizes, structures, stabilities, solubilities, 
and charges.  We found that the appended protein had a large effect on production of the 
monomer protein, with solubility and quaternary structure of the appended protein being 
the best predictors for success.  In contrast, the ability to self-assemble into materials was 
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dominated by Ubx, and the presence or identity of a fused protein had little impact on 
materials assembly.  Although the appended protein can alter the mechanical properties 
of the materials as demonstrated by the EGFP-Ubx fusion, these properties, like those of 
Ubx fibers, (i) can be adjusted by varying fiber diameter and (ii) lie in a biologically 
relevant range (Greer et al.,2009, Huang et el., 2010). 
 
Generating materials from fusion proteins and from a mixture of protein monomers 
allows easy control of the concentration of the functional protein and enables 
incorporation of multiple functionalities.  Because all Ubx-based materials self-assemble 
equally well, mixing Ubx fusions with each other or with plain Ubx precisely and 
predictably determines the concentration of the functional proteins in the resulting 
materials.  This ability allows specific mixtures of functionalities to be incorporated into 
materials.  The potential to functionalize Ubx materials is further enhanced by creating 
double fusion proteins, in which two functional proteins are present at stoichiometric 
levels. Double fusion proteins can also ameliorate the low expression levels or poor 
solubility associated with some single fusion proteins by appending a highly soluble 
protein to the sequence.  In summary, the range of functional proteins that can be 
incorporated into elastomeric protein-based materials is far greater than previously 
established. 
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CHAPTER IV 
USING FUNCTIONALIZED UBX BIOMATERIAL TO MAKE                
BIOCOMPATIBLE MATERIALS FOR STENT USE 
 
4.1 Introduction 
Previous collaborations between Bondos, Bayless and Rice-Ficht laboratories in Texas 
A&M University have already shown that Ubx materials are biocompatible and exhibits 
low immunogenicity (Patterson et al., 2014, Patterson et al. 2015) (Figure 1.3).  In 
addition, Ubx materials adhere to plastic and metal, and thus can be used to coat to a 
variety of shapes and textures of tools for different purposes.  By circular dichroism, 
fluorescence spectrometry, and enzymatic experiments, our laboratory has shown that 
proteins still retain their structures and functions when fused to Ubx and assembled into 
materials (Figure 1.4) (Huang et al., 2011).  VEGF-Ubx materials show strong ability to 
stimulate migration and survival of ECs in vitro and promote angiogenesis in vivo. 
(Appendix) Together, Ubx materials demonstrate great potential to be used in a variety of 
biomedical applications.  Our laboratory first aimed to use Ubx biomaterials to make 
biocompatible and functional stent for deployment during angioplasty surgery. 
 
Cardiovascular disease is the leading cause of death globally (Go et al., 2004). 
Atherosclerosis, one of the major causes of cardiovascular disease, occur when an artery 
wall thickens as a result of accumulation of lipids, cell debris and a mixture of cells 
(foam cells, smooth muscle cells, platelets, etc.)(Hansson and Libby, 2006)    
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Atherosclerosis can narrow coronary arteries and reduce the blood flow to heart, leading 
to heart attack or sudden cardiac death.   
 
Treatments of atherosclerosis include drugs inhibiting the synthesis of cholesterol, diet 
management and angioplasty procedures that include stents and bypass surgery.  In 
angioplasty surgery, stents are often inserted into and physically hold/open the artery 
after clearance of plaque (Howard-Alpe et al., 2007, Iqbal et al., 2003). However, the 
stents are inserted into the damaged part of artery, where inflammation and plaque 
formation are already highly active (Farooq et al., 2011).  The insertion of stent also 
causes damage to the artery during surgery and recruit more platelets to the damaged 
area. In addition, the stent may induce immune responses due to the use of materials 
which are not biocompatible. Damage of arterial walls not only induce the recruitment of 
platelet cells, but also monocytes, macrophages, and neutrophils to the site of injury. 
(Shah, 2003) Macrophages in particular express many growth factors, cytokines, and 
enzymes that facilitate vascular smooth muscle cell migration and proliferation from in 
the tunica intima, which causes the thickening of arterial walls and decreased arterial 
lumen space (Danenberg et al., 2002). Together, plaque formation, recurrence of 
atherosclerosis and re-narrowing of artery often happens within 3-6 months after the 
surgery (Fischman, et al., 1994) (Serruys, et al., 1994), resulting in the need of more 
angioplasty surgeries.  Therefore, a biocompatible stent that can: i) prevent platelet and 
smooth muscle cells binding ii) induce the area to heal without further constricting blood 
flow is needed to improve this treatment and the quality of lives of patients (Avci-Adali 
et al., 2010).  Rapid and selective capture of endothelial cells (ECs) and endothelial 
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progenitor cells (EPCs) on the stent could prevent platelet and smooth muscle cells 
binding and avoid plaque formation and reduce restenosis.  ECs can stimulate re-
endothelialization of injured blood vessels and induce the formation of new blood vessels 
in areas with a low supply of oxygen (Avci-Adali et al., 2010, Shu et al., 2013). Because 
endothelial progenitor cells are present in the blood at very low concentrations, the stent 
needs to be coated with molecules that will not only attract and bind endothelial cells, but 
also subsequently induce them to repair the artery by forming a new inner lining on the 
surface of the implanted stent. Many different molecular strategies have been devised to 
attract and retain ECs at the stent surface, but most rely on coating the surface in a protein 
or peptide that specifically binds ECs. Different strategies to attach these proteins or 
peptides to the stent include adsorption of protein to the stent surface, trapping the 
molecules in the stent plastic, and chemically tethering the molecules to the stent surface. 
 
However, each of these approaches can inactivates many of the protein molecules (Avci-
Adali et al., 2010). Furthermore, proteins are eventually lost from the stent during the 
adsorption and trapping steps because they are not covalently bound to the stent. The 
resulting low density of active proteins or peptides on the stent surface limits the utility of 
this approach. A second problem is that other studies only captured ECs without 
providing any instructions to stimulate ECs to divide and migrate, which are required to 
rapidly reform the inner lining of the artery. Our goal is to design Ubx materials that can 
specifically attract endothelial cells (ECs), but not smooth muscle cells (SMCs) or 
platelets. After implantation into an artery, the nearby endothelial cells and the progenitor 
endothelial cells in blood flow can be recruited by the active molecules on the Ubx 
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material on the coated stent surface.  To achieve this goal, we aim to create multiple Ubx 
fusions that have different functions on regulating the cell behaviors of ECs, SMCs and 
platelet cells. The fusions we planned to make and test are: VEGF (Appendix), SDF-1α, 
bFGF, YIGSR peptide.  Our ultimate goal is to mix these fusions and make a multi-
functional Ubx material that has synergistic effects on inducing in stent-re-
endothelialization and can prevent thrombosis and in-stent restenosis. The functions of 
each fusions and the signal transduction pathways regulated by them are described below. 
 
4.1.1 SDF-1α (CXCL12) 
The stromal cell-derived factor 1α (SDF-1α), also known as C-X-C motif chemokine 12 
(CXCL12), is a chemokine protein.  The receptor for this chemokine is CXCR4, a GPCR 
which was previously called LESTR or fusin (Bleul et al., 1996). The SDF-1α-CXCR4 
interaction used to be considered exclusive (unlike other chemokines and their receptors), 
but recently it was suggested that SDF-1α may also bind the CXCR7 receptor (Burns et 
al., 2006).  Binding of SDF-1α to CXCR4 induces the dimerization of the receptor and 
activation of inhibitory G proteins. Several signal transduction pathways downstream of 
CXCR4 have now been identified, including activation of tyrosine kinases, focal 
adhesion kinase, paxilin, extracellular-signal-regulated kinases, protein kinase C (PKC), 
phospholipase C-γ, and phosphoinositol 3-kinase.   Previous studies suggest that SDF-1α 
has strong effect on endothelial cells.  For example, SDF-1α regulates angiogenesis by 
recruiting endothelial progenitor cells (EPCs) from the bone marrow through a CXCR4 
dependent PI3K/Akt/eNOS pathway (Zheng et al., 2007). SDF-1α also decrease the 
apoptosis of endothelial progenitor cells, which is also through PI3K/Akt/eNOS pathway 
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(Zheng et al., 2008). SDF-1α also has been shown to promote ECs migration through 
activating ERK signaling (Pi et al. 2009, Beverly et al., 2010).  SDF-1α can induce 
angiogenesis by promote endothelial cell chemotaxis and tube formation.  Therefore, 
SDF-1α may be very potent for the stent project because it has the desired effects on 
endothelial cells (ECs), as described above.  However, SDF-1α expresses in most organs 
and is believed to control other physiological responses, for example, it may stimulate the 
mobilization and adhesion of smooth muscle progenitor cells (Andreas et al., 2006).  
Although there is no clear and direct evidence, but the effects of SDF-1α on SMC 
migration may also through PI3K/AKT pathway (Andreas et al., 2006).  Therefore, when 
conduct experiments on the SDF-1α-Ubx fusion, the effects on smooth muscle cells also 
needs to be taken into consideration.   Although SDF-1α -Ubx material may also 
stimulate the migration and proliferation of SMCs and induce restenosis, we hope to see 
that the SDF-1α -Ubx material triggers stronger responses on endothelial cells, for 
example, higher adhesion, migration or survival.  Heparin is a similar example.  Heparin 
coated stent is widely studied and there are already many clinical trials on it. Although 
heparin also induce the proliferation of SMC, but it triggers much higher proliferation 
rate on ECs and therefore compromises its effects on SMCs.     
 
4.1.2 bFGF 
bFGF, the basic fibroblast growth factor, also known as FGF2 or FGF-β, is a member of 
the fibroblast growth factor family (Kim et al., 1998).  bFGF signals through binding 
with FGFR1 and FGFR2 (El-Husseini et al., 1994). FGF is known to be very important 
for new blood vessel growth at the wound site (Werner et al., 2003). Endothelial cells 
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express high levels of FGFR1 and FGFR2 (Turner et al., 2010). FGFs stimulates both 
endothelial cell proliferation and migration mainly through MAPK activation (Turner et 
al., 2010).  PKC activation is also required for FGF-induced endothelial cell proliferation 
and migration (Daviet et al., 1990).  Blocking of PI3K signaling is also shown to inhibit 
the motility of endothelial cells. (Landgren et al., 1998).  Although bFGF also stimulates 
the migration and proliferation of SMCs, some studies have shown that bFGF has strong 
effects on in stent-re-endothelialization that may overwhelm its effects on SMCs 
(Kitamura et al., 2014).   
 
4.1.3 YIGSR peptide 
YIGSR increase the adhesion and migration of ECs, but not SMCs or platelet (Fittkaua et 
al., 2005, Jun et al., 2004, Ruoslahti et al., 1996). YIGSR is a peptide derived from the 
laminin B1 chain. Unlike RGD and PHSRN, the other two common cell binding peptides, 
YIGSR does not interact with the integrin family of cell receptors but with the 67 kDa 
laminin binding protein (LBP) (Avci-Adali et al., 2010). Although YIGSR is derived 
from laminin and facilitate identical cellular adhesion as laminin, YIGSR is unable to 
promote the same signaling triggered by laminin B1 chain (Boateng et al., 2005). 
Therefore, it is difficult to examine the signaling change by YIGSR peptide.  Since we 
want to use YIGSR to promote cell binding of ECs, we will focus on the adhesion 
affinity and migration ability of ECs and SMCs with YIGSR-Ubx fiber.   
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4.2 Materials and methods 
4.2.1 Ubx materials  
Monomers of his-tagged Ultrabithorax splicing isoform Ia, along with SDF-1α, bFGF, 
Ghlerin-Ubx and YIGSR-Ubx (Tsai et al., 2015), were produced in E. coli from the 
pET19b-UbxIa vector and purified as previously described. Ubx fibers were produced by 
the buffer reservoir system, also as previously described (Tsai et al., 2015).  
 
4.2.2 Cell culture  
Primary human umbilical vein endothelial cells (HUVEC) (Lonza, C2517A) were 
cultured and used at passages 3-6. Cells were grown on gelatin-coated tissue culture 
flasks, passaged once per week in M199 growth medium supplemented with heparin, 
bovine hypothalamic extract, fetal bovine serum, antibiotics and gentamycin as 
described.  
 
4.2.3 Migration assay  
HUVECs or GFP-transfected HUVECs were seeded onto gelatin-coated 24-wells plate 
with 300 µl supermedia and allowed to reach confluency (around 24 hours). Supermedia 
was then removed and wells were washed by 300 µl M199 media. Cells were cultured in 
300 µl M199 without serum for 2 hours. M199 media was then replaced by 225 µl M199 
+ 1.5 % fetal bovine serum prior to placement of inoculation loops wrapped with SDF-
1α-Ubx or plain Ubx fibers (4 fibers on each side) onto cell monolayers. After a 16 hour 
incubation in M199 with 1.5% serum, the cells on Ubx fibers were fixed and stained by 
DAPI and imaged using confocal microscopy. 
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4.2.4 Testing signaling triggered by Ubx materials  
Loops wrapped around by SDF-1α-Ubx or plain-Ubx fibers (4 fibers on each side) were 
pulled and rehydrated in a sealed Styrofoam box with wet paper towels for 2 hours. 
Loops with rehydrated fibers were then placed in 24-well tissue culture plate. One T75 
flask with confluent HUVECs was trypsinized and re-suspended by 6.5 ml of 
supermedia.  Suspended cells (125 µl) was seeded directly onto the fibers.  Cells were 
allowed to attach to fibers for 5-10 minutes before an extra 125 µl of supermedia was 
added into each well.  HUVECs were cultured with fibers for 16 hours and the cultured 
media was removed, following by 300 µl of M199 wash to starve the cells. 225 µl of 
M199 and cells were incubated for varying amounts of time as indicated. Loops were 
collected and cells were directly lysed in 1X sample buffer.     
 
4.2.5 Western blot  
Four loops containing attached cells were collected in 125 µl of 1X sample buffer and 
boiled in microcentrifuge tubes for 10 minutes at 95C. Protein lysates were separated by 
SDS-PAGE and transferred to polyvinylidene fluoride membranes (Fisher Scientific). 
After blocking in 5% nonfat dry milk or BSA ( for pERK) at room temperature for 1 
hour, the membranes were incubated with monoclonal antibody against ERK (1:500 in 
TBST; p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb, #4695S, Cell Signaling 
Technology), pERK (1:500 in TBST; Phospho-p44/42 MAPK (Erk1/2)(Thr202/Tyr204) 
Antibody #9101 Cell Signaling Technology), PECAM or GAPDH (1:10,000 in TBST; 
Abcam) at 4 C for 16 hours. The membranes were washed five times before incubation 
with goat anti-rabbit secondary antibody (1:5,000; DAKO) for 2 hours. Immunoreactive 
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proteins were visualized using enhanced chemiluminescence (Millipore) and followed by 
film (Denville Scientific) exposure.  
 
4.3 Results 
4.3.1 SDF-1α-Ubx material promotes endothelial cell migration and attachment in 
vitro 
SDF-1α has been shown to promote ECs migration through activating ERK signaling and 
PI3K/Akt signaling (Pi et al. 2009, Teicher et al., 2010). Therefore, we first asked 
whether SDF-1α-Ubx materials can induce the same effects on ECs. In the migration 
assays, HUVECs or GFP-transfected HUVECs were cultured as a confluent monolayer 
prior to incubation at low serum (1.5%) for 2 hours. Ubx materials were then placed into 
the culture wells and incubated with the cells for 16 hours in media containing low level 
(1.5%) of serum.  The cells were then fixed and stained with DAPI to identify cells that 
migrated onto Ubx materials (Figure 5.1 A-B).  Although the effect is not as strong as 
VEGF-Ubx material (Figure 4.5), significantly more HUVECs migrated onto SDF-1α-
Ubx fibers when compared to control Ubx fibers (Figure 5.1C; p<0.01), indicating that 
VEGF-Ubx materials stimulated migration of ECs in low serum conditions.  
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Figure 4.1 SDF-1α -Ubx fiber promotes enhanced recruitment and migration of 
endothelial cells. SDF-1α-Ubx (A) and plain Ubx (B) fibers were cultured overnight 
with an established monolayer of GFP-transfected HUVECs in low (1.5%) serum. Cells 
were fixed, stained with DAPI (blue), and imaged using confocal microscopy. (C) 
Quantification of the number of cells/100 µm distance attached to plain Ubx vs. SDF-1α-
Ubx fibers. Data were averaged from 10 independent fields in each group from 3 
experiments. Data were analyzed for significance using univariate analysis of variance 
(ANOVA) with * indicating p < 0.01. 
 
 
4.3.2 SDF-1α–Ubx fiber does not induce the ERK signaling in HUVECs  
SDF-1α-Ubx material promotes endothelial cell migration and attachment in vitro, 
suggesting that SDF-1α protein in Ubx material may induce the down steam signaling of 
SDF-1α in HUVECs. The major signaling pathways involved in the SDF-1α induced EC 
migration signal through PI3K/Akt or ERK signaling (Pi et al. 2009, Teicher et al., 2010). 
We tested the signaling changes by seeding HUVECs onto SDF-1α-Ubx fibers and 
culturing the HUVECs / fibers overnight prior to serum starvation. HUVECs were then 
collected and lysed at specific time points after serum starvation (1, 2, 3, 4 hours) and 
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analyzed by western blot. We were not able to detect the signal of phosphorylated AKT.  
This could be due to the fact that the only available anti-pAkt antibody is of poor quality. 
Therefore, we tested whether signaling could be detected via pERK, because the anti-
pERK and Anti-ERK antibodies work well. However, we didn’t observe significant 
difference between the HUVECs, when cultured with SDF-1α–Ubx fibers and plain-Ubx 
fibers (Figure 4.2). 
 
 
 
 
 
 
Figure 4.2 SDF-1α–Ubx fiber does not induce ERK signaling in HUVECs.  HUVECs 
cultured with SDF-1α Ubx fibers and plain Ubx fibers in serum starved environment 
were collected at the specified time, and western blot analyses were used to probe for 
pERK (Thr 202/Tyr 204), ERK and PECAM. 
 
 
4.3.3 Soluble SDF-1α–Ubx stimulates ERK signaling in HUVECs in the same 
pattern as soluble SDF-1α protein   
Although SDF-1α-Ubx material promotes endothelial cell migration and attachment in 
vitro, we were not able to detect the ERK signaling accordingly.  To ensure SDF-1α-Ubx 
fusion is not causing misfolding or loss-of function of SDF-1α protein in the fusion with 
Ubx, we compared the efficacy of soluble SDF-1α–Ubx protein with commercially 
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acquired SDF-1α protein (R&D system, #P48061).  HUVECs were cultured until 
confluency and then serum starved for 2 hours to completely eliminate the signaling 
induced by old serum added media. Soluble SDF-1α–Ubx (25 µM) and SDF-1α protein 
(12.5µM) were then added to stimulate the HUVECs. Because SDF-1α–Ubx is purified 
by one affinity column and the estimated purity is 50-60 % by SDS-PAGE, double the 
SDF-1α–Ubx protein concentration was used to compare with commercial SDF-1α 
protein.  Soluble SDF-1α–Ubx is able to stimulate ERK signaling in HUVECs. pERK 
was detected soon after SDF-1α-Ubx addition (5 minutes), which is comparable to 
commercial SDF-1α protein control and similar to the time course reported previously (Pi 
et al., 2009) (Figure 4.3). We conclude that SDF-1α protein is correctly folded and 
functional in the fusion protein with Ubx.   
 
 
Figure 4.3 Soluble SDF-1α–Ubx stimulates ERK signaling in HUVECs. 
Soluble SDF-1α–Ubx trigger ERK signaling in HUVECs in the same pattern as soluble 
SDF-1α protein (R&D system, #P48061). Ctrl: Control, HUVECs without treatment.   
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4.3.4 Adding linker between growth factors and Ubx does not improve the delivery 
of growth factors to cells 
Soluble SDF-1α-Ubx protein stimulates ERK signaling in HUVECs, which is comparable 
to soluble SDF-1α protein acquired commercially, suggesting that the folding and 
function of SDF-1α protein within this fusion is intact in the monomers.  However, SDF-
1α-Ubx material is not able to trigger ERK signaling when cultured with HUVECs, 
presumably because Ubx : Ubx or SDF-1α : Ubx contacts formed in the materials unfold 
SDF-1α or sequester the SDF-1α interface for receptor binding.  To test this hypothesis, 
we lengthened the linker from Glycine to Glycine-Serine-Glycine-Serine between SDF-
1α protein and Ubx. We also made the same modification in bFGF-Ubx, another potent 
ERK signaling activator of HUVECs. However, we were not able to see any 
improvement by this modification (Figure 4.4).         
 
Figure 4.4 Adding linker between growth factors and Ubx does not improve delivery 
of growth factors to cells.  HUVECs cultured with plain Ubx fibers, SDF-1α-GSGS-Ubx 
fibers and bFGF-GSGS-Ubx fibers in serum starved environment were collected at the 
specified time, and western blot analyses were used to probe for pERK (Thr 202/Tyr 
204), ERK and PECAM. GSGS: Glycine-Serine-Glycine-Serine peptide  
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4.4 Conclusions 
In this chapter, we aimed to make biocompatible and multi-functional Ubx materials for 
stent uses.   To achieve this goal, we planned to make a variety of Ubx fusions with 
growth factor or cell-binding peptide that have specific functions for recruiting ECs or 
preventing the binding of platelet and smooth muscle cells.  We first tested the SDF-1α-
Ubx, both in the forms of soluble protein or in materials. SDF-1α-Ubx material promotes 
the migration of HUVECs. In addition, soluble SDF-1α-Ubx protein shows similar 
efficacy as SDF-1α protein, suggesting the SDF-1α protein is correctly folded and 
functional when produced with Ubx as a fusion protein. However, we were not able to 
detect the ERK signaling triggered by SDF-1α-Ubx material.  Here we propose three 
possible explanations:  
1. We looked at the wrong pathway. Although SDF-1α is known to promote 
HUVECs migration by inducing PI3K/AKT and ERK signaling, in Ubx material, 
it may induce different pathways because the physical interaction between 
HUVECs and material is quite different from the conventional interaction 
between soluble SDF-1α and HUVECs in tissue culture dishes.  
2. SDF-1α-Ubx material indeed triggers the ERK signaling, but we looked at the 
wrong timing. According to the result of Figure 4.3, soluble SDF-1α induces the 
signaling only at a very early time points when the HUVECs has been serum 
starved for 2 hours. In our experiments, HUVECs were directly added onto the 
SDF-1α-Ubx fibers and incubated for overnight prior to serum starvation. The 
signaling induced by SDF-1α protein in HUVECs may be weakened since the 
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cells have been exposed to SDF-1α protein for more than 16 hours, which may 
result in the difficulty of detecting the changes in signaling.         
3. SDF-1α protein is embedded in the material and its binding site is not accessible 
for the receptors on cells.  The observation that the SDF-1α-Ubx material 
promotes more HUVECs migration than plain Ubx-material, may be caused by 
the physicochemical properties of SDF-1α protein rather than specific interaction 
with the receptors.  For example, SDF-1α protein has a predicted +9.0 charge at 
pH 7.2, which may help the attachment of HUVECs.      
To test these explanations, in the future, we first plan to look at different pathways that 
may be induced by SDF-1α-Ubx material. We may also need to modify the experiment 
protocol, in order to maximize the signals and detect the changes in signaling at the right 
timing.    
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CHAPTER V 
OVERALL CONCLUSION AND FUTURE DIRECTION 
 
5.1 Research summary 
In this study, we have made several discoveries. First of all, we discovered the formation 
of dityrosine bonds in Ubx materials, which is correlated to the physical strength of Ubx 
materials. Most importantly, we identified the specific tyrosine residues involved in the 
bond formation, allowing us to manipulate the mechanical properties of Ubx materials in 
the future. Secondly, we have systematically tested the physicochemical effects of the 
fusion proteins on the production and assembly of functional Ubx materials. We found 
that the appended proteins dominate the expression and solubility of the entire fusions. 
Interesting, Ubx fusions show strong and consistent ability to assemble into materials 
despite the physicochemical effects of the appended proteins. We concluded that a far 
wider range of proteins can be successfully incorporated into Ubx materials than 
originally anticipated. Finally, we demonstrated that functional molecules, such like 
VEGF, can be incorporated into Ubx-materials and induce corresponding signaling 
pathway to instruct ECs behaviors in vitro and in vivo. However, successful incorporation 
of proteins into materials is no guarantee that the proteins will remain active within the 
materials, as exemplified by SDF-1α and bFGF. In conclusion, we see Ubx material has 
great potential as a novel protein-based material. In the future, we hope to use this 
material for a variety of biomedical applications.   
 
 
 
 
125 
 
5.2 Compare Ubx material with other protein-based materials 
In Chapter III, we demonstrated that Ubx protein possesses a very strong and consistent 
ability to incorporate appended proteins into materials. Successful Ubx fusions cover a 
much wider range of physicochemical properties than current protein-based materials 
(Huang et al., 2007, Jansson et al., 2014). This unique feature makes Ubx material a very 
attractive system for functionalizing protein-based materials.  Many potential biomedical 
applications could be implemented by the functionalized Ubx materials.  A representative 
example in my studies is the multifunctional tissue engineering scaffold intended to 
stimulate multiple desired cell behaviors (attachment, survival, proliferation) of HUVEC 
at the same time (Appendix and Chapter IV).   This unique advantage of Ubx material is 
likely because Ubx protein not only has elastin-like motifs and spider silk-like motifs that 
promote non-covalent protein-protein interaction (Greer et al., 2009), but also has 
intermolecular dityrosine bonds that crosslink Ubx molecules in materials.   
 
Compared to other protein-based materials, Ubx material also has some challenges need 
to be overcame in the future. First, although Ubx materials can be digested by trypsin 
(Hsiao et al., manuscript in preparation), we have not designed a successful 
programmable hydrolysis or a specific degradation for Ubx material yet, which limits 
Ubx materials’ applications as a biodegradable drug delivery vehicle or a subcutaneous 
biosensor.  Another technique needs to be developed for Ubx materials is the 
method/equipment for making more complex structures of Ubx materials.  At present, we 
are able to make Ubx materials into different morphologies such like film, sheet, fiber 
and bundle. However, some biomedical applications need more complex 3D structures, 
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for example, a sponge-like scaffold for cartilage tissue engineering (Aoki et al., 2003, 
Morita et al, 2002).  Currently, the most common method to make complex protein-based 
structures is electrospinning (Rockwood et al., 2011, Hu et al., 2012).   A typical 
electrospinning device is composed of a Gama High Voltage DC power and a syringe 
pump. Briefly, the material-forming protein solutions form a droplet at the orifice of a 
stainless steel needle. The droplet is then stretched and splayed into a series of fine 
filaments under a high-voltage electric field. The generated nanofibers are collected on 
aluminum foil, silicon die, or glass slides (Qiu et al., 2010).   Recently, 3D-printing 
technique has also been used for making tissue engineering scaffolds (Schacht et al., 
2015). In the Bio-3D printer system, before printing, the protein solution (spider silk 
protein) was pre-gelled overnight at 37 °C and 95 % relative humidity to form hydrogel, a 
robotic bioplotter is then used to dispense the protein gel into different structures. The 
two techniques described above may be useful for Ubx materials to create more complex 
structures, but both need to be further tested and adjusted.       
   
5.3 Suture functional proteins with Ubx material by DiY bonds  
In Chapter V, we discussed that SDF-1α protein may be embedded in the material, 
therefore its binding site is not accessible for the receptors on cells.  To solve this 
problem, we planned to employ the finding we discovered in Chapter II, the dityrosine 
bonds in Ubx-materials.  We first tested the Y167-Y240 bond, the strongest bond found 
in Ubx materials.  The Y240 and Y167 and their surrounding amino acids (around 12-24 
amino acids) were cloned and inserted into the N-terminus of growth factors and Ubx 
protein, respectively.  Y167 peptide inserted Ubx protein will be made as material first. 
 
 
127 
 
Y240 peptide inserted growth factors will then be incubated with the Y167 inserted-Ubx 
material to allow the Y167-Y240 bond to form and link the growth factor to the surface 
of Ubx material.  (Figure 5.1)    
 
 
Figure 5.1 Growth factors or other functional molecules can be potentially linked to 
Ubx-materials by the formation of dityrosine bonds.  
 
 
5.4 Micro-beads for therapeutic protein production 
In 1986, human tissue plasminogen activator (tPA, Genentech) became the first 
recombinant protein therapeutics available on market (Wurm, 2004).  Since then, protein 
therapeutics keeps growing with a compound annual growth rate of 12-13% and the 
market is likely to grow and to reach $141.5 billion in 2017 (according to the report: 
Global Protein Therapeutics Market Forecast to 2015 - Research and Markets, 2012).  
Most recombinant protein pharmaceuticals are produced in mammalian cells, including 
some typical high yield cell lines such as CHO cells or HEK-293 Cells. Although the 
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production yield of mammalian cell lines cannot compete with the high production yield 
in bacteria or yeast systems, mammalian cell lines are irreplaceable therapeutic protein 
producing factories because most proteins require proper posttranslational modifications 
such as glycosylation to gain full functions (Kim et al., 2012).  Early stages of protein 
therapeutics studies are usually conducted in academia or industrial laboratories.  Once 
the protein therapeutics candidates are selected, many rounds of protein engineering, 
modifications and optimization will be performed to pursue the highest specificity, lowest 
side effects and the most optimized efficacy of the lead molecules.  In each round, 
scientists need to produce enough amount of the engineered product for a variety of tests, 
such as affinity assays by surface plasmon resonance, ADCC/CDC assays, 
pharmacokinetic/pharmacodynamic modeling and experiments in animal models 
(Tuntland et al., 2014). To produce enough amount proteins for these assays is always 
challenging in the laboratory, particularly due to the limited space for mammalian cell 
culture. There are several ways to overcome this problem, for example, using multilayer 
cell culture flasks or a rolling bottle cell culture system.  Both methods are designed to 
increase the surface area for cell attachment in the flasks and therefore increase cell 
number and protein yield (Figure 5.2).  An alternative method is using micro-carrier 
beads for cell attachment. The micro-carrier beads can be suspended by the impellers in 
spinning flask. This 3-dimensional culture system fully utilizes the medium in the flask 
and dramatically increases the cell density and protein production in the flask (Figure 
5.3).  However, cells can only attach and survive on the micro-carrier beads for 1-2 
weeks, and the preparation of these beads is time-consuming and costly. To solve this 
disadvantage of conventional micro-carrier beads, we can use functionalized Ubx 
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materials.  There are at least three advantages of Ubx materials as the next generation of 
micro-carrier. 1. Ubx materials are cytocompatible.  A variety of cell types attach to Ubx 
materials well.  We also can design specific binding sites for different cell types to 
maximize cell attachment.  2. We can fuse growth factors (such as EGF or IGF-1) to Ubx 
and make functional materials that promote cell proliferation and inhibit apoptosis, which 
can greatly prolog the production period. 3. Functional molecules are stable and protected 
in the Ubx materials (Figure 3.5A). Ideally, functional molecules will not be digested by 
proteases in the culture media or engulfed by endocytosis. Therefore we can reduce the 
cost of extra supplement  s, compared to conventional culture systems.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 High cell density cell culture systems. (A) Multi-layer cell culture flask. (B) 
Rolling bottle cell culture system.   
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Figure 5.3 Micro-carrier cell culture systems. (A) Cells are attaching to the micro-
carrier beads. (B) Micro-carrier beads can be suspended by the impellers  
in spinning flask.  (Merten, 2015) 
 
 
5.5 Using Ubx-materials as drug delivery vector 
Treatments of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and           
psoriatic arthritis include surgery, physical therapy, nonsteroidal anti-inflammatory drugs 
(NSAIDs), and injection of protein therapeutics. Etanercept is an example of protein 
therapeutics for these diseases.  Etanercept is a dimeric human tumor necrosis factor 
receptor (TNFR) p75-Fc fusion protein made of 2 extra-cellular domains of the human 75 
kD (p75) TNFR that captures the free TNF-α in body fluid (Garrison et al., 1999, Murray 
et al., 1997).  To decrease the injection frequency and improve the quality of lives of 
patients, these types of protein therapeutics are usually modified by fusing with Fc 
domain or BSA to increase half-life (Hutt et al., 2012). However, standard treatment still 
requires an injection every two weeks to one month. To improve this, we can apply Ubx 
material as a drug delivery system.  We can first fuse TNF-α receptor with Ubx and make 
a hydrogel or a small sponge-like material. The material can then be implanted or 
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injected into the knees or other joints of mice to test the biocompatibility.  Ideally, the 
TNF-α Receptor-Ubx will be gradually released and absorb free TNF-α in synovial fluid 
and inhibit local inflammation in knees or other joints.   
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APPENDIX 
FUNCTIONALIZATION OF ULTRABITHORAX MATERIALS WITH VASCULAR 
ENDOTHELIAL GROWTH FACTOR ENHANCES ANGIOGENIC ACTIVITY* 
 
1. Introduction 
The field of tissue engineering (Marler e al., 1998, Nerem et al., 1991, Vacanti et al., 
1999) strives to develop new therapies that replace, restore, or enhance function in 
damaged tissues. Due to the limited diffusion of metabolites and oxygen, cell viability in 
sizeable scaffolds is confined to within a few hundred micrometers of the tissue periphery 
(Bryant et al., 2001, Bursac et al., 1999, Li et al., 2000, Martin et al., 1999, Obradovic et al., 
1999, Papadaki et al., 2001, Tian and George 2011). Rapid formation of blood vessels, 
via neovascularization or angiogenesis, is critical to maintain cell viability within tissue 
engineered scaffolds. Consequently, successful scaffold design must include a strategy to 
vascularize the tissue. 
 
Scaffold perfusion can be achieved by administering angiogenic proteins, which drive 
neovascularization in vivo (Folkman and Klagsbrun 1987, Tabara et al., 2001, Martino et 
al., 2015, Park et al., 2015, Jansson et al., 2014). In particular, vascular endothelial 
growth factor (VEGF) promotes the formation of new blood vessels and can trigger 
endothelial cell (EC) proliferation, migration, and survival through activation of multiple 
signaling pathways (Bayless and Davis, 2003, Carmeliet et al,. 1996, Jakeman et al., 
 
* Reprinted with permission from “Functionalization of Ultrabithorax Materials with Vascular Endothelial Growth 
Factor Enhances Angiogenic Activity” by Howell DW, Duran CL, Tsai SP, Bondos SE, Bayless KJ, 2016. Manuscript 
submitted to Advanced Functional Materials. DOI 10.1002/adfm.201505365 
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1993, Pownall et al., 2010, Shweiki et al., 1993). 
 
Although various strategies have been devised to deliver pro-angiogenic growth factors, 
an effective system to vascularize thick scaffolds is still needed. Methods such as 
microsphere encapsulation (Richardson et al., 2001), hydrogel entrapment (Lee et al., 
2003, Sun et al., 2011, Gnavi et al., 2014, Kim et al., 2010, Yamaguchi et al., 2007), and 
bio-spraying technologies (Patel et al., 2012) provide ECs with pro-angiogenic factors to 
stimulate formation of capillary networks.  
 
An alternate approach is to covalently crosslink the functional proteins to the materials. 
However, the crosslinking process can also inactivate the tethered protein or leave 
chemical residues in the materials, rendering them toxic to cells (MiJung et al., 2014, 
Woolfson et al., 2010). Additionally, the crosslinking strategy can orient some portion of 
the protein such that ligand binding, and hence protein function, is blocked (Hahn, et al., 
2005, Galas et al., 2014). All of these methods result in random distribution of factors 
throughout the scaffold, which may alter the behavior of non-vascular cells. Thus, 
successfully engineered scaffolds must not only present and pattern active stimulatory 
factors, but also do so using non-toxic methods. 
 
Therefore, we propose a new method of delivering growth factors for successfully 
engineering blood vessels in tissue engineered scaffolds. Our lab has developed materials 
composed of the Drosophila melanogaster Hox protein Ultrabithorax (Ubx), which self-
assembles rapidly in mild, aqueous buffers.  Ubx materials can be readily functionalized 
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with VEGF via gene fusion (Huang et al., 2011, Tsai et al., 2015). In this approach, the 
gene encoding a functional protein is fused to the ubx gene without intervening stop 
codons.  As a result, a single polypeptide is produced containing the sequence of both the 
functional protein and Ubx.  We have previously fused small, stable monomeric proteins 
to Ubx that retain activity in the resulting materials (Huang et al., 2011). For Ubx 
materials to be useful as vascular scaffolds, proteins for which incorporation is more 
challenging, due to instability or quaternary structure, must retain activity in Ubx 
materials. Previously, we demonstrated that the VEGF-Ubx and EGFP-VEGF-Ubx 
fusions both self-assemble to form materials (Tsai et al., 2015). In this study, we created 
VEGF-Ubx and EGFP-VEGF-Ubx fusion fibers to test the activity of complex proteins in 
Ubx fibers using in vitro, ex vivo, and in vivo assays. This approach provides a novel 
method for delivering VEGF to activate and promote survival of ECs in a dose-dependent 
manner. Furthermore, when VEGF-Ubx fibers are embedded in collagen, only cells 
interacting with the fiber are influenced by VEGF. Thus, Ubx is a unique material able to 
incorporate active growth factors in a biocompatible material (Patterson et al., 2014, 
Patterson et al., 2015) with tunable mechanical properties (Greer et al., 2011, Howell et 
al., 2015, Huang et al., 2010). To our knowledge, we are the first to append VEGF to 
biomaterials via gene fusion.   
 
2. Material and methods 
2.1 Ubx materials 
Monomers of his-tagged Ultrabithorax splicing isoform Ia, along with EGFP, VEGF, and 
EGFP-VEGF Ubx (Tsai et al., 2015),  were produced in E. coli from the pET19b-UbxIa 
vector and purified as previously described (Patterson et al., 2014). Ubx fibers were 
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produced by the buffer reservoir system, also as previously described (Tsai et al., 2015, 
Huang et al., 2010, Greer et al., 2009). EGFP-Ubx and EGFP-VEGF-Ubx were used 
when possible due to i) increased expression of the monomers in E. coli and ii) ability to 
visualize the fibers using green fluorescence.  The EGFP-fused constructs could not be 
used in immunoassays in which green fluorescence is one of the reporters. 
 
2.2 Cell culture  
Primary human umbilical vein endothelial cells (HUVEC) (Lonza, C2517A) were 
cultured and used at passages 3-6. Cells were grown on gelatin-coated tissue culture 
flasks, passaged once per week in M199 growth medium supplemented with heparin, 
bovine hypothalamic extract, fetal bovine serum, antibiotics and gentamycin as described 
(Bayless et al., 2009).  
 
2.3 Immunofluorescence  
Cell suspensions were incubated with Ubx fibers wrapped around inoculation loops to 
allow cells to attach to fibers and cultured as previously described (Patterson et al., 2014, 
Patterson et al., 2015). For time course experiments, cells cultured on Ubx were transferred 
to new wells containing M199 without serum for 0 to 4 hours. While ECs seeded on VEGF-
Ubx were untreated, 40 ng/ml of soluble VEGF was added to ECs seeded on Ubx alone to 
compare cell responses to immobilized versus soluble VEGF. In all immunofluorescence 
experiments, a freshly made 10% paraformaldehyde stock in PBS (500 L) was added to 
the existing culture media at a final concentration of 4%, and samples were fixed prior to 
two 15 minute washes with a 25 mM Tris, 200 mM glycine solution. Samples were then 
permeabilized with 500 L of 0.5% Triton X-100 solution in PBS for 20 minutes. Wells 
were aspirated and samples were blocked overnight in 500 L 0.1% Triton X-100, 1% 
BSA, 0.2% sodium azide, and 5% goat serum at 4C. Primary antibodies raised against 
ERK (1:100; Cell Signaling Technology), pERK (phosphorylated at T202/Y204) (1:1000; 
Cell Signaling Technology), and pVEGFR2 (phosphorylated at Y1214) (1:300;Cell 
Signaling Technology) were diluted in blocking solution and incubated in the wells for 3 
hours. Loops were washed three times for 10 minutes each in 0.1% Triton X-100 in PBS 
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(500 µl) and incubated with (1:200 dilution) goat anti-rabbit Alexa Fluor 488 and goat anti-
mouse Alexa Fluor 594 conjugated secondary antibodies (Molecular Probes) in blocking 
solution for 1 hour. Loops were washed three times and counterstained with 10 mM 4',6- 
diamidino-2-phenylindole (DAPI; Molecular Probes), placed on a 22 mm X 55 mm 
coverslip and imaged immediately using confocal microscopy on a Nikon Eclipse ti 
equipped with NIS Elements AR 4.10.01 software. 
 
2.4 Migration Assay  
DiI-labeled HUVECs were seeded onto gelatin-coated wells and allowed to reach 
confluency. Cells were then cultured in M199 without serum for 6 hours prior to 
placement of inoculation loops wrapped with EGFP-Ubx or EGFP-VEGF-Ubx fibers 
onto cell monolayers. After a 16 hour incubation in M199 with 1.5% serum the cells on 
Ubx fibers were fixed and immunofluorescence was conducted as described above. 
 
2.5 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 
Fiber wrapped loops, directly seeded with 35,000 cells suspended in 250 µl of growth 
media, were cultured overnight so that cells could attach to Ubx fibers. Growth media was 
aspirated and cells cultured on Ubx fibers were starved for 8 hours in M199 without serum 
and then fixed using paraformaldehyde. A TUNEL assay kit from Abcam was used per 
manufacturers’ protocol and imaged using confocal microscopy as described above. 
 
2.6 Western Blot  
Loops containing attached cells were collected in 60 µl of preheated Laemmli sample 
buffer and boiled in microcentrifuge tubes for 10 minutes at 95C. Protein lysates were 
separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes (Fisher 
Scientific). After blocking in 5% nonfat dry milk or BSA at room temperature for 1 hour, 
the membranes were incubated with monoclonal antisera directed against PECAM 
(1:1000 in TBST; Cell Signaling Technology), ERK (1:1000 in TBST; Cell Signaling 
Technology), pERK (1:1000 in TBST; Cell Signaling Technology), PECAM or GAPDH 
(1:10,000 in TBST; Abcam) at room temperature for 3 hours. The membranes were 
 
 
148 
 
washed three times before incubation with rabbit anti-mouse secondary antibody or goat 
anti-rabbit secondary antibody (1:5,000; DAKO) for 1 hour. Immunoreactive proteins 
were visualized using enhanced chemiluminescence (Millipore) and followed by film 
(Denville Scientific) exposure. For image quantification, images were scanned with a 
FluorChem 8900 digital imaging system (Alpha Innotech, San Leandro, CA). Band 
intensities were measured using NIH ImageJ image analysis software. 
 
2.7 Aortic Ring Assay 
Aortae were harvested from Sv129-Pas mice between 6-10 weeks of age, and prepared as 
described (Baker et al., 2012). Aortae were cut into 0.5 mm segments along the length of 
the vessel, creating rings. Collagen type I was prepared at a concentration of 1.5 mg/ml as 
previously described (Bayless et al., 2009), substituting Opti-MEM for M199. Collagen 
(150 µL) was added per well of a 48-well, glass bottom plates (MatTek) on ice. One 
aortic ring per well was embedded in the collagen, and loops wrapped with EGFP-Ubx or 
EGFP-VEGF-Ubx fibers were placed in the collagen so that the fibers were in close 
proximity to the aortic rings. After the collagen polymerized, 500 µl of Opti-MEM 
containing 2.5% FBS, gentamycin, and 40 ng/mL VEGF was added. Rings were 
incubated at 37 °C with 5% CO2. After 24 hours, VEGF-containing media was removed 
and replaced with media lacking VEGF. After six total days of incubation, samples were 
fixed with 4% paraformaldehyde in PBS for 30 minutes. Wells were rinsed two times for 
30 minutes with Tris-Glycine buffer (0.3% Tris and 1.5% Glycine). After rinsing, 
samples were permeabilized with 500 µl 0.5% Triton X-100 in PBS by rocking for 2 
hours at room temperature and then blocked overnight with 1 ml 0.1% Triton X-100, 1% 
BSA and 1% goat serum in Tris-buffered saline at room temperature. Solutions were 
added containing primary antibodies directed against PECAM-1 (BD Transduction, 
550274) diluted 1:100 in blocking buffer at room temperature with gentle agitation for 3 
hours. After rinsing rings four times for 30 minutes with 1 ml 0.1% Triton X-100 in PBS 
at room temperature, samples were incubated with Alexa Fluor 595-conjugated 
secondary antibodies (Molecular Probes) diluted 1:200 in blocking buffer at 4 °C 
overnight. The samples were then washed overnight at room temperature with 1 ml 0.1% 
Triton X-100 in PBS. Nuclei were stained with 1 µM DAPI (Molecular Probes) for 30 
 
 
149 
 
minutes at room temperature with gentle agitation and imaged as described above. Z-
stack images (5-25 µm) were taken using 0.5 µm steps, compressed, and analyzed using 
Nikon Elements Software. 
 
2.8 Chorioallantoic membrane assay (CAM) 
Fertilized eggs were obtained from the Texas A&M University Poultry Science Center 
(College Station, TX). Eggs were incubated at 37 ⁰C, rotating continuously for 3 days 
before ex ovo culture (Dohle et al., 2009). Eggs were wiped with betadine and cracked 
into sterile weigh boats (VWR) containing appropriate dilutions of penstrep (Gibco), 
fungizone (Sigma), niacin (Sigma), and gentamycin (Gibco). Embryos were covered and 
placed in a humidified incubator (37 °C) for 4 days. Ubx materials wrapped around 
sterile rings of blot paper were placed with fibers perpendicular to established vessels. 
Micrographs were captured the same day Ubx materials were added on a National 
dissection scope (Model DC5-420TH) and then cultured for 48 hours. The embryos were 
then sacrificed and the same field was imaged to assess development of new vessels 
along Ubx fibers. To visualize fibers, images were also captured using illumination with 
UV light. Quantification of vessel growth was determined by comparing the images 
before and after addition of Ubx materials and counting the number of new vessels 
established along fibers. 
 
3. Results 
3.1 Human endothelial cells signal through the ERK pathway when presented with 
VEGF on Ubx materials 
A challenge in creating functionalized materials from protein chimeras has been 
assembling the materials while maintaining the structure and activity of the appended 
functional protein. We have created several active, functionalized materials using Ubx as 
a platform to introduce new activities via formation of protein fusions (Tsai et al., 2015). 
However, thus far only stable, monomeric proteins have been shown to retain activity in 
Ubx materials. To use Ubx as a vascular scaffold, more complex proteins, such as VEGF, 
must be appended that can interact with and direct vascular cells.  During angiogenesis, 
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VEGF signaling stimulates ERK phosphorylation (Thr 202/Tyr 204) downstream of 
VEGFR2 (Dougher et al., 1999, Kendall et al., 1999, Matsumote et al., 2005, Plouet and 
Moukadiri, 1990, Terman et al., 1991, Vaisman et al., 1990, Dent, 2014, Shu et al., 2002, 
Zachary, 2003). To test if VEGF immobilized in Ubx fiber is active, endothelial cells 
were seeded onto Ubx or VEGF-Ubx fibers and cultured overnight. Cells were cultured 
in basal media without serum for 2 hours to remove any non-specific signals from the 
growth media, and probed for ERK and pERK using immunofluorescence (Figure 1 
A,B). While total ERK levels are unchanged, pERK is significantly greater for cells 
cultured on VEGF-Ubx fibers than for cells cultured on Ubx fibers (Figure 1C; p<0.01). 
This indicates that ERK is activated in endothelial cells when presented with VEGF 
appended to Ubx materials.  
 
 
 
Figure 1. Endothelial cells cultured on VEGF-Ubx fibers show significant 
phosphorylation of ERK. ECs seeded on (A) Ubx fibers and (B) VEGF-Ubx fibers were 
cultured overnight and then starved for 2 hours prior to fixation in 4% para. Fibers in all 
panels are indicated by white arrows. Cells were stained for ERK, pERK (T202/Y204), 
and counter stained with DAPI for immunofluorescence imaging using confocal 
microscopy. Scale bars equal 20 µm. (C) Quantification of fluorescence intensity of ERK 
and pERK shows that cells cultured on VEGF-Ubx fibers show a significant increase in 
pERK compared to cells on Ubx fibers (p<0.01, indicated by *). Data are representative 
of 3 experiments and averaged from 25 independent fields in each group (+/- SEM) with 
analysis for significance using univariate analysis of variance (ANOVA) with Tukey's 
honest significant differences (HSD) test posthoc. 
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3.2 Signaling through VEGFR2 by VEGF-Ubx fibers is sustained for longer times 
relative to soluble VEGF 
To verify that VEGF fused to Ubx fibers is signaling through the correct pathway, we 
also tested whether the VEGF receptor VEGFR2 is activated, and thus phosphorylated. 
At the cellular level, VEGF binding to VEGFR2 results in Ca2+ mobilization, 
prostacyclin production, nitric oxide production, and phosphatidylinositol-3-kinase 
(PI3K)/Akt activation in addition to ERK activation (Cunninghan et al., 1995, Gerber et 
al., 1998, Kroll and Waltenberger, 1997, Waltenberger etal., 1994). These events 
cumulatively stimulate endothelial cell proliferation and migration, behaviors required for 
an angiogenic response (Cunninghan et al., 1995, Gerber et al., 1998, Kroll and 
Waltenberger, 1997, Waltenberger etal., 1994). We first verified that VEGF-Ubx leads to 
VEGFR2 activation and thus has the potential to instigate all of these events, ECs were 
seeded onto Ubx and VEGF-Ubx fibers and cultured overnight in growth media prior to 
serum starvation. To compare the effects of soluble VEGF stimulation on VEGF-Ubx 
versus Ubx fibers, ECs cultured on control Ubx fibers were treated with 40 ng/ml soluble 
VEGF at the onset of serum starvation. To examine VEGFR2 presentation on the cell 
surface, cells were fixed, but not permeablized, at 0, 2, and 4 hours and stained for 
VEGFR2. Figure 2A,B shows that VEGFR2 surface presentation is unchanged and 
therefore any changes in receptor phosphorylation during the course of these experiments 
are not a result of VEGFR2 internalization or downregulation. In addition to 
immunofluorescence, western blot analyses were performed to examine VEGFR2 
phosphorylation (pVEGFR2) (Figure 2C). Quantification of pVEGFR2 normalized to 
VEGFR2, shows that VEGFR2  phosphorylation occurs in response to VEGF-Ubx. 
Furthermore, VEGFR2 phosphorylation is sustained at a significantly higher level when 
cells are cultured on VEGF-Ubx fibers compared to plain Ubx in the presence of soluble 
VEGF (Figure 2D; #p<0.02 vs EGFP-Ubx at 2 Hours, *p<0.01 vs EGFP-Ubx at 4 Hours).  
 
Because VEGF is immobilized on Ubx, we tested whether VEGF-Ubx might sustain EC 
activation in the absence of serum. ECs were seeded onto EGFP-Ubx and EGFP-VEGF-
Ubx fibers, cultured overnight in growth media, and then placed under starvation 
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conditions. EGFP-Ubx and EGFP-VEGF-Ubx were used in these experiments due to i) 
increased expression of the monomers in E. coli (Tsai et al., 2015) and ii) an ability to 
visualize the fibers using green fluorescence. Cell lysates from each group were collected 
every hour for western blot analysis of ERK phosphorylation (Figure 3A,B). 
Quantification of pERK normalized to ERK, with PECAM as a loading control, shows 
that ERK activation in ECs cultured on EGFP-VEGF-Ubx fibers can be sustained for 4 
hours, while ERK activation almost completely disappears on EGFP-Ubx materials 
treated with soluble VEGF after an hour (Figure 3C; *p<0.01 vs EGFP-Ubx at 0 Hours; 
#p<0.03 vs EGFP-VEGF-Ubx at 0 Hours; $p<0.04 vs EGFP-VEGF-Ubx at 1 Hour; 
◊p<0.05 vs EGFP-VEGF-Ubx at 2 Hours; and ●p<0.01 vs EGFP-VEGF-Ubx at 3 Hours). 
Thus EC interactions with VEGF-Ubx results in sustained ERK signaling when 
compared to cells cultured on EGFP-Ubx materials treated with soluble VEGF. Rapid, 
yet transient increases in ERK and VEGFR2 phosphorylation in response to soluble 
VEGF are in agreement with other studies. The results from VEGF-Ubx materials are 
similar to other studies in which VEGF is covalently attached to materials (Phelps and 
Garcia, 2010, Shen et al., 2008). However, no study reports signal duration of longer than 
1 hour, while VEGF appended to Ubx sustains signaling for over 4 hours.  
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Figure 2. VEGFR2 cell surface expression is unchanged, while phosphorylation is 
sustained by VEGF-Ubx. (A) Immunofluorescence staining for VEGFR2 surface 
expression in ECs (green) counter stained with DAPI (blue) on Ubx or VEGF-Ubx fibers 
(white arrows). Cells were seeded on materials indicated overnight. Growth medium was 
removed and replaced with M199 alone (VEGF-Ubx) or M199 + 40 ng/ml soluble VEGF 
(Ubx). Cells were fixed at 0, 2, and 4 hours and stained. (B) Quantification of VEGFR2 
fluorescence in the absence of permeabilization using antibodies against the extracellular 
motif in VEGFR2. (C) ECs seeded onto GFP-Ubx and GFP-VEGF-Ubx fibers were 
cultured overnight and then serum starved for up to 4 hours. ECs cultured on Ubx were 
treated with 40 ng/ml soluble VEGF at onset of starvation. Cells were collected, lysed, 
and analyzed using western blot analysis. Membranes were probed for pVEGFR2 (Tyr 
1214), VEGFR2 and PECAM. (D) Quantification of pVEGFR2 normalized to VEGFR2, 
with PECAM as a loading control, shows that VEGFR2 is phosphorylated by VEGF-Ubx 
and can be sustained at a significantly high level. Data were averaged from 5 experiments 
and analyzed for significance using univariate analysis of variance (ANOVA) with 
Tukey's honest significant differences (HSD) test posthoc with # indicating p<0.02 vs 
GFP-Ubx at 2 Hours, * indicating p<0.01 vs GFP-Ubx at 4 Hours.  
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Figure 3. VEGF-Ubx materials sustain ERK signaling in ECs. ECs seeded onto (A) 
EGFP-Ubx and (B) EGFP-VEGF-Ubx fibers were cultured overnight and then starved 
for 4 hours. ECs cultured on EGFP-Ubx were treated with 40 ng/ml soluble VEGF at the 
onset of starvation. Cells were collected at the specified time, and western blot analyses 
were used to probe for pERK (Thr 202/Tyr 204), ERK and PECAM. (C) Quantification 
of pERK band intensities normalized to ERK, with PECAM as a loading control, shows 
that VEGF signaling on Ubx fibers can be sustained for up to 4 hours. Data were 
averaged from 4 experiments and analyzed for significance using univariate analysis of 
variance (ANOVA) with Tukey's honest significant differences (HSD) test posthoc with 
* indicating p<0.01 vs EGFP-Ubx at 0 Hours, # indicating p<0.03 vs EGFP-VEGF-Ubx 
at 1 Hours, $ indicating p<0.04 vs EGFP-VEGF-Ubx at 2 Hours, ◊ indicating p<0.05 vs 
EGFP-VEGF-Ubx at 3 Hours, and ● indicating p<0.01 vs EGFP-VEGF-Ubx at 4 Hours. 
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3.3 VEGF signaling is proportional to VEGF concentration on fibers 
EC responses to VEGF in vitro (Cunningham et al., 1995, Gerber et al., 198) are 
dependent on exposure to adequate concentrations of VEGF (Silva and Mooney, 2010), 
while in vivo, overexpression of VEGF can result in aberrant angiogenesis (Ozawa et al., 
2004) and enhanced angiogenic responses within tumors (Yang et al., 2015, Appelmann 
et al., 2010, Ellis and Hicklin et al., 2008, Olsson et al., 2006). If VEGF in Ubx materials 
is only partially active, the material may not reach the threshold necessary to elicit a 
cellular response. Alternately, a high VEGF concentration may overstimulate cells 
(Ozawa et al., 2004, Olsson et al., 2006). Therefore, to elicit the appropriate cellular 
responses for in vivo vascular scaffolds, it is important to present an effective 
concentration of active VEGF on Ubx materials. Previously, we established that a 
mixture of different ratios of Ubx to EGFP-Ubx produces materials in which EGFP-Ubx 
content in fibers linearly correlates with the percentage of EGFP-Ubx monomer in the 
original protein mixture (Tsai et al., 2015). We used this approach to generate fibers with 
varying VEGF concentrations. ECs were cultured on Ubx materials made from increasing 
ratios of VEGF-Ubx to Ubx, then starved for 2 hours and probed for ERK 
phosphorylation using western blot analysis. Expression of total ERK remained constant 
while levels of pERK increased proportionally with VEGF concentration, up to 75% 
VEGF-Ubx (Figure 4A,B). This VEGF concentration-dependent increase in ERK 
phosphorylation provides further evidence that immobilized VEGF is the active agent.  
Above 75% VEGF-Ubx, the response began to plateau as nearly all of the ERK present 
was phosphorylated. 
 
Because ERK phosphorylation is linearly proportional to VEGF-Ubx concentrations, we 
can infer that VEGF-Ubx and Ubx assemble into materials equally well. To benchmark 
the extent of signaling elicited by VEGF incorporated into Ubx fibers with signaling 
elicited by soluble VEGF monomers, we administered increasing doses of soluble VEGF 
at known concentrations to ECs cultured on Ubx fibers and monitored pERK/ERK ratios 
(Figure 4C,D). VEGF is widely used at the physiological range of 40 to 50 ng/mL, to 
induce EC proliferation and migration (Bayless and Davis, 2003, Shu et al., 202, Bayless 
and Davis, 2004, Bayless et al., 2009, Christenson and Stouffer, 1996, Hermann and 
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Zechariah 2009). The level of pERK/ERK observed with 50 ng/ml soluble VEGF was 
similar to the pERK/ERK level induced by materials containing 25% VEGF-Ubx. 
Therefore, Ubx materials are useful for building in vivo vascular scaffolds because we are 
able to produce fibers with a broad range of VEGF concentrations and, more importantly, 
can generate VEGF levels that elicit comparable signals to physiological doses of soluble 
VEGF. 
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Figure 4. ERK phosphorylation is proportional to the amount of VEGF 
incorporated into Ubx materials. (A) ECs seeded onto fibers composed of an 
increasing ratio of VEGF-Ubx to Ubx fibers were cultured overnight and then starved for 
2 hours prior to lysis in sample buffer and run on acrylamide gel for western blot 
analysis. Membranes were probed for pERK (Thr202/Tyr204), ERK and PECAM. (B) 
ERK and pERK band intensities were normalized to PECAM loading controls from 
respective blots. The ratio of PECAM-normalized pERk/ERK was averaged from 4 
experiments and analyzed for significance using univariate analysis of variance 
(ANOVA) with Tukey's honest significant differences (HSD) test posthoc with * 
indicating p<0.01 vs 0, # indicating p<0.02 vs 25, and $ indicating p<0.04 vs 50. (C)  
ECs seeded onto Ubx fibers were cultured overnight and then starved for 2 hours prior to 
treatment with increasing concentrations of soluble VEGF. After 30 minutes of treatment, 
cell lysates were analyzed by western blotting and probed for pERK, ERK and PECAM. 
(D) Quantification of PECAM-normalized pERK to ERK ratios were performed as in 
panel B. Data were averaged from 4 experiments and analyzed for significance using 
univariate analysis of variance (ANOVA) with Tukey's honest significant differences 
(HSD) test posthoc with * indicating p<0.02 vs 0 ng/ml, # indicating p<0.03 vs 50 ng/ml, 
and $ indicating p<0.01 vs 100 ng/ml. 
 
 
 
 
 
158 
 
3.4 VEGF-Ubx promotes endothelial cell migration and survival in vitro 
VEGF can impact many signaling cascades and elicit a variety of cell behaviors 
(Jakeman et al., 1993, Pownall et al., 2010, Shweiki et al., 1993). Although VEGF-Ubx 
fibers can phosphorylate ERK via VEGFR2 activation, the entire repertoire of VEGF 
functions are not guaranteed to be activated by immobilized VEGF. Therefore we tested 
whether complex cell behaviors, normally regulated by soluble VEGF, can be elicited by 
VEGF-Ubx fibers. In particular, we asked whether VEGF signaling can induce cells to 
migrate in low serum conditions or prevent cells from undergoing apoptosis in GF-
depleted media. In the migration assays, primary human ECs were labeled with DiI, a red 
fluorescent lipophilic dye, and cultured as a confluent monolayer prior to incubation at 
low serum for 6 hours. Ubx materials were then added and incubated with the cells 
overnight in media containing low levels of serum.  The cells were fixed and stained with 
DAPI, a blue fluorescent stain that binds DNA, to identify cells that migrated onto Ubx 
materials (Figure 5A,B). A significantly greater number of cells migrated onto EGFP-
VEGF-Ubx fibers when compared to control EGFP-Ubx fibers (Figure 5C; p<0.01), 
indicating that VEGF-Ubx materials stimulated migration of ECs in low serum 
conditions.  
 
In addition to migration, VEGF functions as a survival factor to inhibit apoptosis 
(Farahani et al., 2005, Yang et al., 2008, Roberts, et al., 2007). To test if Ubx materials 
could provide a way to sustain cell viability under stressful conditions, we cultured an 
equal number of ECs directly on EGFP-Ubx and EGFP-VEGF-Ubx fibers overnight to 
allow for cellular attachment prior to an 8 hour serum starvation. Cells were fixed, 
stained with DAPI, and a TUNEL assay was performed to identify cells undergoing 
apoptosis. While apoptotic (red) cells were detected on EGFP-Ubx fibers (Figure 6A), 
cells that were cultured on EGFP-VEGF-Ubx fibers showed little evidence of apoptosis 
(Figure 6B). Quantification shows a higher retention rate of ECs on EGFP-VEGF-Ubx 
materials than EGFP-Ubx (Figure 6C). Furthermore, these data indicate the majority of 
cells cultured on EGFP-Ubx fibers were lost and the few remaining cells were positive 
for TUNEL staining, while only 7% of cells remaining on EGFP-VEGF-Ubx fibers were 
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TUNEL positive (Figure  6A,C). Therefore, VEGF-modified Ubx fibers can influence EC 
behavior by promoting migration and survival.  
 
 
 
 
Figure 5. EGFP-VEGF-Ubx fibers promote enhanced recruitment and migration of 
endothelial cells. EGFP-Ubx (A) and EGFP-VEGF-Ubx (B) fibers (green, labeled with 
white arrows) were cultured overnight with an established monolayer of DiI-labeled (red) 
endothelial cells in low (1.5%) serum. Cells were fixed, stained with DAPI (blue), and 
imaged using confocal microscopy. Scale bars = 50 µm. (C) Quantification of the number 
of cells/100 µm distance attached to EGFP-Ubx vs. EGFP-VEGF-Ubx fibers. Data were 
averaged from 25 independent fields in each group (+/- SEM) from 4 experiments. Data 
were analyzed for significance using univariate analysis of variance (ANOVA) with 
Tukey's honest significant differences (HSD) test posthoc with * indicating p<0.01. 
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Figure 6. EGFP-VEGF-Ubx fibers prevent endothelial cell apoptosis after 
starvation. ECs seeded on EGFP-Ubx (A) and EGFP-VEGF-Ubx (B) fibers were starved 
for 8 hours and analyzed using TUNEL assays to detect apoptotic cells. White arrow 
indicates Ubx fiber. Scale bars = 10 µm. (C) Quantification of the number of viable and 
TUNEL-positive cells associated with EGFP-Ubx and EGFP-VEGF-Ubx fibers before 
(Time 0) and after 8 hours of starvation. Data shown are representative of 5 experiments 
and averaged from 20 independent fields in each group (+/- SEM).  Statistical 
significance was determined using univariate analysis of variance (ANOVA) with 
Tukey's honest significant differences (HSD) test posthoc with * indicating p<0.01 vs 
Time 0, # indicating p <0.04 vs Time 0, $ indicating p<0.03 vs. EGFP-Ubx, 8 hour 
starvation.  Quantification of TUNEL-positive cells (red) indicated that 95% of cells on 
EGFP-Ubx and only 7% of cells on EGFP-VEGF-Ubx were TUNEL positive. 
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3.5 VEGF-Ubx materials recruit endothelial sprouts in an ex vivo aortic ring assay 
An important aspect of VEGF function is to direct or pattern angiogenic outgrowths. 
Therefore, we used the physiologically relevant aortic ring assay to examine how VEGF-
Ubx interactions might affect vascular tissues. In this assay, angiogenic vessels sprout 
from freshly isolated aortic tissue that is embedded in a collagen matrix, allowing for 
analysis of vascular sprouting in an ex vivo environment. This assay is ideal for these 
experiments due to clearly visible, lumenized, capillary-like structures that develop at a 
rate similar to in vivo angiogenic sprouts (Baker et al., 2012, Masson et al., 2002). 
Importantly, supporting cells, such as pericytes, participate in the formation of 
microvessels, resembling events in vivo.  
 
To examine Ubx interactions with angiogenic sprouts, we modified the aortic ring assay 
by placing Ubx fibers within the collagen gel in close proximity to embedded tissue to 
allow for interaction with newly formed outgrowths as sprouts develop (Figure 7). When 
endothelial sprouts interact with EGFP-VEGF-Ubx fibers, they alter the direction of their 
growth to follow and, in some cases, wrap around EGFP-VEGF-Ubx fibers (Figure 
8A,B; Figure 9). This effect is rarely observed with EGFP-Ubx fibers (Figure 8C,D), 
suggesting that VEGF in EGFP-VEGF-Ubx fibers causes the sprouts to alter direction 
(Figure 8E). Because we observe comparable frequencies of initial contact between 
angiogenic sprouts and EGFP-VEGF-Ubx and EGFP-Ubx fibers, we conclude that 
angiogenic sprouts are responding to VEGF and the effect is not caused by i) durotaxis, 
ii) differences in the mechanical properties of fibers and collagen, or iii) differences in 
sprout attachment to Ubx fibers versus collagen due to the surface chemistry of these 
materials. Importantly, in this assay the VEGF-Ubx fibers buried in collagen form a 
composite material, in which VEGF-modified Ubx fibers guide angiogenic sprouts 
without impacting the behavior of cells within the scaffold but not in contact with the 
fiber.  This ability to ensure and pattern sprout outgrowth by placement of angiogenic 
materials is required for successful tissue engineering scaffolds. 
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   Figure 7. Modification of mouse aortic ring assay for use with Ubx materials 
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Figure 8. EGFP-VEGF-Ubx materials redirect and attract endothelial positive 
outgrowths from aortic rings. Aortic vessels excised from WT mice were divided into 
0.5 mm segments and embedded in 3D collagen matrices with Ubx materials. Aortic 
rings were cultured for 24 hours in growth factor supplemented media to induce 
endothelial sprouts into the collagen. Aortic rings were cultured for an additional 5 days 
in media without growth factors so that EGFP-VEGF-Ubx is the only source of growth 
factors for endothelial sprouts. Cultures were fixed, stained for PECAM (red), and 
counterstained with DAPI (blue). (A) Brightfield and (B) confocal images of EGFP-
VEGF-Ubx cultures show that sprouts will alter their direction to follow and in some 
cases envelop EGFP-VEGF-Ubx fibers (green). Images of EGFP-Ubx cultures using (C) 
brightfield and (D) confocal imaging. Scale bars = 50 µm. In all panels, A-D, arrows 
indicate EGFP-VEGF-Ubx or EGFP-Ubx materials. Solid arrowheads indicate where 
sprouts follow fibers while empty arrowheads indicate fibers that interact but do not 
follow. (E) Quantification of sprout interactions with materials.  Data were collected from 
50 events in 4 experiments.  Values were analyzed for statistical differences using a Chi-
Square test for independence with * indicating p<0.02.  
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Figure 9.  3-dimension confocal image shows endothelial sprouts wrap around the 
EGFP-VEGF-Ubx fiber 
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3.6 VEGF-Ubx directs blood vessel formation in vivo 
Thus far, we have demonstrated that VEGF-modified Ubx fibers can activate the VEGF 
signaling pathway in cell culture and alter the direction of growth of pre-formed 
angiogenic sprouts in the ex vivo aortic ring assay. To test whether EGFP-VEGF-Ubx 
fibers can instigate neovascularization in vivo, the ex ovo chicken embryo chorioallantoic 
membrane (CAM) assay (Bayless and Davis, 2004, Dohle et al., 2009) was modified for 
Ubx fibers. In the modified assay, chicken embryos were transferred to cell culture dishes 
3 days after fertilization and incubated for an additional 4 days. EGFP-Ubx (Figure 10A) 
or EGFP-VEGF-Ubx (Figure 10D) fibers were then placed on the surface of the 
chorioallantoic membrane perpendicular to established vessels and the animals were 
monitored for formation of new vasculature. After 48 hours, new vessels (indicated by 
closed arrowheads) often formed along VEGF-Ubx fibers (Figure 10E,F) while vascular 
development was unaltered by plain Ubx fibers (open arrowheads, Figure 10B,C). 
Quantification of 50 events from 7 experiments revealed that 36% of VEGF-Ubx fibers 
placed on the CAM resulted in new vessel growth, while plain Ubx fibers elicited no new 
vessels (Figure 10G).  These new vessels grew in the same direction as the VEGF-Ubx 
fiber axis. Therefore VEGF-modified Ubx materials can both instigate and direct vascular 
development in vivo. 
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Figure 10. EGFP-VEGF-Ubx fibers elicit more association with vasculature in 
chicken embryo chorioallantoic membrane (CAM) assays. Fertilized eggs were 
humidified, rotating continuously for 3 days before ex ovo culture. Embryos were 
cultured for 4 days prior to the addition of (A-C) EGFP-Ubx and (D-F) EGFP-VEGF-
Ubx materials wrapped around sterile blot paper and placed with fibers perpendicular to 
established vessels. (A,D) Representative brightfield images of the CAM surface 
captured immediately after adding materials. (B,E) Brightfield and (C,F) UV-illuminated 
photographs of the same fields shown in panels A and D 48 hours later. In panels A-E, 
fiber locations are indicated by white arrows. Open arrowhead indicates absence of vessel 
development, while closed arrowheads indicate development of new vessels.  (G) 
Quantification of vessel development induced by Ubx materials. The percentage of 
events where vessels developed in association with materials was quantified for EGFP-
Ubx (0/50 events) and EGFP-VEGF-Ubx (17/50 events). 
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4. Conclusions 
The development of artificial tissues and organs requires scaffolds to physically support 
growth of tissue-specific cells, as well as blood vessels within the scaffold to supply 
those cells with oxygen and nutrients (Marler et al., 1998, Merman, 1991, Vacanti and 
Langer, 1999). In the absence of a functional vasculature, the largest scaffold that can be 
successfully implanted in vivo is 1-2 mm thick (Li et al., 2000, Martin et al., 1999). Thus 
scaffold construction requires a separate set of molecular cues to direct vascular cell 
adhesion, proliferation, migration, and maturation through basement membrane 
deposition. These specific cues must be patterned within the scaffold to elicit appropriate 
cell responses. However, there are currently no methods available to adequately and 
precisely position angiogenic factors in a scaffold. 
 
As a first step toward this goal, we have demonstrated that VEGF, a dimeric protein, 
retains activity when genetically fused to Ubx and incorporated into materials. We show 
that ECs cultured on VEGF-Ubx fibers signal through the appropriate pathway and 
phosphorylate ERK and VEGFR2. In addition, VEGF signaling is extended for a longer 
period of time than any other current approach. Our data shows that VEGF concentration 
in Ubx fibers can be controlled and matched to physiologically relevant concentrations in 
vitro. Cell culture experiments show that VEGF-Ubx induces EC migration and sustains 
cell viability. Angiogenic sprouts change direction and can be guided by VEGF-Ubx 
fibers in an ex vivo aortic ring assay. Finally, in an in vivo CAM assay, VEGF-Ubx fibers 
induce formation of new vasculature when placed on the surface of the chick 
 
 
168 
 
chorioallantoic membrane (Huang et al., 2011, Tsai et al., 2015, Patterson et al., 2014, 
Greer ,et al., 2009, Huang et al., 2010, Howell et al., 2015). 
It is remarkable that VEGF retains its ability to bind and activate VEGFR2 given that 
VEGF is covalently bound to large, solid materials and VEGFR2 is embedded in the cell 
membrane.  This approach not only requires two large objects to be brought into close 
proximity, but also VEGF must be oriented correctly to bind its receptor. The fact that 
this approach is also effective when VEGF is fused in between EGFP and Ubx indicates 
the robustness of this approach. Ubx materials provide additional avenues for further 
optimization: the mechanical properties can be genetically tuned (Howell et al., 2015) 
and, because only 25% of the monomers need to be functionalized with VEGF, space is 
available for incorporating additional angiogenic molecules. Collectively, these data 
demonstrate that Ubx is a unique material able to incorporate active stimulating proteins 
capable of directing cell behavior in vitro and in vivo. 
 
